CLINICAL STUDY PROTOCOL  
EUDRACT  NUMBER: 2019 -004132 -37 
IND NUMBER: 144376  
 
A Phase III Randomized, Double -Masked, Parallel -Group, Multicenter 
Study to Compare the Efficacy, Safety, Tolerability, Pharmacokinetics , and 
Immunogenicity between SCD411 and Eylea® in Subjects with Neovascular 
Age-related Macular Degeneration  
 
SCD411 -CP101  
Sponsor:  SamChunDang Pharm. Co. Ltd.  
351, Hyoryeong -ro, Seocho -gu, Seoul [ZIP_CODE],  
Republic of Korea  
Sponsor Contact:  [CONTACT_661548]:  [PHONE_13685]  
Version of Protocol:  Version 3.0, Final  
Date of Protocol:  24 Jan uary 2022  
Previous Dates and Versions:  Version 2.0, dated 24 November 2020  
Version 1.2 (Country -Specific [Slovakia]), dated 
22 July 2020  
Version 1.1 (Country -Specific [Republic of Korea]), dated 
[ADDRESS_892260]  2020  
Original (Version 1.0), dated 27  March  2020  
 
CONFIDENTIAL  
All financial and nonfinancial support for this study will be provided by [CONTACT_661549].  Co. Ltd . The concepts and information contained in this document or generated 
during the study are considered proprietary and may not be disclosed in whole or in part 
without the expressed, written consent of SamChunDang Pharm. Co. Ltd . 
The study will be conducted according to the International Council for Harmonisation 
harmonised tripartite guideline E6(R2): Good Clinical Practice.  
 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.[ADDRESS_892261] ood all sections of the protocol entitled “ A Phase III Randomized, 
Double -Masked, Parallel -Group, Multicenter Study to Compare the Efficacy, Safety, 
Tolerability, Pharmacokinetics , and Immunogenicity between SCD411 and Eylea® in 
Subjects with Neovascular Age -related Macular Degeneration ” and the accompanying 
investigator’s brochure.  
I agree to supervise all aspects of the protocol and to conduct the clinical investigation in 
accordance with the Final Protocol Version 3.0, date d 24 Jan  2022 , the International Co uncil 
for Harmonisation harmonised tripartite guideline E6(R 2): Good Clinical Practice and all 
applicable government regulations. I will not make changes to the protocol before consulting 
with SamChunDang Pharm. Co. Ltd.  or implement protocol changes without independent 
ethics committee approval except to eliminate an immediate risk to subject s. I agree to 
administer study treatment only to subjects  under my personal supervision or the supervision 
of a subinvestigator.  
I will not supply the investigational drug to any person not authorized to receive it. 
Confidentiality will be protected. Subject  identity will not be disclosed to third parties or 
appear in any study reports or publications.  
I will not disclose information r egarding this clinical investigation or publish results of the 
investigation without authorization from SamChunDang Pharm. Co. Ltd . 
   
Signature [CONTACT_789]   [INVESTIGATOR_661518]/ Organization of Principal 
Investigator    
 
[INVESTIGATOR_661519]. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.[ADDRESS_892262] Selection and Withdrawal Criteria  ................................ ................................ ......35 
4.1 Selection of Study Population  ................................ ................................ ................. 35 
4.1.1  Inclusion Criteria  ................................ ................................ ..................... 35 
4.1.2  Exclusion Criteria  ................................ ................................ .................... 36 
4.1.3  Women of Child -bearing Potential  ................................ .......................... 39 
4.1.4  Approved Methods of Contraception  ................................ ...................... 39 
4.2 Selection of Study Eye  ................................ ................................ ............................ 40 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 5 4.3 Withdrawal of Subjects From Study Treatment and/or the Study  .......................... [ADDRESS_892263] Article Accountability  ................................ ................................ ......48 
5.5 Overdose Management  ................................ ................................ ........................... 48 
5.5.1  Medication Errors  ................................ ................................ .................... 49 
5.6 Masking  ................................ ................................ ................................ .................. 49 
5.6.1  Unmasking  ................................ ................................ ............................... 49 
5.7 Treatment Compliance  ................................ ................................ ............................ 50 
5.8 Prior and Concomitant Therapy  ................................ ................................ .............. 50 
5.8.1  Rescue Treatment  ................................ ................................ ..................... 50 
5.8.2  Prohibited Medications  ................................ ................................ ............ 51 
6 Study Assessme nts and Procedures  ................................ ................................ .................. 54 
6.1 Study Visits  ................................ ................................ ................................ ............. 58 
6.1.1  Screening Phase  ................................ ................................ ....................... 58 
6.1.2  Treatm ent Phase  ................................ ................................ ....................... 59 
[IP_ADDRESS]  Baseline (Day 1)  ................................ ................................ ...................... 59 
[IP_ADDRESS]  Subsequent Treatment Period (Week 4, Week 8, Week  12, Week  16, 
Week 24, Week  28, Week 32, Week 40, Week  44, and Week 48)  ............ 60 
6.1.3  Early Termination/End -of-Study  ................................ ............................. 67 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.[ADDRESS_892264] Corrected Visual Acuity  ................................ ................................ ...68 
6.2.2  Ocular Imaging  ................................ ................................ ........................ 69 
[IP_ADDRESS]  Optical Coherence Tomography  ................................ .............................. 69 
[IP_ADDRESS]  Fluorescein Angiography and Fundus Photography  ................................ 70 
6.3 Safety Assessments  ................................ ................................ ................................ .70 
6.3.1  Medical History and Concomitant Medications  ................................ ......70 
6.3.2  Ophthalmic Examinations  ................................ ................................ .......71 
6.3.3  Adverse Events  ................................ ................................ ........................ 72 
[IP_ADDRESS]  Definitions of Adverse Events  ................................ ................................ .72 
[IP_ADDRESS]  Serious Adverse Events  ................................ ................................ ........... 72 
[IP_ADDRESS]  Eliciting and Documenting Adverse Events  ................................ ............ 73 
[IP_ADDRESS]  Reporting Adverse Events  ................................ ................................ .......73 
[IP_ADDRESS]  Reporting Serious Adverse Events  ................................ .......................... 74 
[IP_ADDRESS]  Suspected Unexpected Serious Adverse Reactions  ................................ .75 
[IP_ADDRESS]  Assessment of Severity  ................................ ................................ ............ 75 
[IP_ADDRESS]  Assessment of Causality  ................................ ................................ .......... 76 
[IP_ADDRESS]  Follow -Up of Subjects Reporting Adverse Events  ................................ ..76 
6.3.4  Clinical Laboratory Evaluations  ................................ .............................. 76 
6.3.5  Vital Signs  ................................ ................................ ................................ 77 
6.3.6  Electrocar diograms  ................................ ................................ .................. 77 
6.4 Pharmacokinetic Assessments  ................................ ................................ ................ 78 
6.5 Immunogenicity Assessments  ................................ ................................ ................. 79 
6.6 Independent Data Monitoring Committee  ................................ .............................. 79 
6.7 Pregnancy  ................................ ................................ ................................ ................ 80 
6.8 Sample Collections  ................................ ................................ ................................ .80 
7 Statistical and Analytical Plan  ................................ ................................ .......................... 81 
7.1 Estimands and Intercurrent Events  ................................ ................................ ......... 81 
7.2 Sample Size Determination ................................ ................................ ..................... 84 
7.3 Analysis Sets  ................................ ................................ ................................ ........... 85 
7.4 Description of Subgroups to be Analyzed  ................................ .............................. 86 
7.5 Statistical Analysis Methodology  ................................ ................................ ........... 86 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 7 7.5.1  Efficacy Analyses  ................................ ................................ .................... 86 
[IP_ADDRESS]  Primary Efficacy Outcome Measures  ................................ ...................... 87 
[IP_ADDRESS]  Secondary Efficacy Outcome Measures  ................................ .................. 89 
7.5.2  Pharmacokinetic Analyses  ................................ ................................ .......90 
7.5.3 Immunogenicity Analyses  ................................ ................................ .......90 
7.5.4  Safety Analyses  ................................ ................................ ........................ 90 
7.5.5  Other Analyses  ................................ ................................ ......................... 92 
[IP_ADDRESS]  Background Characteristics  ................................ ................................ .....92 
[IP_ADDRESS].[ADDRESS_892265] Disposition  ................................ ................................ ......92 
[IP_ADDRESS].2  Demographics and Baseline Characteristics  ................................ 92 
[IP_ADDRESS].3  Prior and Concomitant Medications  ................................ ............ 92 
[IP_ADDRESS].4  Medical History  ................................ ................................ ........... 92 
[IP_ADDRESS]. [ADDRESS_892266] Information and Consent  ................................ ................................ ........... 95 
10 Investigator’s Obligations  ................................ ................................ ................................ [ADDRESS_892267]  ................................ ................................ ................................ ......... 98 
10.5  Adverse Events and Study Report Requirements  ................................ ................... 98 
10.6  Records Retention  ................................ ................................ ................................ ...98 
10.7  Publications  ................................ ................................ ................................ ............. 98 
11 Study Managem ent ................................ ................................ ................................ ........... 99 
11.1  Monitoring  ................................ ................................ ................................ .............. 99 
11.1.1  External Data Monitoring Committee  ................................ ..................... 99 
11.1.2  Monitoring of the Study  ................................ ................................ ........... 99 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.[ADDRESS_892268] ................................ ................................ ................................ ................. 102 
13 Appendices  ................................ ................................ ................................ ..................... 104 
13.1  Appendix 1: S lit Lamp Examination - Grading Scale  ................................ .......... 104 
13.2  Appendix 2: Assessment of Vitreous Cells - Grading Scale  ................................ .[ADDRESS_892269] of Tables  
Table  5-1: Prohibited Medications  ................................ ................................ ...................  52 
Table  6-1: Schedule of Events  ................................ ................................ ..........................  55 
Table  6-2: Clinical Laboratory Evaluations  ................................ ................................ ..... 77 
Table  6-3: Sampling Window  ................................ ................................ ...........................  [ADDRESS_892270] of Figures  
Figure 3 -1: Study Schema ................................ ................................ ................................ .. 33 
 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 9 Protocol Synopsis  
Protocol N umber:  SCD411 -CP101  
Title:  A Phase III Randomized, Double -Masked, Parallel -Group, 
Multicenter Study to Compare the Efficacy, Safety, Tolerability, 
Pharmacokinetics , and Immunogenicity between SCD411 and 
Eylea® in Subjects with Neovascular Age -related Macular 
Degeneration  
Sponsor:  SamChunDang Pharm. Co. Ltd.  
351, Hyoryeong -ro, Seocho -gu, Seoul [ZIP_CODE], Republic of Korea  
Study Phase:  Phase  III 
Study S ites: Approximately 155 study sites and 14 countries  
Indication:  Neovascular Age -related Macular Degeneration  
Rationale:  SCD411 is being developed as a biosimila r to the reference product 
Eylea® (aflibercept) . Based on the proposed extensive analytical 
comparability testing, comparative nonclinical testing, and 
comparative clinical studies  using the same licensed reference 
product, the current study is designed to  evaluate comparability 
between SCD411 and aflibercept. Based on the data from 
aflibercept clinical studies VIEW 1, VIEW 2, COPERNICUS, 
GALILEO, VIBRANT, VIVID, VISTA, and MYRROR, wet age-
related macular degeneration ( AMD ) is considered as the most 
suitable condition to prove similarity between SCD411 and 
aflibercept as the reference product.  
The available data regarding the pharmacokinetics (PK) of the 
reference product suggests that a proper PK characterization will not 
be po ssible after single intravitreal (IVT) administration. In a PK 
substudy of Eylea in 6 neovascular wet AMD patients with frequent 
sampling, maximum plasma concentrations  (Cmax) of free 
aflibercept (systemic) were low, with a mean of approximately 
0.02 µg/m L (range 0 to 0.054) within [ADDRESS_892271] dose s of SCD411.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 10 As aflibercept is a therapeutic protein, there is a potential for 
immun ogenicity. No case s of active neutralizing antibodies (NAb) 
were observed  after administration of Eylea. It is evident that 
immunogenicity is not presenting a substantial safety concern in 
patients treated with aflibercept injections. There was no substant ial 
difference in the proportion of patients test ing positive for anti-drug 
antibodies (ADA)  in different indications, including wet AMD. 
Based on this observation, the indication chosen for this study  is 
expected to provide sound data for comparing the im munogenicity 
of the test product (SCD411) with that of Eylea.  
The clinical part of the comparison will be based on clinical efficacy 
and safety data obtained after IVT administration to subjects with 
wet AMD in the current pi[INVESTIGATOR_2397] . 
Objectives:  The primary objective of this study is:  
• To prove the equivalence of SCD411 as compared to Eylea 
(aflibercept) in best corrected visual acuity (BCV A) after 
8 weeks of treatment among subjects with wet AMD . 
The secondary objectives of this study are:  
• To compare the safety and tolerability of SCD411 and 
aflibercept  
• To compare the efficacy of SCD411 and aflibercept after 
8 weeks and 52 weeks of treatment demonstrated  by [CONTACT_661550] A, 
central retinal thickness (CRT), and choroidal 
neovascularization (C NV) 
• To compare the immunogenicity of SCD411 and aflibercept 
by [CONTACT_661551] -
SCD411  antibodies.  
The exploratory objective s of this study are: 
• To compare PK parameters of SCD411 and aflibercept  
• To quantif y free and bound aflibercept and SCD411.  
Estimands:  The primary estimand for the primary objective is the mean 
treatment difference in BCV A change from baseline at Week  8. At 
Week  52, the primary estimand of interest is the mean treatment 
difference in BCV A change from baseline at Week  52. For the 
primary estimand, any observations post receipt of rescue therapy  in 
the study eye will be set to missing, thereby  [CONTACT_661552] . For each of 
the Week  [ADDRESS_892272] rescue will not be set to missing but will be 
included in the mixed -effects  model for repeated measures 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 11 (MMRM ) analysis. The secondary estimands are constructed to 
estimate the treatment effect while including the impact of rescue 
therapy , which may better reflect actual real -world outcomes , where 
rescue therapy  would likely be given when lack of efficacy is seen.  
Study Population:  Each subject must meet all of the following inclusion criteria to be 
enrolled in this study:  
1. Capable of understanding the written informed consent, provides 
signed and witnessed written informed consent, and agrees to 
comply with pro tocol requirements  
2. Age ≥50 years  
3. Active choroidal subfoveal, juxtafoveal, or extrafoveal 
neovascularization lesions secondary to AMD evidenced by 
[CONTACT_228628] (FA)  in the study eye at screening and 
confirmed by [CONTACT_73475]  
4. The BCVA letter score of 73 to 35 using original series Early 
Treatment Diabetic Retinopathy Study (ETDRS) charts or 2702 
series number charts in the study eye at screening and at Week  0 
(Day  1) prior to randomization. In addition, fellow eye should not 
be less than [ADDRESS_892273] injection of aflibercept/SCD411  
6. Males with female partners of child -bearing  potential must agree 
to use protocol -defined methods of contraception and agree to 
refrain from donating sperm throughout the study until [ADDRESS_892274] injection of aflibercept/SCD411 . 
7. The area of CNV making up either 50% or more of the total 
lesion area and confirmed by [CONTACT_661553]:  
1. Any prior ocular (in the study eye and fellow eye) or systemic 
treatment or surgery for neovascular AMD except dietary 
supplem ents or vitamins  
2. Any prior or concomitant therapy with another investigational 
agent to treat neovascular AMD in the study eye, except dietary 
supplements or vitamins  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 12 3. Fellow eye shows signs of AMD that, in investigator ’s medical 
opi[INVESTIGATOR_1649], may need any  treatment during study period  
4. Any prior treatment with anti -vascular endothelial growth factor 
(VEGF) agents in the both eyes (ie, completely treatment naïve 
subjects only to be included)  
5. Total lesion size >30.5 mm2, including blood, scars, atrophy,  
fibrosis,  and neovascularization as assessed by [CONTACT_661554]  
6. Central retina thickness of <300 µm in the study eye and 
confirmed by [CONTACT_73475]  
7. Subretinal hemorrhage that is either 50%  or more of the total 
lesion area, or if the blood is under the fovea and is 1 or more disc 
areas in size in the study eye and confirmed by [CONTACT_178842] . (If the blood is under the fovea, then the fovea must be 
surrounded 270  degrees by [CONTACT_661555] .) 
8. Scar or fibrosis, making up >50% of the total lesion in the study 
eye and confirmed by [CONTACT_73475]  
9. Scar, fibrosis, or atrophy involving the center of the fovea in the 
study eye and confirmed by [CONTACT_73475]  
10. P resence of retinal pi[INVESTIGATOR_661520]  
11. Lens Opacity Classification System II (LOCS II) grade IV 
cataract  in the study eye , or other significant cataract in the study 
eye that in the Investigator’s  opi[INVESTIGATOR_661521]  
12. Active intraocular/periocular infection and  inflammation in 
either eye  
13. History of any vitreous hemorrhage in the study eye wi thin 
4 weeks prior to the Screening Visit  
14. Presence of other causes of CNV in the study eye as confirmed 
by [CONTACT_491195]  
15. History or clinical evidence of diabetic retinopathy, diabetic 
macular edema , or any other vascular disease affecting the retina, 
other than AMD, in either eye  
16. Prior vitrectomy in the study eye  
17. History of retinal detachment, treatment, or surgery for retinal 
detachment in the study eye  
18. History of macular hole of Stage 2 and above in the study eye as 
confirmed by [CONTACT_661556]. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.[ADDRESS_892275] within 1 month of Day  1 
Note: A subject with uncomplicated neodymium yttrium aluminum 
garnet (Nd:YAG) laser capsulotomy performed for secondary 
opacification of the posterior capsule in intraocular lens  implanted 
eye within 3  months prior to Day 1 in the study eye will be 
conside red as eligible.  
20. Presence of aphakia in the study eye.  
21. History of glaucoma -filtering surgery within 3  months of Day 1 
in the study eye.  Anti-glaucoma laser surgeries will not be 
considered exclusionary.  
22. History of corneal transplant in the stud y eye.  
23. History or evidence of any other clinically significant disorder, 
condition or disease (eg, co -existence of retinal vein occlusion, 
radiation retinopathy, diabetic retinopathy, glaucoma under 
treatment) in the study eye that, in the opi[INVESTIGATOR_1101] t he investigator, 
would pose a risk to subject safety or interfere with the study 
evaluation, procedure or complication  
24. Uncontrolled hypertension defined as systolic blood pressure 
(BP) > 160 mmHg or diastolic BP >100 mmHg under appropriate 
antihypertens ive treatment  
25. Hypersensitivity to aflibercept or medications used in this study 
(fluorescein, mydriatic eye drops, etc.)  
26. Pregnancy or lactation at the Screening Visit and/or at baseline 
for women of child -bearing  potential  
27. Any contraindication to IVT injection according to the 
investigator’s clinical judgment  
28. History of thrombotic events (eg, stroke, transient ischemic 
attacks, pulmonary embolism, deep vein thrombosis, or myocardial 
infarction)  
29. History or evidence of cardiac conditions w ith congestive 
cardiac failure result ing in marked limitation on physical activity or 
inability to perform any physical activity without discomfort ; 
subjects  with ventricular arrhythmia requiring ongoing treatment; or 
subjects  with atrial fibrillation  
30. History of laser therapy in the macular region in the study eye  
31. Any prior or concomitant treatment with IVT corticosteroids 
injection, IVT corticosteroid implant, subtenon corticosteroids, or 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 14 peribulbar corticosteroids in the study eye 6  months before the 
Screening Visit  
Note: For IVT corticosteroid implant, the exclusion period would be 
36 months  from the date of the procedure to the date of screening  
32. Any prior or concomitant treatment involving the macula with 
photodynamic therapy with verteporfin , transpupi[INVESTIGATOR_178717], radiation therapy, or retinal laser treatment (eg, focal 
laser photocoagulation) in the study eye  
33. Any prior or concomitant treatment with pan -retinal 
photocoagulation 90  days in the study eye before the Screening Visit  
34. Any concomitant or prior treatment with ethambutol (2  weeks 
prior to randomization ); deferoxamine and topi[INVESTIGATOR_052] (4  weeks 
prior to randomization ); tamoxifen, hydroxychloroquine, 
chloroquine, or vigabatrin (8  weeks prior to randomization ), and 
amiodarone  (12 weeks prior to randomization ) 
35. Any investigational product for the treatment of ocular 
conditions (in either eye) and systemic conditions 30  days or 5  half-
lives (whichever is longer), prior to randomization , and throughout 
the study, except dietary supplements or vitamins  
36. Intraoc ular pressure ≥25 mmHg in spi[INVESTIGATOR_109786] -glaucoma 
treatment  
37. Any prior or ongoing systemic medical condition (including but 
not limited to infectious, inflammatory, psychiatric, neurological, 
renal, hepatic, respi[INVESTIGATOR_661522]) or cli nically 
significant screening laboratory value that in the opi[INVESTIGATOR_661523] a safety risk, interfere with study 
compliance and follow -up, or confound data interpretation 
throughout the study period.  
Study Design:  This is a Phase  III, randomized, double -masked , parallel -group, 
multicenter  study  to demonstrate biosimilarity of SCD411 compared 
to Eylea (aflibercept) among adult subjects with neovascular ( wet) 
AMD. Subjects will be randomly assigned  in 1:[ADDRESS_892276] 
IVT injection on Day  1 and subsequent IVT injection on Weeks 4, 8, 
16, 24, 32, 40, and 48. The End -of-Treatment (EOT) Visit will be 
scheduled for Week  48. Subjects who discontinue the study 
treatment early should have the reasons for treatment 
discontinuation documented on the Treatment Discontin uation page 
of the electronic case report form ( eCRF ). Treatment 
discontinuation in the study is defined as subjects discontinuing the 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 15 study treatment due to adverse even t/lack of efficacy/rescue 
treatment but not limited to th ese conditions. Every effort should be 
made to have  such subjects remain in the study and continue with 
their regularly  scheduled visits and assessments until Week  [ADDRESS_892277] should be prematurely withdrawn  from the study , then the 
Early Termination (ET) Visit should be completed as soon as 
possible after discontinuing the study treatment but no later than 28 
days after discontinuation. The End-of-Study (EOS) Visit will occur 
[ADDRESS_892278] management and study assessments will be 
masked to study treatment assignment.  The investigator  involved in 
performing the IVT injections will be unmasked to study treatment.  
Estimated Study 
Duration:  The total study duration is approximately 55  weeks, including a 
screening duration up to 3 weeks, treatment duration up to 
48 weeks, and a follow -up duration up to 4 weeks.  
Efficacy 
Assessments:  Efficacy will be summarized for the study eye only.  
Primary endpoint:  
• Change from baseline in BCV A as measured by [CONTACT_661557] 2702 chart s at Week 8 . 
Secondary endpoints:  
• Change from baseline in BCV A as measured by [CONTACT_661558] 2702 chart s at Week 52  
• Change from baseline in CRT at Week 8 as assessed by 
[CONTACT_7349] ( OCT ) 
• Change from baseline in CRT at Week [ADDRESS_892279]  
• Change from baseline in CNV area at Week 8  
• Change from baseline in CNV area at Week 52  
• Percentage of subjects who gain at least 15  letters in BCV A 
as measured by [CONTACT_661559] 2702 chart s compared 
with baseline at Week  8 
• Percentage of subjects who gain at least 15 letters in BCV A 
as measured by [CONTACT_661559] 2702 chart s compa red 
with baseline at Week  52. 
Pharmacokinetic 
Assessments:  Pharmacokinetic  parameters include area under the concentration -
time curve from time zero to the last quantifiable time point (AUC 0-
t), AUC from zero to the end of the dosing period (AUC 0-tau), AUC 
from zero to infinite time (AUC 0-inf), C max, time to reach maximum 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 16 plasma  concentration (t max), and elimination half -life (t 1/2), of 
SCD411 and aflibercept . Quantification of free and bound 
aflibercept and SCD411 in plasma  will be performed using blood  
samples at predose and at + 1 day, +3 days, +7 days, +14 days, and 
+[ADDRESS_892280] (Day  1) and third (Week  8) doses.  
Immunogenicity 
Assessments:  Immunogenicity assessments and endpoints include the evaluation 
of development of anti -SCD411  or anti -aflibercept antibodies using 
blood samples taken at Baseline, at Weeks 4, 8, 20, 36, and 52.  The 
samples will be evaluated for titer of anti -SCD411 or 
anti-aflibercept antibodies.  
Neutralizing antibodies will be tested when ADA results are 
confirmed to be  positive.  
Safety 
Assessments:  Safety endpoints include adverse events (AEs), vital signs, and 
laboratory assessments up to Week  52. Safety is also evaluated 
during follow -up (4 weeks after EOT). If a subject is discontinued 
from the study, all the ET Visit procedures should be performed 
even if they are outside the allowed study window.  
Study Drug, 
Dosage, and Route 
of Administration:  One IVT injection containing 2 mg dose of either SCD411 or 
aflibercept (as per randomization) every 4  weeks for 3  consecutive 
doses, followed by 1  injection every 8  weeks.  
Rescue Treatment  In the study eye, r escue treatment for neovascular AMD is not 
permitted at any point in time . If it is observed that efficacy is not 
achieved by [CONTACT_104841], as determined by [CONTACT_093] , 
subjects can be considered for rescue treatment after Week  4 if any 
1 of the following conditions are met as assessed by [CONTACT_661560]:  
• Decrease of visual acuity letter score of [ADDRESS_892281] as sessment and/or  
• An increase in intraretinal fluid, subretinal fluid, or 
subretinal hyper -reflective material, that in the investigator’s 
opi[INVESTIGATOR_661524]’s neovascular 
AMD . 
Subjects who  will receive rescue treatment need to discontinue the 
study treatment and should have the reason for treatment 
discontinuation documented on the Treatment Discontinuation page 
of the eCRF and continue with their regularly  scheduled visits  and 
assessments until Week [ADDRESS_892282] should be prematurely 
withdraw n from the study , then the ET Visit should be completed as 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 17 soon as possible after discontinuing the study  treatment but no later 
than 28 days after discontinuation . 
Sample Size:  The equivalence margin agreed upon with European Medicines 
Agency (EMA) and Pharmaceuticals and Medical Devices Agency 
(PMDA) was determined using the data presented from MARINA 
(and ANCHOR) and VIEW studies. The data w ere used to estimate 
the efficacy of aflibercept compared to the placebo treatment in 
subjects with wet AMD. It was shown that in MARINA, subjects on 
average lost 2.[ADDRESS_892283] compa red to the 
placebo would be estimated as approximately 9.3 to 10 letters. A 
margin of 3.8  letters would be translated to a preservation of 59% to 
62% of the difference between Eylea and sham  and is less than a 
1 line change in visual acuity . Equivalence di scussions for EMA and 
PMDA were based upon a 95% confidence interval ( CI) approach or 
2 one-sided tests (TOST) at the α=0.025 level.  
The US Food and Drug Administration (FDA) requested a tighter 
equivalence margin of 3  letters but agreed equivalence can be  
determined from a 90% CI approach (equivalent to TOST at the 
α=0.05 level).  
Standard deviation (SD) for the mean change from baseline at early 
visits (Weeks 4 to 12) based on observed data for the full analysis 
set (FAS) ranged from and 8.[ADDRESS_892284] 80% power for the FDA, EMA, and PMDA 
analyses for the range of SD considered when using TOST  on data 
from a parallel -group design. For the FDA analysis based on 
equivalence lim its of -3.0 and 3.0 letters, α=0.05 significance level 
(90% CI), assuming the true difference between the means is 0.0, 
power of 91% is achieved for SD of 10.4 letters and power of 80% 
is achieved for SD of 11.8 letters. For the EMA and PMDA analyses 
based  on equivalence limits of -3.8 and 3.8  letters, α=0.025 
significance level (95% CI), assuming the true difference between 
the means is 0.0, power of 98% is achieved for SD of 10.4 letters 
and power of 92% is achieved for SD of 11.8 letters when sample 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 18 size is 266 per treatment arm. Considering approximately  5% loss 
from randomization  through Week 8, the total sample size required 
is 560.  
A subset of 4 0 subjects (2 0 per group) will be selected for collection 
of PK samples. The sample size is not test-driven since no 
equivalence test will be performed for PK parameters.  
Analysis Sets  The following analysis sets will be used in the statistical analyses:  
Full Analysis Set (FAS):  All randomized subjects who receive d at 
least 1 injection of the study drug.  
Modified FAS (mFAS) : All randomized subjects who received at 
least [ADDRESS_892285] 1 postbaseline 
BCV A assessment in the study eye.  
Per-protocol Set (PPS):  All subjects in the FAS, excluding those 
with significant protocol violations.  
Safety Set (SAF):  All subjects receiving at least 1  injection of the 
study drug.  
Pharmacokinetic Analysis Set (PK Set):  The subset of subjects in 
FAS who have sufficient evaluable blood samples to be included in 
the PK Set.  
The primary set  for efficacy analysis will be the FAS; however, for 
the EMA submission, the primary efficacy endpoint must meet 
equivalence for both the FAS and PPS. PMDA also requires an 
efficacy analysis to be conducted based on the mFAS without 
multiple impu tation  (MI)  as a supportive analysis . The SAF will be 
the primary analysis set for safety, tolerability, and immunogenicity 
analyses.  
Efficacy will be assessed for the study eye only.  
Statistical 
Methods:  Primary Analysis:  
The primary analysis of the chan ge from baseline in BCV A as 
measured by [CONTACT_661561] 2702 chart s through 8 weeks of 
treatment will be performed via MMRM including data for the 
Week 4 and Week 8 visits . The model will include the change from 
baseline as the dependent variable; tr eatment , visit,  and visit -by-
treatment  as fixed effects,  and baseline BCV A as a covariate. 
Equivalence will be determined if the upper and lower CI limits for 
the difference between treatments are within the equivalence 
margins.  
The primary null hypothesis  (H0) and alternative hypothesis (H1) 
are: 
H0: ∆ ≥M or ∆ ≤ -M 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 19 H1: -M< ∆ <M  
where ∆ indicates the mean difference between the 2  treatment 
groups in the change from baseline in ETDRS letter score or 2702 
chart s at Week 8 and M represents the equivalence margin.  
Based on discussions with regulatory agencies, separate  equivalence 
CIs and equivalence margins will be used for FDA submissions  and 
other regulatory agencies  versus submissions to EMA  and PMDA.  
For the FDA submission  and other regulatory agencies , a 90% CI 
(equivalent to TOST  evaluated at an α of 0.05) will be assessed 
using an equivalence margin of 3 letters. For the EMA  and PMDA, 
a 95% CI (equivalent to TOST  evaluated at an α of 0.025) will be 
assessed using an equivalence margin of 3.8 letters.  Other regulatory 
submissions are assumed to follow the FDA guidance.  
Estimates  of the treatment difference and corresponding 90% (FDA  
and other countr ies) and 95% (EMA/PMDA) CIs will be provided. 
The primary analysis set for the FDA , PMDA , and any other  
submissions will be the FAS. Fo r the EMA submission, both the 
FAS and PPS are considered primary analysis and equivalence will 
need to be shown for both analysis sets. The analysis will be 
performed using multiple imputed data under the missing at random 
(MAR) assumption. The primary an alysis will set post  rescue 
assessments to missing prior to the MI procedure.  
 
Secondary Analyses:  
The estimated mean treatment difference in the change from 
baseline in BCV A as measured by [CONTACT_661559] 2702 
chart s through 52 weeks along with the  corresponding 90% and 
95% C Is from the same MMRM model as used in the primary 
analysis but including data from all weeks through Week [ADDRESS_892286] or 
change from baseline in CNV will be based on the MMRM model 
similar to the one used for the analysis of change from baseline in 
BCV A, with the corresponding 95% CI for the estimates of 
treatment differences at Week 8 and Week 52 presented. Raw values 
and changes from baseline will be summarized by [CONTACT_661562]. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 20 using descriptive statistics.  Data after the receipt of rescue  therapy 
will be set t o missing prior to the MMRM analysis.  Multiple 
imputation will not be performed , and no sensitivity analyses will be 
performed . 
The percentage of subjects who gain ≥15 letters in BCV A as 
measured by [CONTACT_661559] 2702 chart s at postbaseline 
visits (Week  8 and Week 52) compared with baseline will be 
summarized and 95% CI for the proportions in each treatment arm 
and difference in proportions between treatment arms will be 
presented. For subjects who have missing assessments at 
corresponding postbasel ine visits  or who received rescue therapy 
prior to a visit will be assumed to have a gain of <15 letters in 
BCV A (eg, nonresponder imputation).  No sensitivity analyses will 
be performed.  
 
Safety Analyses  
An overall summary of AEs will be presented, and treatment -
emergent AEs will be summarized by [CONTACT_39812]. Results of the following safety evaluations will be 
summarized with observed values and change from baseline: vital 
signs, ECGs, laboratory examinations including chemistry, 
hematology, and urinalysis. The results of slit lamp examination, 
dilated fundoscopy, intraocular pressure , and vision check will be 
summarized using descriptive statistics at each visit and applicable 
time point, as applicable.  
 
Pharmacokinetic Analysis  
The PK parameters (AUC 0-t, AUC 0-tau, AUC 0-inf, Cmax, tmax, t1/2) from 
the 2  treatment groups will be summarized using n, arithmetic mean, 
percent coefficient of variation (% CV), geometric mean, geometric 
%CV , SD, median, minimum and maximum values in the PK 
analysis set.  
 
Immunogenicity Analysis  
The analysis on immunogenicity will be descriptive. Results will be 
summarized with observed values and change from baseline for 
ADA titers (in log scale) by [CONTACT_661563]. The 
number and proportion of ADA -positive subjects and ADA -negative 
subjects will be summarized by [CONTACT_661564].  NAb  will be tested when ADA results are confirmed to 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.[ADDRESS_892287] enrollment and data cleaning/programming 
activities.  
Version and Date 
of Protocol:  Version 3.0 
24 Jan uary 2022 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.[ADDRESS_892288] research organization  
CRT  central retinal thickness  
CV coefficient of variation  
DME  diabetic macular edema  
ECG  electrocardiogram  
EDC  Electronic Data Capture  
eCRF  electronic case report form  
EMA  European Medicines Agency  
EOS  end-of-study  
EOT  end-of-treatment  
ET early termination  
EU European Union  
ETDRS  Early Treatment Diabetic Retinopathy Study  
FA fluorescein angiography  
FAS full analysis set  
FDA  US Food and Drug Administration  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.[ADDRESS_892289]  optical coherence tomography  
OTC  over-the-counter  
PDT  photodynamic therapy  
PI [INVESTIGATOR_63168] (s) 
PlGF  placental growth factor  
PMDA  Pharmaceuticals and Medical Devices Agency  
PPS per-protocol set  
RVO  retinal vein occlusion  
SAE  serious adverse event  
SAF safety set 
SAP statistical analysis plan  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.[ADDRESS_892290] deviation  
S[LOCATION_003]R  suspected unexpected serious adverse reaction  
t1/[ADDRESS_892291]  2 one -sided tests  
VA visual acuity  
VEGF  vascular endothelial growth factor  
WHODRUG  World Health Organization Drug Dictionary  
 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 25 1 Introduction  
1.1 Background  
SCD411 is a proposed biosimilar of Eylea® having aflibercept as the active substance that 
binds to vascular endothelial growth factor A (VEGF -A) and produced in Chinese hamster 
ovary cells by [CONTACT_12060]. Aflibercept, the drug substance of Eylea, is a 
recombinant fusion protein con sisting of 2  identical polypeptide chains, each comprising the 
second Ig domain of the human vascular endothelial growth factor (VEGF) receptor  [ADDRESS_892292] Ig domain of the human VEGF receptor 2, with both polypeptide chains fused to the 
Fc domain of human IgG1 ( Avery et al 2017 ). 
Aflibercept acts as a soluble decoy receptor that binds VEGF -A and Placental Growth Factor 
(PlGF) with higher affinity than their natural receptors, and thereby [CONTACT_661565]  (Papadopoulos et al 2012 ). SCD411 is under 
development for the same indications approved for Eylea in [LOCATION_002] of America ([LOCATION_003]), 
European Union (EU), and Japan which are  neovascular (wet)  age-related macular 
degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy, macular edema 
following retinal vein occlusion (RVO) , and AMD  with subfoveal choroidal 
neovascularization (CNV)  (Eylea® 2019 ; European Medicines Agency 2018; Santen  2012 ). 
Neovascular (wet) AMD is characterized by [CONTACT_661566] . Leakage of blood and fluid 
from CNV may cause retinal thickening or edema and/or sub -/intra -retinal hemorrhage, 
resulting in loss of visual acuity (V A)  (Schneider et al 2005 ). 
Other drugs of this class include ranibizumab (Lucentis®) and pegapta nib sodium 
(Macugen®). However, aflibercept shows some differences over other VEGF blockers, 
enabling prolongation of the interval between 2  intravitreal (IVT) injections and a decrease 
of the number of injections needed by [CONTACT_661567]:  
• A higher affinity (~0.5 pM dissociation constant for VEGF165 and ~0.36 pM for 
VEGF121) than a humanized monoclonal antibody  (Papadopoulos et a l 2012 ; García -
Quintanilla et al 2019 ) 
• A longer circulating half -life compared to soluble receptor constructs which have 
been studied in animals  (García -Quintanilla et al 2019 ) 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 26 • A binding to the related angiogenic factors such as PlGF1 and PlGF2 (Dixon et al 
2009 ) and Galectin -1 (Kanda et al 2015 ), thought to be advantageous in certain 
disease situations, including retinal neovascularizations.  
The development of SCD411 involves stepwise similarity exercises starting with comparison 
of the structural characteristics, physicochemical properties, and biological activities, 
follow ed by a series of in vitro and in vivo nonclinical studies, followed by a Phase  III 
equivalence study  to demonstrate biosimilarity between SCD411 and Eylea.  
1.[ADDRESS_892293] articles of 500  L and 
2000  L batches to demonstrate similarity between SCD411 and Eylea, as follows:  
• In vivo repeated -dose toxicity study in cynomolgus monkeys of 13 weeks with a 
4-week recovery  period  was conducted. No SCD411 -related mortality occurred. No 
SCD411 - or Eylea-related macroscopic or microscopic observations or effects on 
organ weight parameters were noted.  
• A single -dose pharmacokinetic ( PK) study in pi[INVESTIGATOR_661525] 
[ADDRESS_892294] ( IP) was injected at the first stage followed by [CONTACT_661568] , a single -dose PK study was repeated in pi[INVESTIGATOR_661525] 
[ADDRESS_892295]. Eylea and SCD411 (free) exposu re is relatively similar in 
serum and vitreous humor.  There were no measurable concentrations of Eylea -VEGF 
complex in vitreous humor (right eye). Furthermore, there were no measurable 
concentrations of Eylea -VEGF complex or SCD411 -VEGF complex in serum an d no 
analytes measurable in vitreous humor left (eye not dosed). In order to secure safety 
in clinical studies , animal tests were conducted using [ADDRESS_892296] Eylea® (aflibercept) . 
Based on the proposed extensive analytical comparability testing, comparative nonclinical 
testing, and comparative clinical studies  using the same licensed reference product, the 
current study is designed to evaluate c omparability between SCD411 and aflibercept. Based 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.[ADDRESS_892297] suggests that a proper PK 
characterization will not be possible after single IVT administration. In a PK substudy of 
Eylea in 6 neovascular wet AMD patients with frequent sampling, maximum plasma 
concentrations (Cmax) of free afli bercept (systemic) were low, with a mean of approximately 
0.02 µg/m L (range 0 to 0.054) within [ADDRESS_892298] all patients  (Eylea® 2019 ). It is evident that 
in some cases no m easurable systemic levels of free aflibercept were registered after IVT 
administration. Hence, a comparative PK evaluation in patients with AMD will likely not 
provide any information of relevance to support biosimilarity. Although the systemic 
exposure of  SCD411 is expected to also be very low at steady state, there is no previous 
human data on SCD411, and thus this assumption requi res experimental support. Hence, PK 
assessment will be performed in the current study  following the first and the third dose s of 
SCD411.  
As aflibercept is a therapeutic protein, there is a potential for immunogenicity. No cases of 
active neutralizing antibodies (NAb) were observed after administration of Eylea. It is 
evident that immunogenicity is not presenting a substantial saf ety concern in patients treated 
with aflibercept injections. There was no substantial difference in the proportion of patients 
testing positive for anti-drug antibodies (ADA)  in different indications, including wet AMD  
(Eylea® 2019 ). Based on this observat ion, the indication chosen for this study  is expected to 
provide sound data for comparing the immunogenicity of the test product (SCD411) with that 
of Eylea.  
The clinical part of the comparison will be based on clinical efficacy and safety data obtained 
after IVT administration to subjects with wet AMD in the current pi[INVESTIGATOR_2397] . 
1.4 Benefit -risk Assessment  
More detailed information about the known and expected b enefits and risks and reasonably 
expected adverse events (AEs) of SCD411 may be found in the investigator’s brochure.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 28 2 Study Objectives , Estimands,  and Endpoints  
2.1 Primary Objective  
The primary objective of this study  is: 
• To prove the equivalence of SCD411 as compared to Eylea (aflibercept) in best 
corrected visual acuity (BCV A) after 8 weeks of treatment among subjects with wet 
AMD  
2.2 Secondary Objective s 
The secondary objective s of this study are: 
• To compare the safety and tolerability of SCD411 and af libercept  
• To compare the efficacy of SCD411 and aflibercept after 8  weeks and 52 weeks of 
treatment demonstrated by [CONTACT_661550] A, central retinal thickness (CRT), and CNV  
• To compare the immunogenicity of SCD411 and aflibercept by [CONTACT_661569] -SCD411  antibodies  
2.3 Exploratory Objective s 
The exploratory  objective s of this study are: 
• To compare PK parameters of SCD411 and aflibercept  
• To quantif y free and bound aflibercept and SCD411.  
2.4 Endpoints  
Efficacy will be summarized for the study  eye only.  
2.4.1 Primary Endpoint  
• Change from baseline in BCV A as measured by [CONTACT_661570]  (ETDRS ) letters score or 2702 chart s at Week 8  
2.4.2 Secondary Endpoints  
• Safety endpoints include AEs, vital signs, and laboratory assessments up to Week 52 . 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 29 • Efficacy endpoints are:  
o Change from baseline in BCV A as measured by [CONTACT_661561] 
2702 chart s at Week 52 . 
o Change from baseline in CRT at Week 8 as assessed by [CONTACT_15503] (OCT) . 
o Change from baseline in CRT at Week [ADDRESS_892299] 15 letters in BCV A as measured 
by [CONTACT_661561] 2702 chart s compared with baseline at Week 52 . 
• Immunogenicity endpoints include the evaluation of development of anti -SCD411  or 
anti-aflibercept antibodies using blood samples taken at Baseline, at Weeks 4, 8, 20, 
36, and 52.  Neutralizing antibodies  will be tested when ADA results are confirmed to 
be positive.  
2.4.[ADDRESS_892300] 
quantifiable time point (AUC 0-t), AUC from zero to the end of the dosing period (AUC 0-tau), 
AUC from zero to infinite time (AUC 0-inf), Cmax, time to reach maximum plasma  
concentration (t max), and elimination half -life (t 1/2), of SCD411 and aflibercept. 
Quantification of free and bound aflibercept and SCD411 in plasma  will be performed using 
blood samples at predose , and at +1 day, +3 days, +7 days, +14 days, and +[ADDRESS_892301] dose . At Week 8 , PK samples  will be taken predose,  and at +1  day, +3  days, +7  days, 
+14 days, and +[ADDRESS_892302] (Week 8) dose  (Table  6-3). 
2.[ADDRESS_892303] is the mean 
treatment difference in BCV A change from baseline at Week 52.  For the primary estimand, 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.[ADDRESS_892304] rescue will not be set to missing but will be included in the mixed -effects model for 
repeated measures (MMRM ) analysis. The secondary estimands are co nstructed to estimate 
the treatment effect while including the impact of rescue therapy , which may better reflect 
actual real -world outcomes , where rescue therapy  would likely be given when lack of 
efficacy is seen.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 31 3 Investigational Plan  
3.1 Study Design  
This i s a Phase III, randomized, double -masked, parallel -group , multicenter  study  to 
demonstrate biosimilarity of SCD411 compared to Eylea (aflibercept) among adult subjects 
with neovascular ( wet) AMD.  
Approximately 560 subjects with wet AMD will be enrolled  in this study across 
approximately 155  sites in 1 4 countries. Upon  entry into the study, subjects will be assigned 
a screening number. Subjects who meet all inclusion and none of the exclusion criteria will 
return to the clinic on Day 1 for further evaluation. Subjects who continue to meet all 
inclusion and none of the exclusion cri teria will be randomly assigned  and treat ed on Day  1. 
At this visit, the subjects will be randomly assigned  in 1:[ADDRESS_892305] 3  injections and every 8 weeks thereafter until Week 48 as de tailed in the 
Schedule of Events ( Table  6-1). A schematic of the study design is presented in  Figure 3-1. 
The details of the implemen tation in Interactive Response Technology ( IRT) will be provided 
in the IRT manual and the randomization specification form.  
This study includes a screening duration up to  3 weeks, treatment duration up to  48 weeks, 
and follow -up duration up to  4 weeks; th us, the total duration of study participation is 
approximately up to 55 weeks.  
All subjects will be assessed once every 4 weeks as detailed in the Schedule of Events 
(Table  6-1). The End -of-Treatment (EOT) Visit will be scheduled for Week  48. Subjects who 
discontinue the study treatment early should have the reasons for treatment discontinuation 
documented on the Treatment Discontinuation page of the electronic case report form 
(eCRF ). Treatment discontinuation in the study is defined as subjects discontinuing the study 
treatment due to AE/lack of eff icacy/rescue treatment but not limited to these conditions. 
Every effort should be made to have such subjects remain in the study and continue with 
their regularly  scheduled visits and assessments until Week  [ADDRESS_892306] should be prematurely withdrawn  from the study , then the Early 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 32 Termination  (ET)  Visit should be completed as soon as possible after discontinuing the 
treatment but no later than 28 days  after discontinuation. The End-of-Study (EOS) Visit will 
occur [ADDRESS_892307] in the study.  
The study design incorporates an Independent Data Monitoring Committee (IDMC) that will 
review ongoing safety and will also make recommendations to the sponsor as described in 
the IDMC Charter. Details of the IDMC are given in Section  6.6. 
An interim analysis will be performed once approximately 200 subjects  complete the 
Week  52 Visit and all subjects complete the Week 24 Visit or discontinue early from the 
study . Details of the interim analysis are  given in Section  7.5.6 . 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
Page 33 Figure 3-1: Study Schema  
 
Abbreviations: EOS , end-of-study; EOT , end-of-treatment; ET, early termination; IVT, intravitreal . 
 

SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.[ADDRESS_892308], 
aflibercept.  
Selection of Doses in the Study  
Eylea has been approved for the treatm ent of wet AMD when administered as IVT injection 
of 2 mg (0. 05 mL) every 4 weeks (approximately every 28 days, monthly) for the first 
3 months, followed by 2 mg (0.05 m L) injection once every 8 weeks (2  months). This dosage 
has been found to be efficaciou s in subjects with wet AMD and has an acceptable safety 
profile.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.[ADDRESS_892309] meet all of the following criteria to be enrolled in this study:  
1. Capable of understanding the written informed consent, p rovides signed and witnessed 
written informed consent , and agrees to comply with protocol requirements . 
2. Age ≥50 years . 
3. Active choroidal subfoveal, juxtafoveal, or extrafoveal neovascularization  lesions 
secondary to AMD  evidenced by [CONTACT_661571] (FA)  in the study eye at 
screening and confirmed by [CONTACT_73475] . 
4. The BCV A letter score of 73 to 35 using original series ETDRS charts or 2702 series 
number charts in the study eye at screening and at Week 0 (Day 1) prior to 
randomi zation. In addition, fellow eye should not be less than [ADDRESS_892310] injection of aflibercept/SCD411  (Section  4.1.3  and 
Section  4.1.4 ). 
6. Males with female partners of child -bearing  potential must agree t o use 
protocol -defined methods of contraception and agree to refrain from donating sperm 
throughout the study until [ADDRESS_892311] injection of aflibercept/ SCD411.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 36 7. The area of CNV making up either 50% or more of the total lesion area and confirmed  
by [CONTACT_73475].  
4.1.2 Exclusion Criteria  
Subjects meeting any of the following criteria at the Screening Visit will be excluded from 
the study:  
1. Any prior ocular (in the study eye  and fellow eye ) or systemic treatment or surgery for 
neovascular AM D except dietary supplements or vitamins  
2. Any prior or concomitant therapy with another investigational agent to treat 
neovascular AMD in the study eye, except dietary supplements or vitamins  
3. Fellow eye shows signs of AMD that, in investigator ’s medical opi[INVESTIGATOR_1649], may need any 
treatment during study period  
4. Any prior treatment with anti -VEGF agents in the both eyes (ie, completely treatment 
naïve subjects only to be included)  
5. Total lesion size >30.5 mm2, including blood, scars , atrophy, fibrosis, and 
neovascularization as assessed by [CONTACT_661572]  
6. Central retina thickness of <300 µm in the study eye  and confirmed by [CONTACT_171124]  
7. Subretinal hemorrhage that is either 50% or more of the tota l lesion area, or if the 
blood is under the fovea and is 1 or more disc areas in size in the study eye  and 
confirmed by [CONTACT_73475] . (If the blood is under the fovea, then the fovea 
must be surrounded 270  degrees by [CONTACT_295690] .) 
8. Scar or fib rosis, making up >50% of  the total lesion in the study eye  and confirmed by 
[CONTACT_73475]  
9. Scar, fibrosis, or atrophy involving the center of the fovea in the study eye  and 
confirmed by  [CONTACT_73475]  
10. Presence of retinal pi[INVESTIGATOR_661526]. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 37 11. Lens Opacity Classification System II (LOCS II) grade IV cataract  in the study eye , or 
other significant cataract in the study eye that in the Investiga tor’s opi[INVESTIGATOR_661527]  
12. Active intraocular/periocular infection and  inflammation in either eye  
13. History of any vitreous hemorrhage in the study eye within [ADDRESS_892312] within 1 month 
of Day  1 
Note: A subject with uncomplicated neodymium yttrium aluminum garnet (Nd:YAG) 
laser capsulotomy performed for secondary opacification of the posterior capsule in 
intraocular lens  implanted eye within 3  months prior to Day  1 in the study eye will be 
considered as eligible.  
20. Presence of aphakia i n the study eye  
21. History of glaucoma -filtering surgery  within 3  months of Day 1  in the study eye.  Anti-
glaucoma laser surgeries will not be considered exclusionary.  
22. History of corneal transplant in the study eye  
23. History or evidence of any other clinically s ignificant disorder, condition or disease 
(eg, co -existence of RVO , radiation retinopathy, diabetic retinopathy, glaucoma under 
treatment) in the study eye that, in the opi[INVESTIGATOR_871], would pose a risk to 
subject safety or interfere with the study evaluation, procedure or complication  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 38 24. Uncontrolled hypertension defined as systolic blood pressure (BP)  >160 mmHg or 
diastolic BP >100 mmHg under appropriate antihypertensive treatment  
25. Hypersensitivity to aflibercept or medications used in this study  (fluorescein, 
mydriatic eye drops, etc.)  
26. Pregnancy or lactation at the Screening Visit and/or at baseline for women of 
child -bearing  potential  
27. Any contraindication to IVT injection according  to the investigator’s clinical judgment  
28. History of thrombotic events (eg, stroke, transient ischemic attacks, pulmonary 
embolism, deep vein thrombosis, or myocardial infarction)  
29. History or evidence  of cardiac conditions with congestive cardiac failure result ing in 
marked limitation on physical activity or inability to perform any physical activity 
without discomfort ; subjects  with ventricular arrhythmia requiring ongoing treatment; 
or subjects  with atrial fibrillation  
30. History of laser therapy in the macular region in the study eye  
31. Any prior or concomitant treatment with IVT corticosteroids injection , IVT 
corticosteroid implant, subtenon corticosteroids, or peribulbar corticosteroids  in the 
study eye  6 months before the Screening Visit  
Note: For IVT corticosteroid implant, the exclusion period would be 36 months  from 
the date of the procedure to the date of screening . 
32. Any prior or concomitant treatment involving the macula with photodynamic therapy 
(PDT) with verteporfin, transpupi[INVESTIGATOR_66284], radiation therapy, or retinal 
laser treatment (eg, focal laser photocoagulation)  in the study eye  
33. Any prior or concomita nt treatment with pan -retinal photocoagulation 90  days in the 
study eye before the Screening Visit  
34. Any concomitant or prior treatment with ethambutol (2  weeks prior to randomization ); 
deferoxamine and topi[INVESTIGATOR_052] (4  weeks prior to randomization ); tamoxifen,  
hydroxychloroquine, chloroquine, or vigabatrin (8  weeks prior to randomization ), and 
amiodarone (12  weeks prior to randomization ) 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 39 35. Any IP for the treatment of ocular conditions (in either eye)  and systemic conditions  
30 days or 5 half-lives (whichever is l onger ), prior to randomization, and throughout 
the study, except dietary supplements or vitamins  
36. Intraocular pressure ≥ 25 mmHg in spi[INVESTIGATOR_109786] -glaucoma treatment   
37. Any prior or ongoing systemic medical condition (including but not limited to 
infectious, in flammatory, psychiatric, neurological, renal, hepatic, respi[INVESTIGATOR_661528]) or clinically significant screening laboratory value that in 
the opi[INVESTIGATOR_661529] a safety risk, interfere with study 
compliance and follo w-up, or confound data interpretation throughout the study 
period.  
4.1.3 Women of Child -bearing  Potential  
Women of child -bearing  potential are defined as premenopausal women physiologically 
capable of becoming pregnant.  
Women of non -child -bearing  potential are d efined as women meeting any of the following 
criteria:  
• Older than 5 0 years with amenorrhea for >2  years or older than 60  years with 
amenorrhea for >1 year . In both  cases, f ollicle -stimulating hormone (FSH) and 
luteinizing hormone (LH) levels are performed at screening  to ensure these subjects 
are not pregnant . 
• Has undergone hysterectomy . 
• Has undergone bilateral oophorectomy . 
• Has undergone bilateral salpi[INVESTIGATOR_1656] . 
4.1.4 Approved Me thods of Contraception  
Appro ved methods of contraception include oral contraceptives, intrauterine device, 
medically acceptable barrier methods (diaphragm or condom), implantable or injectable 
contraceptives or removable birth control device, and/or steril ization. Subjects practicing 
abstinence and coitus interrupt us (pull out method) must agree to use an approved method of 
contraception during the study and until [ADDRESS_892313] injection.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 40 4.2 Selection of Study Eye  
Only one eye ( study eye) must meet  all the inclusion criteria and none of the exclusion 
criteria.  
Fello w eye should not show any signs of AMD that, in the investigator’s medical opi[INVESTIGATOR_1649], 
may need any treatment during study period.  
4.3 Withdrawal of Subjects From  Study Treatment and/or  the Study  
The duration of the study for each subject is defined as the date  the subject  signs the written 
informed consent form (ICF) up to the last EOS V isit, which is 28 days after the 
End-of-Treatment ( EOT ) Visit.  
Subjects may withdraw from the study at any time at his/her own request or may be 
withdrawn at any time at the discretion of the investigator and/or sponsor for safety, 
behavioral, or administrative reasons. If the subject withdraws consent for disclosure of 
future information, the sponsor may retain and continue to use any data collected before such 
a withdrawal of consent.  
4.3.1 Discontinuation From Study Treatment  
In rare instances, it may be necessary for a participant to permanently discontinue (definitive 
discontinuation) the study treatment. If the IP is definitively discontinued, the  Treatment 
Discontinuation page of the eCRF should be completed. Every effort should be made to have  
such subjects remain in the study and continue with their regularly schedu led visits  and 
assessments until Week  [ADDRESS_892314] should undergo ET Visit assessments 
as soon as possible after discontinuing the study treatment but no later than 28 days  after 
discontinuation, as described in the Schedule of Events  (Table  6-1).  
A subject  may discontinue from the study treatment for any of the following reasons : 
• Subject has a serious or intolerable AE that , in the investigator’s opi[INVESTIGATOR_1649] , requires 
discontinuation from the study treatment.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 41 • Decision by [CONTACT_661573].  
• Pregnancy.  
• A subject misses either  of the first 2  doses (IVT injection of IP at Week  0 [Day  1] or 
Week  4) after randomization.  
• Decision by [CONTACT_661574] a reason (eg, a suspi[INVESTIGATOR_661530], the subject enrolling in multiple clinical studies, lack of compliance) other than 
that of an AE. 
• Certain specific criteria for treatment discontinuation include:  
• Development of rhegmatogenous retinal detachment or stage 3 or 4 macular holes . 
• A decrease in BCV A of ≥[ADDRESS_892315] assessment of V A . 
• A subretinal hemorrhage involvin g the center of the fovea or if the size of the 
hemorrhage is ≥50% of the total lesion area . 
• Clinical signs of irreversible ischemic visual function loss.  
4.3.[ADDRESS_892316] may withdraw from the study for any of the following reasons:  
• Death. 
• Lost to follow -up. 
• Protocol deviation  which may adversely affect the subject’s safety and/or integrity of 
data as agreed by [CONTACT_1755]/or upon request from the Sponsor . 
• The subject has symptoms or an intercurrent illness not consistent with t he protocol 
requirements or that justify withdrawal . 
• The subject withdraws consent . 
• If a subject withdraws his/her consent, the investigator must inquire the reasons for 
consent withdrawal as to whether it is related to the study (eg, documented lack of 
efficacy, AE or pregnancy); however, the subject may refuse to provide such reason.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.[ADDRESS_892317] withdraws from the study  treatment or active 
participation in the study , the reason(s) for withdrawal shall be recorded by [CONTACT_661575].   
Every  effort should be made to have such subjects remain in the study and continue with 
their regularly scheduled visits  and assessments until Week  [ADDRESS_892318] discontinues the study treatment due to an 
AE/serious AE (SAE ) or if AEs/SAEs were ongoing at the time of discontinu ation, the 
subject will be followed -up until resolution or stabilization.   
4.3.4 Screen Failures  
Screen failures are defined as subjects who consent to participate in the clinical study but are 
not subsequently randomized to the study treatments. A minimal set o f screen failure 
information is required to ensure transparent reporting of screen failure subjects to meet the 
Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to 
respond to queries from regulatory authorities. Minimal info rmation includes demography, 
screen failure details, eligibility criteria, and any SAEs.  
Subjects who do not meet the criteria for participation in this study may not be rescreened . 
Image  retransmission requested from the central image center due to any possible technical 
issues  is not considered to be rescreening.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.[ADDRESS_892319] to follow -up if he/she repeatedly fails to return for 
scheduled visits and is unable to be contact[CONTACT_9298].  The following actions  must 
be taken if a subject fails to return to the clinic for a required study visit:  
• The site must attempt to contact [CONTACT_49878], counsel the subject on the importance of maintaining the assigned visit 
schedule and  ascertain whether or not the subject wishes to and/or should continue in 
the study  
• In cases in which the subject is deemed lost to follow -up, the investigator or designee 
must make every effort to regain contact [CONTACT_1155] (where possibl e, [ADDRESS_892320]’s last known mailing address or 
local equivalent methods). These contact [CONTACT_244181]’s medical record  
• Should the subject continue to be unreachable, he/she will be considered to have 
withdrawn from the study with a primary reason of lost to follow -up. 
4.3.[ADDRESS_892321] been 
collected (if required), and a study site closure visit has been performed. Reasons for study 
termination may i nclude, but are not limited to:  
• Medical or ethical reasons affecting the continued performance of the study  
• Difficulties in the recruitment of subjects  
• Cancellation of drug development.  
The investigator may initiate study site closure at any time, provided  there is reasonable 
cause and sufficient notice is given in advance of the intended termination. Reasons for the 
early closure of a study site by [CONTACT_135690], but are not limited to:  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 44 • Failure of the investigator to comply with t he protocol, the requirements of the 
institutional review board ( IRB)/ independent ethics committee ( IEC) or local health 
authorities, the sponsor's procedures, or Good Clinical Practice ( GCP ) guidelines  
• Inadequate recruitment of participants by [CONTACT_093].  
4.3.7 Replacements  
Dropout subjects will not be replaced in the study.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 45 5 Study Treatments  
5.1 Method of Assigning Subjects to Treatment Groups  
All subjects will be centrally randomized in a 1:1 ratio to recei ve SCD411 or aflibercept IVT 
injections at the baseline/randomization visit (Day  1) using IRT. Randomization will be 
stratified by [CONTACT_661576] (yes/no). Before the study is initiated, the log in 
information and directions for the IRT will be provided to each site. Only qualified study 
staff and those delegated the responsibility of study drug administration should administer 
the study drug injections.  
If a subject visits the site outside of the visit window for a dosing visit  until Week  8:  
• During the 4 -week intervals dosing: assessment and dosing can be done within a 
window of ±[ADDRESS_892322] IP dosing  window is out of  the 
allowed window interval , dosing should be skipped.  
• During the 8-week intervals  dosing: as sessment and dosing should be done within the 
window of ±7 days . In this case, the interval between the 2 doses should not be less 
than 49 days and not more than 63 days . 
Study treatment will be dispensed at the study visits summarized in  the Schedule of Events 
(Table  6-1). 
5.2 Treatments Administered  
Subjects who complete the study screening  and baseline  assessments and meet all the 
eligibility criteria will enter the study and will be randomly assigned  in a 1:1 ratio on Day  1 
to receive SCD411 or aflibercept. Details of study treatments that will be administered during 
the study are provided below in  Section  5.3. 
Subjects will receive their randomized study treatment injections as per the Schedule of 
Events ( Table  6-1) and according to the procedur e manual . Clinic staff involved in the 
injection tray assembly, anesthetic preparation, and study drug preparation and administration 
will follow appropriate aseptic techniques to minimize the risk of potential AEs associated 
with IVT injections.  If the pre-procedure IOP is equal to or greater  than 30  mmHg, the IVT 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 46 injection will not be administered  (either withheld or delayed) until the IOP is decreased to 
acceptable safety levels as per the investigator’s medical judg ment . 
The IVT injection procedure should be carried out under controlled aseptic conditions. 
Adequate anesthesia and a topi[INVESTIGATOR_191285] -spectrum microbicide and antibiotics can be given 
as per the system organ class in World Health Organization Drug Dictionary (WHODRUG) 
and this information should be recorded in the eCRF.  
Immediately following the IVT injection, subjects should be checked by [CONTACT_661577]/finger counting vision  for subject safety. The information will not be 
captured in the eCRF. If sub jects can recognize hand movement/finger counting vision 
immediately following the IVT injection, then the subjects should be transferred from the 
unmasked staff to the masked staff. If subjects cannot recognize hand movement/finger 
counting vision immedia tely following the IVT injection, then the unmasked staff should 
further investigate the reason. If required, a sterile paracentesis needle should be available for 
the injecting physician to ensure control of excessive IOP elevation . 
The safety data for IO P and dilated fundoscopy after administration of the study treatment 
will be  collected by [CONTACT_661578]. The information will be captured in the eCRF.  
Following the injection, the masked team will measure IOP and evaluate subjects  for any 
injection -related ophthalmic changes and AEs. 
Subjects should be instructed to report any symptoms suggestive of endophthalmitis  or 
retinal detachment (eg, eye pain, redness of the eye, photophobia, blurring of vision) without 
delay.  
Dosing visits will be allowed within ±[ADDRESS_892323] injections and within 
±7 days for the fourth injection onwards of the scheduled dosing visit date (except Week 0 
[Day 1], visit window not allowed). All applications outside of the specified windows will be 
captured a protocol deviation.  
5.2.[ADDRESS_892324] is newly 
diagnosed with neovascular AMD or has worsening neovascular AMD in the fellow eye . The 
fellow eye should be treated only with Eylea as per  investigator’s discretion . In this case,  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.[ADDRESS_892325] not be used. The glass vial is for  a single -use only. The 
study injections should be inspected visually prior to administration.  
The active sub stances are aflibercept and SCD411. One vial contains 100 µL, equivalent to 
4 mg aflibercept. One vial delivers a dose of 2 mg aflibercept in 50 µL.
 
Each vial should only be used for the treatment of a single eye. After injection, the used vial 
should be placed back within the box and resealed at the site to prevent unintentional 
unmasking.  
Manufacturer details of the study treatment and Eylea will be provided in the pharmacy 
manual.  
The following drug supplies will be used in the study:  

SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 48 Study Treatment Name:  [CONTACT_661643]411  Eylea (Aflibercept)  
Dosage Formulation:  Solution for intravitreal injection  Solution for intravitreal injection  
Unit Dose Strength(s)/  
Dosage Level(s):  Single -use vial containing 0.1 mL 
(40 mg/mL) aflibercept biosimilar  
solution  Single -use vial containing 0.1 mL 
(40 mg/mL) aflibercept  solution  
Route of 
Administration:  Intravitreal injection  Intravitreal injection  
Dosing Instructions:  0.05 mL  
of solution containing 2 mg  0.05 mL  
of solution containing 2 mg  
Packaging and 
Labeling:  Study injection formulations will be 
provided in vials in cartons. Each 
carton and vial will have the multi -
country booklet label along with them 
which follows regulatory 
requirements.  The current study will use EU -licensed 
Eylea as comparator d rug. Study 
injection formulations will be provided 
in vials  in cartons. Each carton and 
vial will have the multi -country 
booklet label along with them which 
follows regulatory requirements.  
5.4 Management of Clinical Supplies  
5.4.1 Study Drug Packaging and Storage  
Study treatment products should be stored in a refrigerator (2ºC to 8ºC) and should not be 
frozen. The vial should be kept in its outer carton in order to protect from light.  
5.4.[ADDRESS_892326] be promptly reported to the [COMPANY_003] Drug Safety Center. Overdoses without signs or 
symptom s do not need to be recorded as AEs; in case of any AEs associated with the 
overdose, these should be reported on relevant AE/SAE sections in the eCRF.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.[ADDRESS_892327] research 
organization ( CRO ), and imaging teams will also be masked to the study treatment. Only  the 
unmasked investigator  involved in performing the IVT injections will be unmasked to study 
treatment. These individuals are not allowed to discuss treatment and/or subject outcome 
with masked study staff, including the evaluating investi gator . 
5.6.[ADDRESS_892328]’s treatment assignment will not be broken until the end of the study unless medical 
treatment of the subject depends on knowing the study treatment the subject received.  In the 
event that the treatment assignment needs to be unma sked because of a medical emergency, 
the PI [INVESTIGATOR_661531]’s treatment allocation.  
The PI [INVESTIGATOR_661532] . The investigator should not share any un masked  information with the sponsor 
and monitoring team. The treatment assignment will be un masked  through IRT. Reasons for 
treatment un masking  must be clearly explained and ju stified in the eCRF. The date on which 
the code was broken along with the identity of the person responsible for breaking the code, 
must also be documented in the eCRF.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.[ADDRESS_892329]’s Day [ADDRESS_892330]’s eCRF. The minimum 
requirement is that drug name [CONTACT_160531]. This will 
include all prescription drugs, herbal products, vitamins, minerals, and over-the-counter 
(OTC ) medications. Any changes in concomitant me dications also will be recorded in the 
subject’s eCRF.  
Any concomitant medication deemed necessary for the welfare of the subject during the 
study may be given at the discretion of the investigator. However, it is the responsibility of 
the investigator to ensure that details regarding the medication are recorded in full in the 
eCRF.  Information on prior and c oncomitant medications is collected within 30 days prior to 
signing the ICF  or longer if the investigator considers relevant . Prohibited medications ar e 
collected from prior to duration of prohibition of use for this study  (Table  5-1). 
5.8.1 Rescue Treatment  
In the study eye, r escue treatment for neovascular AMD is not permitted at any point in time . 
If it is observed that efficacy is not achieved by [CONTACT_104841], as determined by [CONTACT_1275] , subjects can be considered for rescue treatment after Week  4 if any 1  of the 
following con ditions are met as assessed by [CONTACT_661579]:  
• Decrease of VA letter score of [ADDRESS_892331] assessment and/or  
• An increase in intraretinal fluid, subretinal fluid, or subretinal hyper -reflective 
material that , in the investigato r’s opi[INVESTIGATOR_1649] , is related to progression of the subject’s 
neovascular AMD  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.[ADDRESS_892332] should be 
prematurely withdrawn  from the study , then the ET Visit should be completed as soon as 
possible after discontinuing the study treatment but no later  than 28 days after 
discontinuation . 
5.8.2 Prohibited Medications  
The details of the prohib ited medications during the study are presented in  Table  5-1. 
Concurrent use of systemic or IVT anti-VEGF agents ; IVT, subtenon , or peribulbar  
corticoste roids in study eye are not permitted , except as required to treat AEs . 
In addition, the  use of photocoagulation or PDT with verteporfin are prohibited during the 
study. Antimicrobial drops can be used at the discretion of the investigator.
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
Page 52 Table  5-1: Prohibited Medications  
Medication/Therapy  Eye (Study Eye or Study Eye and Fellow Eye or Either)  Duration of Prohibition  
Ocular therapy/treatment list  
IVT anti -VEGF treatment to treat 
neovascular AMD  Study  eye 
Note: Treatment of fellow eye will be allowed  at any time during the 
study if  a subject has newly diagnosed neovascular AMD or 
worsening neovascular AMD in fellow eye . The fellow eye should be 
treated only with Eylea as per investigator’s discretion.  Ever before and to EOS/ET Visit  
IVT injection of c orticosteroids (eg, 
triamcinolone acetonide) or intravitreal  
- Corticosteroid implant  
-Subtenon corticosteroids  
-Peribulbar corticosteroids  Study eye  6 months before screening and 
throughout the study period  
 
For IVT corticosteroid implant, the 
exclusion period would be 36 months  
from the date of the procedure to the 
date of screening  
Treatment involving macula with PDT  with 
verteporfin, transpupi[INVESTIGATOR_66284], 
radiation therapy, or retinal laser treatment 
(eg, focal laser photocoagulation)  Study eye  Prior to screening and throughout the 
study period  
Treatment with pan -retinal photocoagulation  Study eye  90 days pr ior to screening and 
throughout the study period  
Systemic medications  
Systemic anti -VEGF agents  NA Within 90 days prior  to randomization  
and throughout the study  
Deferoxamine  NA 4 weeks prior to randomization  and 
throughout the study period  
Tamoxifen  NA 8 weeks before  randomization  and 
throughout the study period  
Hydroxychloroquine , 
Chloroquine  NA 8 weeks before randomization  and 
throughout the study period  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
Page 53 Medication/Therapy  Eye (Study Eye or Study Eye and Fellow Eye or Either)  Duration of Prohibition  
Vigabatrin  NA 8 weeks before randomization  and 
throughout the study period  
Ethambutol  NA 2 weeks before randomization  and 
throughout the study period  
Topi[INVESTIGATOR_661533] 4 weeks prior to randomization and 
throughout the study period  
Amiodarone  NA 12 weeks prior to randomization  and 
throughout the study period  
Other investigational products  
Systemic IP to treat neovascular AMD  NA Prior to screening and throughout the 
study period  
Ocular IP to treat neovascular AMD  Study eye and fellow eye  Prior to screening and throughout the 
study period  
Ocular IP to treat any ocular disease  Study eye and fellow eye  30 days or 5 half -lives prior to 
randomization  (whichever is longer ), 
and throughout the study period  
Systemic IP (excluding dietary supplements, 
vitamins and minerals) to treat systemic 
diseases  NA 30 days or 5 half -lives prior to 
randomization  (whichever is longer ), 
and throughout the study period  
Abbreviations: AE , adverse event; AMD , age-related macu lar degeneration; EOS , end-of-study; ET , early termination; IP , investigational product; IVT , 
intravitreal; NA , not applicable; PDT, photodynamic therapy; VEGF , vascular endothelial growth factor . 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.[ADDRESS_892333]. The investigator or designee will also sign 
the ICF.  
The Schedule of Events  is presented in  Table  6-1. 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
Page 55 Table  6-1: Schedule of Events  
Assessment  Screening  Treatment  ETa/EOSb 
Study Day  –21 to 0 Baseline/1  29 57 85 113 141 169 197 225 253 281 309 EOT /337 365 
Study Week  -3 1 4 8 12 16 20 24 28 32 36 40 44 48 52 
Visit Time Window (days)    ±2 ±2 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 
Study Visit  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
Informed consent  X               
Demographic information (incl. 
height and weight)  X               
Inclusion/exclusion criteria  X X              
Ocular and systemic medical 
history  X               
Slit lamp examinationc X X X X X X X X X X X X X X X 
Dilated fundoscopyd X X X X X X X X X X X X X X X 
Pregnancy teste X X             X 
Prior and concomitant ocular and 
systemic medicationsf X X X X X X X X X X X X X X X 
Randomizationg  X              
SCD411 or a flibercept injection h  X X X  X  X  X  X  X  
Pre-injection IOPi X X X X X X X X X X X X X X X 
Post-injection IOP and vision 
checki  X X X  X  X  X  X  X  
BCVAj X X X X X X X X X X X X X X X 
OCTk X X X X X X X X X X X X X X X 
FA and FPl X   X           X 
Laboratory assessmentsm X X X X   X        X 
Vital signsn X X X X X X X X X X X X X X X 
ECG X   X           X 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
Page 56 Assessment  Screening  Treatment  ETa/EOSb 
Study Day  –21 to 0 Baseline/1  29 57 85 113 141 169 197 225 253 281 309 EOT /337 365 
Study Week  -3 1 4 8 12 16 20 24 28 32 36 40 44 48 52 
Visit Time Window (days)    ±2 ±2 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 
Study Visit  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
AEs X X X X X X X X X X X X X X X 
Immunogenicity sampleso  X X X   X    X    X 
PK samplesp  X  X            
 
Abbreviations: AEs, adverse events; BCVA, best corrected visual acuity; ECG, electrocardiogram; EOS, end -of-study; EOT, end -of-treatment; ET, early termination;  FA, 
fluorescein angiography; FP, fundus photography; FSH, follicle -stimulating hormone; IOP, intraocular pressure; IVT, intravitreal; LH, luteinizing hormone; OCT, optical 
coherence tomography; PDT, photodynamic therapy; PK, pharmacokinetics; SAE, serious  adverse event; VA, visual acuity; VEGF, vascular endothelial growth factor.  
a For subjects who discontinue study treatment and choose to withdraw from the study or if, in the opi[INVESTIGATOR_871],  the subject should be prematurely withdrawn  
from th e study , ET Visit assessments are to be performed as soon as possible after discontinuing the study treatment but no later than 28 d ays after discontinuation . 
b End-of-study assessments are to be performed 28 days after the EOT.  
c Slit lamp examination will be performed on both eyes at all the planned scheduled visits during the study.  
d Dilated fundoscopy will be performed on the study eye at all the planned scheduled visits during the study, including the tim e prior to IVT injection of the study drug, and 
within 60±30 minutes after IVT injection of the study drug, and at any time during the visit at ET/EOS Visit.  
e Serum pregnancy test will be done at screening, and urine pregnancy test at baseline, ET, and EOS Visits  for female subjects of child -bearing potential. If urine pregnancy test 
is positive, serum pregnancy test should be performed; if found positive, study treatment will be discontinued, and the subje ct should continue with their regularly scheduled 
visits and assessments until Wee k [ADDRESS_892334] meets all inclusion and none of the exclusion criteria at both screening and D ay 1. This is inclusive of BCVA scoring.  
h Rescue treatment for the study eye is no t permitted at any point in time. Subjects can be considered for rescue treatment after Week 4 if the following conditions ar e met as 
assessed by [CONTACT_286823]: VA letter score decrease of [ADDRESS_892335] assessment, an increase in intraretinal fluid, subretinal fluid, or subretinal 
hyper -reflective material, that in the investigator’s opi[INVESTIGATOR_661524]’s neovascular AMD. Subjects who will receive rescue treatment need to 
discontinue the study treatm ent and should have the reason for treatment discontinuation documented on the Treatment Discontinuation page of the eCRF and continue with 
all their regularly scheduled visits and assessments until Week  [ADDRESS_892336] should be prematurely withdrawn  from the study , then the ET Visit should be completed as soon as possible after discontinuing the 
study treatment but no later than 28 days after discontinuation.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
Page 57 i Intraocular pressure will be measured on both eyes at screening,  and on the study eye prior to IVT injection of the study drug, and 60±30 mins after IVT injection of the study 
drug at each visit from baseline/Day 1 to EOT (48 weeks). If the pre -procedure IOP is equal to or greater than 30 mmHg, IVT injection will not be administered (either 
withheld or delayed) until IOP is decreased to acceptable safety levels as per investigator’s medical judg ment . IOP should be measu red after OCT and FA are completed to 
avoid corneal erosion. Finger counting test to be performed immediately after the IVT injection of the study drug. IOP will a lso be performed at any time during the ET/EOS 
Visit.  
j Best corrected VA testing will be don e for both eyes and should be performed prior to the dilation of pupi[INVESTIGATOR_8324], FA, and OCT assessments, and prior to the IVT inject ion of the 
study drug. B CVA  will also be performed at any time during the visit at ET/EOS Visit. A decrease in VA of ≥[ADDRESS_892337] assessment of VA should be reported as 
AEs/SAEs as appropriate. If there is a decrease in VA of ≥[ADDRESS_892338] device registered by [CONTACT_661580]  52 
(EOS visit) or ET Visit. 
l At screening, FA and FP will be performed on both eyes  and those images will be sent to the central reading center. At Week 8  and ET/EOS , FA and FP will be performed on 
the study eye (prior to IVT injection of the study drug  at Week 8 ). Those images will be sent to the central reading center. Site staff who will perform FA and FP in this study 
must be certified by [CONTACT_661581]. Only FP/FA devices certified by [CONTACT_491195] a re allowed t o be used in this study. If 1 or more 
FP/FA devices are certified at an investigational site, a subject must use the same FP/FA device consistently from Screening to Week 52 (EOS Visit) or ET Visit.  
m Hematology, chemistry, and urinalysis samples will be c ollected prior to IVT injection of the study drug. Urine samples will be collected prior to performing FA to avoid false 
elevations in urine protein values. No pregnancy test is required for women of non -child -bearing potential. For women of child -bearing potential, serum pregnancy test will be 
performed at screening and in case of a positive urine test during the study; urine pregnancy test will be performed at the Baseline, ET and EOS Visits; the FSH and LH levels 
to be measured at screening for women of child -bearing potential. Hematology, chemistry, and urinalysis samples will also be performed at any time during the visit at 
ET/EOS Visit.  
n Includes blood pressure, respi[INVESTIGATOR_697], heart rate, and temperature. On days when study injections will be admi nistered, vital signs should be measured prior to IVT 
injection of the study drug.  Vital signs  will also be performed at any time during the ET/EOS Visit.  
o Immunogenicity samples should be collected prior to IVT injection of the study drug and prior to FA  assessment when performed on the same day. Immunogenicity will also 
be performed at any time during the visit at ET/EOS Visit. N eutralizing antibodies  will be tested when anti-drug antibodies  results are confirmed to be positive.  
p Quantification of free and bound SCD411 and aflibercept will be performed for subjects who agree to participate in the PK substudy using blood sampl es at predose, and at 
+1 day, +3 days, +7 days, +14 days, and +[ADDRESS_892339] injection (Week  8). 
 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.[ADDRESS_892340] within 
21 days before the baseline/study treatment. The following information will be recorded and 
procedures will be performed at the Screening Visit:  
• Eligibility (inclusion/exclusion) criteria  
• Demographic information including height and weight  
• Ocular and systemic medical history  
• Prior  and concomitant  ocular and systemic medications  
• Vital signs  
• ECG  
• BCV A measured by [CONTACT_661559] 2702 charts  
• Slit lamp examinati on 
• Pre-injection IOP of both eyes  
• Dilated fundoscopy  
• OCT  
• FA 
• Fundus photography ( FP) 
• Laboratory assessments including hematology, chemistry, and urinalysis  
• Serum pregnancy test , FSH, and LH levels will be measured for women of 
child -bearing  potential  
• AEs 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 59 6.1.2 Treatment Phase  
[IP_ADDRESS]  Baseline  (Day 1)  
During the Day 1 Visit  at baseline , all inclusion/exclusion criteria should be reviewed prior to 
randomization and study treatment injection. Subjects  will be randomly assigned  to [ADDRESS_892341] 
treatment injection on Day 1.  
Assessments on Day  1 include the following:  
Ocular:  
• BCV A measured by [CONTACT_661559] 2702 chart s 
• Slit lamp examination  
• Pre-injection IOP  
• Dilated fundoscopy  
• OCT  
• Post-injection IOP and vision check  
The IOP is measured on both eyes at screening, and on the study eye prior to IV T injection of 
the study drug, and 60±30  mins after IV T injection of the study drug at each visit  from 
baseline/Day 1 to EOT (48 weeks) . The IOP is to be measured after OCT and FA are 
completed to avoid corneal erosion.  
Dilated f undoscopy is measured on the  study eye prior to IV T injection of the study drug and 
within 60±30 minutes after IV T injection of the study drug.  
Nonocular:  
• Concomitant ocular and systemic medications  
• Vital signs  
• Urine pregnancy test for female subjects of child -bearing  potential  
• Labor atory assessments including hematology, chemistry, and urinalysis  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 60 • AEs 
• Immunogenicity sample collection  
• PK sample collection . 
Other baseline assessments will be same as that for other visits as detailed in Section [IP_ADDRESS] . 
[IP_ADDRESS]  Subsequent Treatment  Period (Week 4, Week 8, Week  12, 
Week  16, Week 24, Week  28, Week 32, Week 40, Week  44, and 
Week 48)  
All study procedures should be performed on the same day . Following completion of the 
evaluations, the IV T injection will be administered on  the same day of every visit . Only in 
rare circumstances with reason well documented on the eCRF , the IV T injection may be 
administered the next day . 
Study treatment will b e injected on Week 4, Week 8, Week  16, Week  24, Week  32, Week 40, 
and Week 48.  
Week [ADDRESS_892342] critical visit for assessment of the primary endpoint assessment for US 
Food and Drug Administration (FDA), Japan Pharmaceuticals and Medical Devices Agency 
(PMDA), and European Medicines Agency (EMA) Committee on Human Medicinal 
Products submissions. Thus, every effort should be made to adhere to the visit schedule for 
the subjects.  
The following procedures/assessments will be performed and information will be  recorded 
during the treatment period:  
Week 4  
Ocular:  
• BCV A measured by [CONTACT_661559] 2702 chart s 
• Slit lamp examination  
• Pre-injection IOP  
• Dilated fundoscopy  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 61 • OCT  
• Post-injection IOP and vision check  
Nonocular:  
• Concomitant ocular and systemic medications  
• Vital signs  
• Laboratory assessments including hematology, chemistry, and urinalysis  
• AEs 
• Immunogenicity sample collection  
Week 8  
Ocular:  
• BCV A measured by [CONTACT_661559] 2702 chart s 
• Slit lamp examination  
• Pre-injection IOP  
• Dilated fundoscopy  
• OCT  
• FA 
• FP 
• Post-injection IOP and vision check  
Nonocular:  
• Concomitant ocular and systemic medications  
• Vital signs  
• Laboratory assessments including hematology, chemistry, and urinalysis  
• ECG  
• AEs 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 62 • Immunogenicity sample collection  
• PK sample collection  
Week 12  
Ocular:  
• BCV A measured by [CONTACT_661561] 2702 charts  
• Slit lamp examination  
• Pre-injection IOP  
• Dilated fundoscopy  
• OCT  
Nonocular:  
• Concomitant ocular and systemic medications  
• Vital signs  
• AEs 
Week 16  
Ocular:  
• BCV A measured by [CONTACT_661559] 2702 charts  
• Slit lamp examination  
• Pre-injection IOP  
• Dilated fundoscopy  
• OCT  
• Post-injection IOP and vision check  
Nonocular:  
• Concomitant ocular and systemic medications  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 63 • Vital signs  
• AEs 
Week 20:  
Ocular:  
• BCV A measured by [CONTACT_661561] 2702 charts  
• Slit lamp examination  
• Pre-injection IOP  
• Dilated fundoscopy  
• OCT  
Nonocular:  
• Concomitant ocular and systemic medications  
• Vital signs  
• Laboratory assessments including hematology, chemistry, and urinalysis  
• AEs 
• Immunogenicity sample collection  
Week 24  
Ocular: 
• BCV A measured by [CONTACT_661559] 2702 charts  
• Slit lamp examination  
• Pre-injection IOP  
• Dilated fundoscopy  
• OCT  
• Post-injection IOP and vision check  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 64 Nonocular:  
• Concomitant ocular and systemic medications  
• Vital signs  
• AEs 
Week 2 8 
Ocular:  
• BCV A measured by [CONTACT_661561] 2702 charts  
• Slit lamp examination  
• Pre-injection IOP  
• Dilated fundoscopy  
• OCT  
Nonocular:  
• Concomitant ocular and systemic medications  
• Vital signs  
• AEs 
Week 32  
Ocular:  
• BCV A measured by [CONTACT_661559] 2702 charts  
• Slit lamp examination  
• Pre-injection IOP  
• Dilated fundoscopy  
• OCT  
• Post-injection IOP and vision check  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 65 Nonocular:  
• Concomitant ocular and systemic medications  
• Vital signs  
• AEs 
Week 36  
Ocular:  
• BCV A measured by [CONTACT_661561] 2702 charts  
• Slit lamp examination  
• Pre-injection IOP  
• Dilated fundoscopy  
• OCT  
Nonocular:  
• Concomitant ocular and systemic medications  
• Vital signs  
• AEs 
• Immunogenicity sample collection  
Week 40  
Ocular:  
• BCV A measured by [CONTACT_661559] 2702 charts  
• Slit lamp examination  
• Pre-injection IOP  
• Dilated fundoscopy  
• OCT  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 66 • Post-injection IOP and vision check  
Nonocular:  
• Concomitant ocular and systemic medications  
• Vital signs  
• AEs 
Week 4 4 
Ocular:  
• BCV A measured by [CONTACT_661561] 2702 charts  
• Slit lamp examination  
• Pre-injection IOP  
• Dilated fundoscopy  
• OCT  
Nonocular:  
• Concomitant ocular and systemic medications  
• Vital signs  
• AEs 
Week 48  
Ocular:  
• BCV A measured by [CONTACT_661559] 2702 charts  
• Slit lamp examination  
• Pre-injection IOP 
• Dilated fundoscopy  
• OCT  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 67 • Post-injection IOP and vision check  
Nonocular:  
• Concomitant ocular and systemic medications  
• Vital signs  
• AEs 
Note: PK samples will be collected on the first and the third injection on Day  1 and Week  8 
at the following time  points: predose, +1 day, +3 days, +7 days, +14 days, and +28 days after 
the study treatment injections.  
6.1.3 Early Termination/End -of-Study  
The end of the study is defined as the date of the last visit of the last subject in the study . 
For subjects who discontinue study treatment , the Treatment Discontinuation page of the 
eCRF should be completed . Every effort should be made to have such subjects remain in the 
study and continue with their regularly scheduled visits  and assessments until Week  [ADDRESS_892343] should return for the ET Visit as soon as possible after the 
discontinuation but  no later than 28 days after discontinuation. End-of-Study Visit 
assessments will be conducted 28 days after the EOT  at Week  52. 
The following procedures/assessments will be performed at the ET/EOS Visit:  
Ocular:  
• Slit lamp examination  
• Dilated fundoscopy  
• IOP 
• BCV A measured by [CONTACT_661559] 2702 charts  
• OCT  
• FA (at ET/EOS)  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 68 • FP (at ET/EOS)  
Nonocular:  
• Urine pregnancy test  for female subjects of child -bearing  potential  (at ET/EOS)  
• Concomitant ocular and systemic medications  
• Laboratory assessments  (at ET/EOS)  
• Vital signs  
• ECG (at ET and EOS Visit s) 
• AEs 
• Immunogenicity samples (at  ET and  EOS Visit s) 
If a subject is discontinued from the study, all the ET Visit procedures should be performed 
even if they are outside the allowed study window.  
6.[ADDRESS_892344] corrected visual acuity will be measured at the scheduled visits as indicated in the 
Schedule of Events ( Table  6-1) by [CONTACT_128841]. BCV A will also be performed at any 
time during the visit at ET/EOS Visit. If the light bulbs are not changed yearly or burned in 
properly, it will be considered a deviation. The V A examiners are masked to study arm 
assignments. Visual acuity testing will be don e for both eyes and should be performed prior 
to the dilation of pupi[INVESTIGATOR_8324], FA, and OCT assessments  and prior to the IVT injection of the study 
drug. Visual acuity testing will be  consistently  assessed  from Screening to Week  52 (EOS 
visit) or ET Visit  using e ither original series ETDRS charts or [ADDRESS_892345] from Screening to Week 52 (EOS Visit) or ET Visit.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 69 A Visual Acuity Specifications Procedure Manual and training materials will be provided to 
all sites. All examiners will require certification prior to performing this assessment as part of 
the study.   
A decrease in VA of ≥[ADDRESS_892346] assessment of V A should be reported as 
AEs/SAE as appropriate. If there is a decrease in V A of ≥ [ADDRESS_892347] and FA /FP will be used to measure 
CNV .  
[IP_ADDRESS]  Optical Coherence Tomography  
A reading center manual along with training materials will be provided to all sites which will 
provide information on standardized procedures for the co llection, storage, and transmission 
of the images. Prior to any study images being taken at the sites, site personnel and 
equipment must be assessed  and certified through test images  using instruments and  software  
approved  by [CONTACT_73475]. Only trained and certified site staff delegated with the 
responsibility of image collection should perform this  test. The OCT imaging should be 
performed on the study eye prior to the IVT injection of the study drug.  Those images will be 
sent to the central reading center.  
All OCT devices must be registered in an investigational site by [CONTACT_661582]. The subject should consistently use the same 
OCT device from Screening to Week 52 (EOS Visit) or ET Visit. The devices should be 
registered by [CONTACT_661580]  52 (EOS Visit) or ET Visit 
and OCT images will be sent to the central reading center.  
If a subject misses a visit during which ocular images should be taken, the images should be 
collected at the next scheduled visit.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 70 [IP_ADDRESS]  Fluorescein Angiography  and Fundus Photography  
At screening, FA and FP will be performed on both eyes and those images will be sent to the 
central  reading center. At Week  8 and ET/EOS Visit , FA and FP  will be performed on the 
study eye  (prior to IV T injection of the study drug  at Week 8 ) and th ose images will be sent 
to the central reading center . Site staff  who will perform FA  and FP  in this study must be 
certified by [CONTACT_661583]. Only FA /FP device s 
certified by [CONTACT_661584]. If 1 or more FA/FP 
devices are certified at an investigational site, the same FA /FP device  should be  consistently 
used from Screening to Week  52 (EOS Visit) or ET Visit in each subject . 
In the event a subject is suspected to have a new active CNV in the study eye, an OCT should 
be performed to confirm the diagnosis. An optional FA will be performed . 
6.3 Safety Assessments  
Safety endpoints include AEs, vital signs,  ECGs,  ophthalmological examinations, and 
laboratory assessments up to Week  52. Safety is also evaluated during follow -up (4  weeks 
after EOT).  
6.3.[ADDRESS_892348] 5  years 
should be captured for all subjects. Any significant previous ocular surgeries, procedures 
and/or medications or treatments used for these conditions should be recorded. History of 
thrombotic events , IVT anti -VEGF treatment, treatment involving macula with PDT with 
verteporfin, transpupi[INVESTIGATOR_66284], radiation therapy, or retinal laser treatment  should 
be reviewed in detail.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 71 6.3.2 Ophthalmic Examinations  
Routine ophthalmological examinations will be performed at indicated visits in the Schedule 
of Events ( Table  6-1) and include  the following : 
• Biomicroscopy s lit lamp examination ( anterior chamber flare, anterior chamber cells, 
vitreous cells  opacities and haze ) will be performed on both eyes at screening and 
prior to IV T injection of the study drug . Slit lamp will also be performed at any time 
during the visit at ET/EOS Visit. Please see Section  13.1 (Appendix  1) and 
Section  13.2 (Appendi x 2) for grading scale s. 
• Dilated fund oscopy includ es evaluation of retina and vitreous ( vitreal overall 
assessment; macular overall assessment; retina overall assessment; and optic nerve 
overall assessment ). A standard method of indirect ophthalmoscopy (ie , using a 
head -mounted light source and a 20 -30 lens) will be performed  by [CONTACT_661585]/study staff  on the study eye prior to IV T injection of the study drug and within 
60±30 minutes after IV T injection of the study drug . Dilated fundoscopy will also be 
performed at any time during the visit at ET/EOS Visit. Dilated fundoscopy 
assessments should be performed at all assessment visits as mentioned in Table  6-1. 
Intraocular pressure is a part of routine study assessment. A measurement of IOP will be 
conducted using either Goldmann applanation tonometer  or Tono -pen.  
The same method of IOP measurement must be used in each subj ect from Screening to 
Week  52 (EOS Visit) or ET Visit. Intraocular pressure will be measured by [CONTACT_661585]/study staff on both eyes at screening,  and on the study eye  prior to IV T injection of the 
study drug, and 60±30 min utes after IV T injection of the study drug at each visit  from 
baseline/Day  1 to EOT (48  weeks) . When IOP is measured prior to IV T injection of the study 
drug, IOP should be measured after OCT and FA are completed to avoid corneal erosion.  IOP 
will also be performed at a ny time during the visit at ET/EOS Visit.  
Finger counting test is a part of post-injection  procedures and is to be performed by [CONTACT_661586].  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 72 6.3.3 Adverse Events  
[IP_ADDRESS]  Definitions  of Adverse Events  
The investigator is responsible for reporting all AEs that are observed or reported during the 
study, regardless of their relationship to study drug  or to IVT injection procedure  or their 
clinical significance.  
An AE is defined as any untoward medical occurr ence in a subject enrolled into this study 
regardless of its causal relationship to study drug  or to IVT injection procedure . Subjects will 
be instructed to contact [CONTACT_661587].  
A treatment -emergent AE (TEAE) is defined as any event not present before exposure to 
study drug or any event already present that worsens in either intensity or frequency after 
exposure to study drug.  
[IP_ADDRESS]  Serious Adverse Events  
An SAE is defined as any event th at: 
• results in death  
• is immediately life threatening  
• requires inpatient hospi[INVESTIGATOR_1081]  
• results in persistent or significant disability/incapacity  
• is a congenital anomaly/birth defect  
Important medical events that may not result in death, be life threatening, or require 
hospi[INVESTIGATOR_37347], based upon appropriate medical judgment, 
they may jeopardize the subject or may require medical or surgical intervention to prevent 
1 of the outcomes listed in this definition. Examples of such medical events include allergic 
bronchospasm requiring intensive treatment in an emergency room or at home, blood 
dyscrasias or convulsions that do not result in inpatient hospi[INVESTIGATOR_5186] n, or the development of 
drug dependency or drug abuse.  Simple emergency room visits (ex cluding hospi[INVESTIGATOR_661534] m idnight) are not reported as an SAE.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 73 In addition to the above criteria, the following criteria would be considered as SAEs and are 
to be reported as SAEs:  
• Development of rhegmatogenous retinal detachment or stage 3 or 4 macular holes.  
• A decrease in BCV A of ≥[ADDRESS_892349] assessment of V A.  
A decrease in VA of ≥[ADDRESS_892350] assessment of V A should be repor ted as 
AEs/SAE as appropriate. If there is a decrease in V A of ≥[ADDRESS_892351] assessment 
of V A or if there is a decrease in V A to the level of Light Perception or worse, it should be 
reported as an SAE.  
[IP_ADDRESS]  Eliciting and Documenting Adverse Events  
Adverse events will be assessed beginning at enrollment (date of signed informed consent) 
and up to [ADDRESS_892352] been 
hospi[INVESTIGATOR_057], had any accidents, used any new medications, or changed concomitant 
medication regimens (both prescription and OTC  medications).  
In addition to subject observations, AEs identified from any study data (eg, laboratory values, 
electrocardiogram [ ECG ] changes , etc. ) or identified from review of other documents (eg, 
subject diaries) that are relevant to subject safety  will be documented on the AE page in the 
eCRF . 
[IP_ADDRESS]  Reporting Adverse Events  
All AEs reported or observed during the study will be recorded on the AE page in the eCRF. 
Information to be collected includes the following:  
• drug treatment  
• dose 
• event term  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 74 • time of onset  
• investigator -specified assessment of severity and relationship to study drug  and to 
IVT injection  procedure  
• time of resolution of the event  
• seriousness  
• any required treatment or evaluations  
• outcome  
Adverse events resulting from concurrent illnesses, reactions to concurrent illnesses, 
reactions to concurrent medications, or progression of disease states must also be reported. 
All AEs will be followed to adequate resolution. The Medical Dictionary for Regulatory 
Activities (MedDRA) will be used to code all AEs.  
Any medical condition that is present at the time that the subject is screened but does not 
deteriorate should not be reported as an AE. However, if it deteriorates at any time during the 
study, it should be recorded as an AE.  
A decrease in VA of ≥[ADDRESS_892353] assessment of V A should be reported as an 
AE/SAE, as appropriate. If there is a decrease in V A of ≥[ADDRESS_892354] results (hematology, clinical chemistry, or urinalysis) or other 
safety assessments (eg, ECGs or vital sign measurements), including those that worsen from 
baseline, felt to be clinically significant in the medical and sc ientific judgment of the 
investigator are to be recorded as AEs or SAEs.  
However, any clinically significant safety assessments that are associated with the underlying 
disease, unless judged by [CONTACT_661588]’s baseline condi tion, 
are not to be reported as AEs or SAEs.  
[IP_ADDRESS]  Reporting Serious Adverse Events  
Any AE that meets SAE criteria ( Section  [IP_ADDRESS] ) must be reported by [CONTACT_661589], Inc immediately (ie, within 24 hours) after the time site personnel first learn about the 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 75 event  through the Electronic Data Capture (EDC) system, or if unable to do so due to 
technical issues, by 1 of the back -up mechanisms provided (eg, fax) . The following contact 
[CONTACT_661590]:  
 [COMPANY_003], Inc , Pharmacovigilance   
 SAE NA Safety Hotline -  
 SAE NA Fax line -  
 SAE EMEA/ APAC Safety Hotline -  
 SAE EMEA/ APAC Fax line -  
[IP_ADDRESS]  Suspected Unexpected Serious Adverse Reactions  
The sponsor will promptly evaluate all suspected unexpected serious adverse reactions 
(S[LOCATION_003]Rs) against cumulative product experience to identify and expeditiously communicate 
possible new safety findings to investigators, IRBs/IECs, and applicable health author ities 
based on applicable legislation.  
To determine reporting requirements for single AE cases, the sponsor will assess the 
expectedness of these events using the investigator’s brochure . 
The sponsor will compare the severity of each S[LOCATION_003]R and the cumulati ve event frequency 
reported for the study with the severity and frequency reported in the applicable reference 
document.  
Reporting requirements will also be based on the investigator's assessment of causality and 
seriousness, with allowance for upgrading b y the sponsor as needed.  
[IP_ADDRESS]  Assessment of Severity  
The severity, or intensity, of an AE refers to the extent to which an AE affects the subject’s 
daily activities. The intensity of the AE will be rated as mild, moderate, or severe using the 
following criteria : 

SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 76 Mild:  These events require minimal or no treatment and do not interfere with the 
subject’s daily activities.  
Moderate:  These events result in a low level of inconvenience or concern with the 
therapeutic measures. Moderate events may cause some interference with 
normal functioning.  
Severe:  These events interrupt a subject’s usual daily activity and may require 
systemic drug therapy or other treatment. Severe events are usually 
incapacitating.  
 
Changes in the severity of an AE should be document ed to allow an assessment of the 
duration of the event at each level of intensity to be performed.  
[IP_ADDRESS]  Assessment of Causality  
The investigator’s assessment of an AE’s relationship to study drug and IVT injection 
procedure is part of the documentation process, but it is not a factor in determining what is or 
is not reported in the study.  If there is any doubt as to whether a clini cal observation is an AE, 
the event should be reported.  
The relationship or association of the test article in causing or contributing to the AE will be 
characterized using the following classification and criteria:  
Unrelated:  This relationship suggests that there is no association between the study drug 
or the IVT injection procedure and the reported event.  
Related : This relationship suggests that there is an association between the study drug 
or the IVT injection procedure and the reported event . 
[IP_ADDRESS]  Follow -Up of Subjects Reporting Adverse Events  
All AEs must be reported in detail on the appropriate page in the eCRF and followed to 
satisfactory resolution, until the investigator deems the event to be chronic or not clinically 
significant, or until the subject is considered to be stable . 
6.3.4 Clinical Laboratory Evaluations  
Clinical laboratory assessments will be performed as indicated in Table  6-1. Collection of 
blood and urine will occur at the study site and the samples will be shipped to a central 
laboratory for analysis. All samples (including urine) should be collected prior to IVT 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 77 injection of the study drug; urine samples will be collected prior to  FA assessment  to avoid 
false elevations in urine protein values . Hematology, chemistry, and urinalysis samples will 
also be performed at any time during the visit at ET/EOS Visit. Procedures for collection and 
processing of blood and urine are provided in the laboratory manual.  
Table  6-2 presents the laboratory analyses that will be performed during the study.  
Table  6-2: Clinical Laboratory Evaluations  
Clinical Chemistry  Hematology  Urinalysis  For Wom en 
Alanine 
aminotransferase  
Albumin  
Alkaline phosphatase  
Aspartate 
aminotransferase  
Blood urea nitrogen  
Creatinine  
Creatine kinase  
Total and direct 
bilirubin  Basophils  
Eosinophils  
Hematocrit  
Hemoglobin  
Lymphocytes  
MCV  
Monocytes  
Neutrophils  
Platelet count  
RBC  count  
RBC morphology  
WBC  count  Bilirubin  
Blood  
Glucose  
Ketones  
Leukocyte  esterase  
Nitrite  
Occult blood  
pH 
Protein  
Specific gravity  
Urobilinogen  Serum pregnancy test : At 
Screening Visit for  women  of 
child -bearing potential  (serum 
β-hCG, follicle -stimulating 
hormone, luteinizing 
hormone)  
Urine pregnancy test : At 
baseline, ET, and EOS visits 
for women  of child -bearing 
potentiala 
Abbreviations: EOS, end -of-study;  ET, early termination ; hCG , human ch orionic gonadotropin; MCV , mean 
corpuscular volume; RBC, red blood cell; WBC, white blood cell . 
a. If urine pregnancy test is positive, serum pregnancy test should be performed; if found positive, study 
treatment will be discontinued.  
6.3.[ADDRESS_892355] of body temperature, respi[INVESTIGATOR_697], blood pressure (systolic and 
diastolic), and heart rate measurement.  
On injection visits, vital signs will be measured prior to IVT injection of the study drug . Vital 
signs will also be performed at any time during the ET/EOS Visit. Vital signs should be taken 
with the subject in a seated position after resting for 5 minutes. Vital signs will be measured 
before venipuncture.  
6.3.6 Electrocardiograms  
An ECG could be done  for safety and assessed by [CONTACT_661591], Week  8, 
and at the EOS /ET Visit.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 78 6.4 Pharmacokinetic Assessments  
Blood samples, for determination of concentrations of SCD411 and aflibercept, will be 
collected at the time  points specified in the Schedule of Events ( Table  6-1) and detailed 
sampling window is provided in  Table  6-3. As per the Schedule of Events, additional visits 
will be arranged for collecting the PK blood samples. Quantification of free and bound 
SCD411 and aflibercept will be performed for subjects who agree to participate in the PK 
substudy using blood samples drawn at predose, and at +1 day, +3  days, +7  days, +14  days, 
and +[ADDRESS_892356] injection  (Week 8) . Samples should be 
collected before performing FA, when performed on the same day. Plasma  concentrations of 
SCD411 and aflibercept will be determined using validated analytical procedures. PK 
parameters assessed in the study include A UC 0-t, AUC 0-tau, AUC 0-inf, Cmax, tmax, and t1/2. 
Additional details of PK analysis are available in the PK manual.  
Table  6-3: Sampling Window  
Study Day /Week  Time  
(Relative to  Dosing)  Time in Hours  
(Visit Window ) PK Immunogenicity  
Day 1  
 0 (Predose)  0 X X 
+1 day  24 (±1 hour)  X  
+ 3 days  72 (±2 hours)  X  
+7 days  168 (±6 hours)  X  
+14 days  336 (±1 day)  X  
+28 days (Week 4)1 672 (±2 days)  X X 
Week 8  0 (Predose)  0 X X 
+1 day  24 (±1 hour)  X  
+ 3 days  72 (±2 hours)  X  
+7 days  168 (±6 hours)  X  
+14 days  336 (±1 day)  X  
+28 days  672 (±2 days)  X  
Week 20     X 
Week 36     X 
Week  52/End-of-Study     X 
1 This blood sample should be collected before Week 4 injection.  
 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 79 6.5 Immunogenicity Assessments  
Blood samples for immunogenicity analysis will be collected at Baseline (predose), at 
Weeks  4, 8, 20, 36, and 52  as indicated in the Schedule of Events ( Table  6-1). Detailed 
sampling window is provided in  Table  6-3. Samples should be collected before the IVT 
injection of the s tudy drug and prior to F A assessment when performed on the same day. The 
samples will be evaluated for anti -SCD411 or anti -aflibercept antibodies.  
Neutralizing antibodies (NAb) will also be evaluated only if ADA test positive.  
6.6 Independent Data  Monitoring Committee  
An IDMC will be established for the study. The IDMC and associated parties (CRO 
Pharmacovigilance, Data management, sponsor as well as the CRO for IDMC management) 
will function under the terms of an IDMC Charter. The IDMC will compri se 3 voting 
members  (including 1 independent [unmasked ] biostatistician ) and [ADDRESS_892357] the safety interests of subjects and all others who may possibly be 
exposed to the study drug and to make recommendations to the sponsor. The IDMC (without 
the sponsor or CRO personnel  involved in the conduct of the study ) will review efficacy and  
safety data in an un masked  manner.  
The voting members of the  IDMC will participate in a closed, unmasked session , following 
the blinded presentation of data to discuss recommendations. During these sessions, the 
IDMC members will be able to review unmasked safety data  and efficacy data . Only the 
voting  members, unblinded independent biostatistician, and the [COMPANY_003] Data Monitoring 
Coordinators will be present in the closed meetings.  
Two IDMC meeting s will be held : one safety meeting will be held approximately [ADDRESS_892358] completed the Week  8 Visit. After each meeting, the IDMC members will make 
a decision to continue the study without change, modify the study  or enrollment to be placed 
on hold , or study termination. A ny decision to terminate the study will be based on clinical 
judgment only and no formal stoppi[INVESTIGATOR_661535]. The sponsor is obligated to inform 
the study sites, IRB/IEC and Competent Authorities of the IDMC recommendations 
according to country -specific requirements.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.[ADDRESS_892359] be reported using the  same procedures as an SAE (Section [IP_ADDRESS] ) eg, a 
clinical study  pregnancy form. To ensure subject safety, each pregnancy must be rep orted to 
the sponsor within [ADDRESS_892360] be 
followed -up to determine outcome (including spontaneous miscarriage, elective termination, 
normal  birth, or congenital abnormality ) and status of mother and child , even if the subject  
was discontinued from the study . Pregnancy complications and elective terminations for 
medical reasons must be reported as an AE or SAE. Spontaneous miscarriage s must be  
reported as an SAE.  Pregnancy outcomes can be collected for the female partners of any 
male subjects who participated  in this study , provided their verbal consent is obtained prior to 
collecting this information . 
Any SAE occurring in association with a pr egnancy, brought to the investigator’s attention 
after the subject has completed the study, and considered by [CONTACT_160524], must be promptly reported to  the sponsor.  
No pregnancy test is required for women of non -child -bearing potential. Serum pregnancy 
test will be performed for women of child -bearing potential at the Screening Visit. At 
Baseline, ET , and EOS Visits, a urine pregnancy test will be performed and if fou nd positive, 
then the serum pregnancy test should be performed. If serum pregnancy test results are 
positive, the study treatment should be discontinued , and the subjects should continue with 
regularly scheduled visits and assessments until Week  52 after d iscontinuation , unless the 
subjects withdraw consent , in which circumstance ET Visit procedures should be conducted ; 
the subject or the female partner of any male subject  should be followed for safety until the 
outcome of the pregnancy is known . 
6.[ADDRESS_892361] during the study for 
PK, immunogenicity, and safety evaluation s will be  provided in the  laboratory manual.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 81 7 Statistical and Analytical Plan  
The objectives and endpoints for this study are described in Section 2. This section focuses 
on key aspects for the analysis and reporting of efficacy and safety endpoints. Details for all 
endpoint analyses will be provided in the final statistical analysis plan (SAP), which will be 
finalized prior to the Week 8 and interim database lock.   
Based on discussions with regulatory agencies which resulted in acceptance of different 
equivalence margins, different efficacy analyses will be performed for FDA submissions and 
other regulatory agencies versus submissions to EMA  and PMDA. As the agencies will 
independently assesses efficacy based on their specific criteria, no adjustment for multiple 
comparisons will be required.  
7.1 Estimands and Intercurrent Events  
Week 8  
Primary  Estimand: The primary estimand is the mean treatment difference in BCV A change 
from baseline at Week 8. For the EMA, the primary analysis will be assessed for both the full 
analysis set (FAS) and per -protocol set (PPS). For the FDA, PMDA, and any other 
submissions, the primary analysis will be performed for the FAS. The primary estimand 
treats subjects in the analysis as if subjects do not receive rescue therapy .  
Target Population: Subjects with wet AMD as defined in the enrollment criteria.  
Endpoint: Change from baseline in BCV A at Week 8 . 
Treatment Condition(s): Dosing at Day 1, Week 4 , and Week 8 with one of the following: 
SCD411 or aflibercept, both without rescue therapy . 
Population -level Summary: The difference in mean change from baseli ne in BCV A at 
Week  8 between SCD411 and aflibercept and the corresponding confidence interval (CI) for 
the mean difference.  
Intercurrent Events and Strategies to Address Intercurrent Events  
• Discontinuation  of study eye study treatment with continued partic ipation in study 
without receipt of rescue therapy  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 82 o Treatment Policy  – no imputation; use observed data  
• Receipt of rescue therapy  in the study eye  
o Hypothetical approach – data after receipt of rescue will be set to missing and 
post rescue data will be imputed employing multiple imputation (MI) assuming 
missing at random (MAR) using randomized treatment -based Markov Chain 
Monte Carlo (MCMC) methodolog y. 
• Discontinuation from study, regardless of reason  
o Hypothetical approach – missing data after discontinuation will be imputed via 
MI assuming MAR  using randomized treatment -based MCMC methodology.  
Rationale for Strategy: As the primary objective of this s tudy is to show biosimilar 
equivalence between SCD411 and aflibercept, the primary estimand is constructed to 
estimate the treatment effect under the assumption that all subject s take study treatments 
without the use of rescue therapy  while allowing for su bjects to discontinue study treatment. 
Multiple imputation under MAR  assumptions results in treatment estimates as if subjects 
continued as on their original treatment. Treating discontinuation as MAR  and setting the 
post rescue assessment to missing prior  to performing MI was chosen to avoid inflation of 
the SCD411 treatment effect. Subjects who receive rescue therapy  or discontinue will have 
shown lack of efficacy in assessments, so the MAR approach should be conservative if the 
test treatment is not equi valent  to or less efficacious than the reference product.  
Secondary Estimand: A secondary estimand for the primary efficacy endpoint is the mean 
treatment difference in BCV A change from baseline at Week [ADDRESS_892362] actual real -world outcomes , where 
rescue would likely be given when lack of efficacy is seen.  
Week 52  
Primary Estimand:  The primary estimand is the mean t reatment difference in BCV A change 
from baseline at Week  52. For the EMA, the primary analysis will be assessed for both the 
FAS and PPS. For the FDA, PMDA, and any other submissions, the primary analysis will be 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 83 performed for the FAS. The primary estimand  treats subjects in the analysis as if subjects do 
not receive rescue therapy . 
Target Population:  Subjects with wet AMD as defined in the enrollment criteria.  
Endpoint : Change from baseline in BCV A at Week 52  
Treatment Condition(s):  Dosing at Day 1, Week 4 , Week 8, Week 16, Week 24, Week  32, 
Week 40, and Week 48 with one of the following: SCD411 or aflibercept, both without 
rescue therapy.  
Population -level Summary:  The difference in mean change from baseline in BCV A at Week 
52 between SCD411 and aflibercept  and the corresponding CI for the mean difference.  
Intercurrent Events and Strategies to Address Intercurrent Events  
• Discontinuation of study eye study treatment with continued participation in study 
without receipt of rescue therapy  
o Treatment Policy – no imputation; use observed data  
• Receipt of rescue therapy  in the study eye  
o Hypothetical approach – Data after receipt of rescue will be set to missing and 
post rescue data will be imputed employing MI assuming MAR  using randomized 
treatment -based MCMC methodology.  
• Discontinuation  from study, regardless of reason  
o Hypothetical app roach – Missing data after discontinuation will be imputed via 
MI assuming MAR  using randomized treatment -based MCMC methodology.  
Rationale for Strategy: As the primary objective of this study is to show biosimilar 
equivalence between SCD411 and aflibercep t, the primary estimand is constructed to 
estimate the treatment effect under assumption that all subjects  take study treatments without 
the use of rescue therapy  while allowing for subjects to discontinue study treatment. Multiple 
imputation under MAR  assumptions results in treatment estimates as if subjects continued on 
their original treatment. Trea ting discontinuation as MAR  and setting the post rescue 
assessment to missing prior to performing MI was chosen to avoid inflation of the SCD411 
treatment eff ect. Subjects wh o receive rescue therapy or discontinue will have shown lack of 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.[ADDRESS_892363].  
Secondary Estimand: A secondary estimand for the secondary  efficacy endpoint is the mean 
treatment difference in BCV A change from baseline at Week [ADDRESS_892364]  actual real -world outcomes , where 
rescue would likely be given when lack of efficacy is seen . 
7.2 Sample Size Determination  
The equivalence margin agreed upon with EMA and PMDA was determined using the data 
presented from MARINA (and ANCHOR) and VIEW studies.  These data were used to 
estimate the efficacy of aflibercept compared to the placebo treatment in subjects with wet 
AMD. It was shown that in MARINA, subjects on average lost 2.[ADDRESS_892365] compared to the placebo would be esti mated as approximately 9.3 to 10 letters. A 
margin of 3.8  letters would be translated to a preservation of 59% to 62% of the difference 
between Eylea and sham  and is less than a 1 line change in VA. Equivalence discussions for 
EMA and PMDA were based upon a 95% CI approach or 2 one-sided tests (TOST) at the 
α=0.[ADDRESS_892366].  
The FDA  requested a tighter equivalence margin of 3  letters but agreed equivalence can be 
determined from a 90% CI approach (equivalent to TOST at the α=0.05 level).  
Standard deviat ion (SD) for the mean change from baseline at early visits (Weeks 4 to 12) 
based on observed data for the FAS ranged from and 8.73 to 11.99 considering all treatment 
groups from VIEW1 and from 7.4 to 11.0 letters for the VIEW2 study (DHHS 2011  [Eylea 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 85 Statistical Review, Appendix Tables A.1 and A.2 ]). For power calculations, a range of SD 
between 10.[ADDRESS_892367] 80% 
power for the FDA, EMA, and PMDA analyses for the range of SD considered when using 
TOST  on data from a parallel -group design. For the FDA analysis based on equivalence 
limits of -3.0 and 3.0 letters, α=0.05 signific ance level (90% CI), assuming the true 
difference between the means is 0.0, power of 91% is achieved for SD of 10.4 letters and 
power of 80% is achieved for SD of 11.8  letters. For the EMA and P MDA analyses based on 
equivalence limits of -3.8 and 3.8  letters, α=0.025 significance level (95% CI), assuming the 
true difference between the means is 0.0, power of 98% is achieved for SD of 10.4 letters and 
power of 92% is achieved for SD of 11.8 letters when sample size is 266 per treatment arm. 
Considering  approximately 5% loss from randomization through Week 8, the total sample 
size required is 560.  
A subset of 4 0 subjects (2 0 per group) will be selected for collect ion of  PK samples. Th e 
sample size is not test -driven since no equivalence test will be performed for PK parameters.  
7.3 Analysis Sets  
The following analysis sets will be used in the statistical analyses.  
Full Analysis Set (FAS) : All randomized subjects who receive d at least 1  injection of the 
study drug.  
Modified FAS (mFAS) : All randomized subjects who received at least [ADDRESS_892368] 1 postbaseline BCV A assessment in the study eye.  
Per-protocol Set (PPS) : All subjects in the FAS, excluding those w ith significant protocol 
violations.  
Safety Set (SAF) : All subjects receiving at least 1  injection of the study drug.  
Pharmacokinetic Analysis Set (PK Set) : The subset of subjects in FAS who have sufficient 
evaluable blood samples to be included in the PK Set.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 86 The primary set for efficacy analysis will be the FAS; however, for the EMA submission, the 
primary efficacy endpoint must meet equivalence for both the FAS and PPS. PMDA also 
requires an efficacy analysis to be conducted based on the mFAS without MI as a supportive 
analysis . The SAF will be the primary analysis set for safety, tolerability, and 
immunogenicity analyses.  
7.4 Description of Subgroups to be Analyzed  
Subgroup analyses will be performed by [CONTACT_11338]/country and important demographic/baseline 
characteri stics; however, the study is not powered for treatment comparisons within 
subgroups. Details of subgroups analyses will be provided in the SAP. 
7.5 Statistical Analysis  Methodology  
The data will be analyzed by [CONTACT_23638]/or designated CRO. Any data analys is carried 
out independently by [CONTACT_661592].  
Tabulations of summary statistics, graphical presentations, and statistical analyses will be 
performed with SAS® software, version 9.4 o r higher.  
Descriptive statistics for continuous variables in summary tables will include the number of 
subjects in the analysis (n), mean, SD, median, and range (minimum, maximum). Descriptive 
statistics for categorical variables in summary tables will inc lude counts and percentages. 
Graphical summaries of the data may be presented.  
The most recent nonmissing measurement collected prior to the first administration of study 
drug will be used as the baseline value.  
All data obtained on the eCRF will be provid ed in separate data listings showing individual 
subject values by [CONTACT_6982], if applicable.  
Unless otherwise specified, the missing data will not be imputed.  
7.5.1 Efficacy Analyses  
Efficacy analyses will be based on the study eye only.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 87 [IP_ADDRESS]  Primary E fficacy Outcome Measures  
The pre -postchange in BCV A as measured by [CONTACT_661559] [ADDRESS_892369] of the clinical studies  
performed for Eylea: GALILEO, COPERNICUS, VISTA, VIVID, and MYRR OR and was 
also assessed as a secondary endpoint in the clinical studies  VIEW  [ADDRESS_892370] is reached. This makes a 
comparison between 2  similar products after 8  weeks of  treatment more sensitive as 
compared to an endpoint after 52  weeks of treatment.  
The primary analysis of the change from baseline in BCV A as measured by [CONTACT_661593] 2702 chart s through 8 weeks of treatment will be performed  via MMRM including 
data for the Week 4 and Week 8 visits. The model will include the change from baseline as 
the dependent variable; treatment , visit, and visit -by-treatment  as fixed effects, and baseline 
BCV A as a covariate. An unstructured covariance matrix will be used.  In the event of 
convergence issues, compound -symmetry will be used instead. Rubin’s rules will be used to 
combine the estimates from the MMRM analyses and the estimated mean treatment 
difference at Week 8 along with the corresponding 90% and 95% CIs will be p resented . 
Equivalence will be determined if the upper and lower CI limits for the difference between 
treatments are within the equivalence margins. Raw values and changes from baseline at 
Week 4 and Week 8 will be summarized by [CONTACT_661594] . 
The primary null hypothesis (H0) and alternative hypothesis (H1) are:  
H0: ∆ ≥M or ∆ ≤ -M 
H1: -M< ∆ <M  
where ∆ indicates the mean difference between the 2 treatment groups in the change from 
baseline in ETDRS letter s core or 2702 chart s at Week 8 and M represents the equivalence 
margin.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 88 Based on discussions with regulatory agencies, separate  equivalence CIs and equivalence 
margins will be used for FDA submissions  and other regulatory agencies  versus submissions 
to EMA and PMDA. Submissions to other regulatory agencies will be assumed to follow 
FDA guidance.  
For the FDA submission  and other countries submission , a 90% CI (equivalent to TOST  
evaluated at an α of 0.05) will be assessed using an e quivalence margin of 3 letters. If the 
upper bound of the 90% CI is less than 3 and the lower bound is greater than -3, then study 
success will be claimed. For the EMA  and PMDA, a 95% CI (equivalent to TOST  evaluated 
at an α of 0.025) will be assessed usin g an equivalence margin of 3.8 letters.  If the upper 
bound of the 95% CI is less than 3.[ADDRESS_892371] squares mean estimate of treatment difference and corresponding 90% (FDA  and 
other countries ) and 95% (EMA/PMDA) CIs will be provided . The primary analysis set for 
the FDA , PMDA , and any other  submissions will be the FAS. For the EMA submission, both 
the FAS and PPS are considered primary analysis and equivalence will need to be sho wn for 
both analysis sets.  
As a sensitivity analysis, a n analysis of covariance (ANCOVA ) model comparing the change 
from baseline in BCV A at Week  [ADDRESS_892372] study  discontinuation/ rescue therapy  BCV A score s using the 
LOCF and BOCF prior to MMRM analysis  (intermittent missing data will be considered 
MAR and not imputed)  for both the FAS and PPS . In addition, an ANCOV A model 
comparing the change from baseline in BCV A at Week [ADDRESS_892373] study  discontinuation/ rescue 
therapy  BCV A values using LOCF and BOCF approaches  for the FAS and PPS . 
Additionally, the MMRM analysis will be performed using data from MI including a tippi[INVESTIGATOR_661536]. Observations after receipt of rescue t herapy  will be set to missing prior to the 
MI. M ultiple imputation  assuming MAR will be applied to all missing data. After conclusion 
of MI, post study  discontinuation/ rescue therapy  observations for the SCD411 arm will have 
fixed value C added to the impu ted values. The imputed data , includ ing the fixed penalty , 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 89 will be analyzed by [CONTACT_661595]. A range of values 
for C will be considered to identify the point at which equivalence can no longer be claimed. 
Details will be provided in SAP.  
Supportive analysis for the primary endpoint will be performed based on the mFAS per the 
PMDA’s request. Data after receipt of rescue therapy will be set to missing without 
employing MI. Both  the MMRM and ANCOV A analyses will be performed using the non -
imputed data.  
[IP_ADDRESS]  Secondary Efficacy  Outcome Measures  
The estimated mean treatment difference in the change from baseline in BCV A as measured  
by [CONTACT_661561] 2702 charts through 52 weeks along with the corresponding 90% 
and 95% CIs from the same MMRM model as used in the primary analysis but including data 
from all weeks through Week 52 will also be presented  for the FAS and PPS . 
The e stimated mean treatment difference at Week 52 along with the corresponding 90% and 
95% CIs will also be presented  using the same MMRM and ANCOV A models as used in the 
Week [ADDRESS_892374] study  discontinuation 
assessments or after receipt of rescue therapy  prior to performing the MMRM and ANCOV A 
analysis  (intermittent missing data will be considered MAR and not imputed). Additionally, 
the MMRM analysis will be performed using data from MI including a tippi[INVESTIGATOR_661537] . 
The analysis of change from baseline in CRT as assessed by [CONTACT_661596] A, with the corresponding 95% CI for the estimates of treatment 
differences at Week 8 and Week 52 presented . Raw values and changes from baseline will be 
summarized by [CONTACT_2070].  Data after receipt of rescue 
therapy  will be set to missing prior to the MMRM analysis. Multiple imputation will not be 
performed , and no  sensitivity analyses will be performed.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 90 The percentage of subjects who gain ≥15 letters in BCV A as measured by [CONTACT_661597] 2702 charts at postbaseline visits (Week 8 and Week 52) compared with baseline will be 
summarized and 95% CI for the proportions in each treatment arm and differenc e in 
proportions between treatment arms  will be presented.  For subjects who have missing 
assessments at corresponding postbaseline visits  or who received rescue therapy  prior to a 
visit will be assumed to have a gain of <15 letters in BCV A (eg, nonresponde r imputation).  
No sensitivity analyses will be performed.  
7.5.2 Pharmacokinetic Analyses  
The PK parameters (AUC 0-t, AUC 0-tau, AUC 0-inf, Cmax, tmax, t1/2,) from the 2  treatment groups 
will be summarized using n, arithmetic mean, percent coefficient of variation ( % CV), 
geometric mean, geometric %CV , SD, median, minimum and maximum values in the PK 
analysis set.  
7.5.3 Immunogenicity Analyses  
The analysis on immunogenicity will be descriptive. Results will be summarized with 
observed values and change from baseline for AD A titers (in log scale) by [CONTACT_661598]. The number and proportion of ADA -positive subjects and ADA -negative subjects 
will be summarized by [CONTACT_115399].  NAb  will be tested 
when ADA results are confirmed to be positive. The number and proportion of N Ab subjects 
will be summarized by [CONTACT_115399] . 
7.5.4 Safety Analyses  
Safety variables include incidence of AEs (or TEAEs), laboratory test results,  ECG results,  
and vital signs. All safety analyses will be based on the SAF. No formal statistical analysis of 
the safety data will be performed.  
Adverse events will be coded according to the MedDRA in the study. The number and 
percentage of subjects experiencing an AE will be summarized by [CONTACT_661599]. AEs will be classified as pretreatment or treatment -emergent.  
Pretreatment AEs  are defined as AEs that are reported or worsened after signing the ICF up 
to the first dose date of study drug.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.[ADDRESS_892375] va riables will be summarized by [CONTACT_142547] (number of subjects, mean, SD, minimum, maximum, and mean change from 
baseline). Shift tables (low, normal, high) between baseline and postbaseline time  points will 
be pre sented by [CONTACT_109058]. Laboratory tests with categorical results 
that cannot be analyzed by [CONTACT_661600]. Data obtained from laboratory tests  not required by [CONTACT_661601].  
The result s of slit lamp examination, dilated fund oscopy , IOP , and vision check will be 
summarized using descriptive statistics at each visit and applicable time point, as applicable.  
Separate summaries will be presented.  
Descriptive statistics of vital signs and change from baseline at each visit will be presented 
by [CONTACT_1570].  
Descriptive statistics of ECG parameters and change from baseline at each visit will be 
presented by [CONTACT_1570].  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 92 7.5.5 Other Analyses  
[IP_ADDRESS]  Background Characteristics  
[IP_ADDRESS].[ADDRESS_892376] Disposition  
The number and percentage of subjects who are included in each analysis set and who 
complete and discontinue the study  will be summarized by [CONTACT_661602]. 
[IP_ADDRESS].2  Demographics and Baseline Characteristics  
Demographic information: age, sex, ethnicity, height, weight, body mass index, and other 
baseline measures such as ETDRS letter score  or 2702 chart , CRT and CNV , will be 
summarized by [CONTACT_73328], using descriptive statistics. Ocular measures will 
be summarized for the study eye only.  
[IP_ADDRESS].[ADDRESS_892377] version of WHODRUG E nhanced during the study, and tabulated by 
[CONTACT_661603], using counts and percentages, separately for:  
• Prior medication: medication that starts before the first dose of study drug, regardless 
of when the medication stops.  
• Concomit ant medication: medication first received at or after the first dose of study 
drug, medication received before first dose of study drug and continued after first 
dose, or medication with missing stop date.  
Medication that starts before the first dose of st udy drug and continued after the first dose 
will be classified as both prior and concomitant medication. Medications with a missing start 
date will be considered to have a start date before the first dose of study drug. Ocular 
medications will be summarize d separately for the study eye and fellow eye.  
[IP_ADDRESS].[ADDRESS_892378].  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 93 [IP_ADDRESS].5  Study Drug Exposure and Compliance  
Exposure to study drug and dosing compliance will be summarized for the SAF using 
summary statistics.  
The compliance will be summarized by [CONTACT_661604], as a percentage of 
the planned number of dosing occasions.  
7.5.6 Interim Analyses  
The primary analysis of efficacy and all other efficacy and safety analyses will be conducted 
at the Week 8  database lock ; ie, after all subjects have completed the Week [ADDRESS_892379] enrollment 
and data cleaning/programming activities.  
As the primary study endpoint is the bioequivalence comparison at Week 8, no type I error 
adjustments are required as the analysis performed after the Week 8 database lock are 
considered final for the primary efficacy endpoint. No type I error adjustments are  planned 
for the secondary efficacy endpoints; therefore, no error adjustments will be performed due 
to the interim analys is as all analyses after the primary analysis at the Week 8 database lock 
are considered secondary analyses.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 94 8 Data Quality Assurance  
This study will be conducted according to the International Council for Harmonisation (ICH) 
E6(R2) risk and quality processes described in  the applicable procedural documents . The 
quality management approach to be implemented in this study will b e documented and will 
compl y with the  current ICH guidance on quality and risk management . 
8.[ADDRESS_892380] data into an EDC  system . The analysis dat a sets 
will be a combination of these data and data from other so urces (eg, laboratory data).  
Clinical data management will be performed in accordance with applicable [COMPANY_003] standards 
and data cleaning procedures to ensure the integrity of the data, eg, removing errors and 
inconsistencies in the data. Adverse event terms will be coded using the MedDRA, an 
internal validated medica l dictionary , and concomitant medications will be coded using 
WHODRUG . 
After database lock, each study site will receive a CDRO M containing all of their site 
specific eCRF data.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.[ADDRESS_892381]  
Federal regulations and the ICH guidelines require that approval be obtained from an 
IRB/IEC before participation of human subjects in rese arch studies. Before study onset, the 
protocol, ICF, advertisements to be used for the recruitment of study subjects, and any other 
written information regarding this study to be provided to the subject must be approved by 
[CONTACT_1201]/IEC. Documentation of all  IRB/IEC approvals and of the IRB/IEC compliance with 
ICH harmonised tripartite guideline E6(R 2): GCP will be maintained by [CONTACT_11775].  
All IRB/IEC approvals should be signed by [CONTACT_1201]/IEC chai rman or designee and must 
identify the IRB/IEC name [CONTACT_3816], the clinical protocol by [CONTACT_21759], and the date approval or a favorable opi[INVESTIGATOR_11744].  
The investigator is responsible for providing written summaries of the pro gress and status of 
the study  at intervals not exceeding 1  year or otherwise specified by [CONTACT_1201]/IEC. The 
investigator must promptly supply the sponsor or its designee , the IRB/IEC, and , where 
applicable, the institution,  with written reports on any chang es significantly affecting the 
conduct of the study or  increasing the risk to subjects . 
9.[ADDRESS_892382] Information and Consent  
A written informed consent in compliance with regulatory authority regulations (eg, US Title 
21 Code of Federal Regulations [CFR ] Part 50 ) shall be obtained from each subject before 
entering the study or performing any unusual or nonroutine procedure that involves risk to 
the subject. An informed consent template may be provided by [CONTACT_434002]. If any institution -speci fic modifications to study -related procedures are proposed or 
made by [CONTACT_779], the consent should be reviewed by [CONTACT_661605]/IEC for review and approval  prior to the start of 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.[ADDRESS_892383] will be 
asked to give consent to participate in the study by [CONTACT_12568].  
The investigator shall retain the signed origina l ICF(s) and give a copy of the signed original 
form to the subject.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 97 10 Investigator’s Obligations  
The following administrative items are meant to guide the investigator in the conduct of the 
study but may be subject to change based on industry and government  standard operating 
procedures , working practice documents , or guidelines. Changes will be reported to the 
IRB/IEC but will not result in protocol amendments.  
10.[ADDRESS_892384] , except as necessary for monit oring , inspection by [CONTACT_174275],  and auditing by [CONTACT_456], its designee, the FDA, other countries regulatory 
agencies,  or the IRB/IEC.  
The investigator and all employees and coworkers involved with this study may not disclose 
or use for any pur pose other than performance of the study any data, record, or other 
unpublished, confidential information disclosed to those individuals for the purpose of the 
study. Prior written agreement from the sponsor or its designee must be obtained for the 
disclos ure of any said confidential information to other parties.  
10.[ADDRESS_892385]’s disease.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 98 10.3 Investigator Documentation  
Prior to beginning the study, the investigator will be asked to comply with ICH E6(R 2) 8.[ADDRESS_892386] ance with  
the principles of ICH E6(R 2) and all applicable national, state, and local laws , guidelines,  or 
regulations.  Study information from this protocol will be posted on publicly available clinical 
trial registers before enrollment of subjects begins.  
10.5 Adverse Events  and Study Report Requirements  
By [CONTACT_661606]/or IRB/IEC according to the timeline and method outlined in the protocol. In addition, 
the investigator agrees to submit annual reports to the study site  IRB/IEC as appropriate.  
10.[ADDRESS_892387] approval of a 
marketing application in an ICH region or after the completion or formal discontinuation of 
clinical development of the IP, whichever is the longer period . These documents should be 
retained for a l onger period, however, if required by [CONTACT_661607]. It is the responsibility of the sponsor to inform the 
investigator/institution as to when these documents no longer need to be retained.  
10.7 Publi cations  
After completion of the study, the data may be considered for reporting at a scientific 
meeting or for publication in a scientific journal. In these cases, the sponsor will be 
responsible for these activities and will work with the investigators to  determine how the 
manuscript is written and edited, the number and order of authors, the publication to which it 
will be submitted, and other related issues. The sponsor has final approval authority over all 
such issues.  
Data are the property of the spons or and cannot be published without prior authorization 
from the sponsor, but data and publication thereof will not be unduly withheld.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 99 11 Study Management  
11.1 Monitoring  
11.1.1  External Data Monitoring Committee  
An IDMC will be established for the study. Two IDMC meetin gs will be held : one safety 
meeting will be held approximately [ADDRESS_892388] completed the Week  8 Visit. After 
each meeting, the IDMC will make a recommenda tion to the sponsor regarding the study to 
continue without change, modify the study or enrollment to be placed on hold, or study 
termination. The sponsor is obligated to inform the study sites, IRB/IEC, and regulatory 
agency of the IDMC recommendations ac cording to country -specific requirements  
(Section  6.6).  
11.1.[ADDRESS_892389] operatin g procedures.  
11.1.3  Inspection of Records  
Investigators and institutions involved in the study will permit study -related monitoring, 
audits, IRB/IEC review, and regulatory inspections by [CONTACT_21766]. In the event of an audit  or inspection , the investigator agrees to allow the sponsor, 
representatives of the sponsor, or a regulatory agency (eg, FDA)  access to all study records.  
The investigator should promptly notify the sponsor and [COMPANY_003] of any audits  or inspections 
scheduled by [CONTACT_661608][INVESTIGATOR_661538].  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.[ADDRESS_892390] be submitted in writing to the investigator’ s 
IRB/IEC for approval before subjects can be enrolled into an amended protocol.  
11.2.[ADDRESS_892391]’s source 
documentation any deviation from the approved protocol. The investigator may  implement a 
deviation from, or a change of, the protocol to eliminate an immediate hazard to study 
subjects without prior IRB/IEC approval. As soon as possible after such an occurrence, the 
implemented deviation or change, the reasons for it, and any proposed protocol amendments 
should be submitted to the IRB/IEC for review and approval, to the sponsor for agreement, 
and to the regulatory authorities, if required.  
A deviation from the protocol is an unintended or unanticipated departure from the 
proced ures or processes approved by [CONTACT_135785]/IEC and agreed to by [CONTACT_1275]. A significant deviation  occurs when there is nonadherence to the protocol by [CONTACT_160529] a significant,  additional risk to the subj ect. Significant 
deviations  can include nonadherence to  inclusion or exclusion criteria , or nonadherence to 
FDA regulations or ICH GCP guidelines , and will lead to the subject being withdrawn from 
the study ( Section  4.3). Significant protocol deviations may include below but not limited to 
the following deviations:  
• ICH/GCP deviation  
• Deviation from inclusion/exclusion criteria  
• Deviation on study treatmen t randomization  
The IRB/IEC should be notified of all protocol deviations in a timely manner.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.[ADDRESS_892392] visit . 
11.4 Final Report  
Upon completion of the interim and final analyses of the study, the investigator, where 
applicable, should inform the institution; the investigator/institution should provide the 
IRB/IEC with a summary report of the study’s outcome and the sponsor and regulatory 
authorities with any reports required.  
The sponsor will ensure that the clinical study reports are prepared and provided to the 
regulatory agencies  as required by [CONTACT_1214]. The sponsor will 
also ensure that the clinical study reports in marketing applications meet the standards of the 
ICH harmonised triparti te guideline E3: Structure and c ontent of clinical study r eports.  
Where required by [CONTACT_25435], an investigator signatory will be 
identified for the approval of the clinical study report s. 
Upon completion of the clinical study report s, the sponsor will provide the investigator with 
the full summary of the study results. The investigator is encouraged to share the summary 
results with the study subjects, as appropriate.  The s tudy results will be  posted on publicly 
available clinical trial registers.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.[ADDRESS_892393]  
Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pi[INVESTIGATOR_377427], See R, et al. Systemic 
pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and 
ranibizumab. Ret ina (Philadelphia, Pa). 2017;37(10):1847 -58. 
Department of Health and Human Services (DHHS), Food and Drug Administration, Center 
for Drug Evaluation and Research, Office of Translational Sciences, Office of Biostatistics 
(US). Statistical Review and Evalu ation. Aflibercept ophthalmic solution (VEGF Trap -Eye). 
2011 [cited 2022 Jan 24] [application number 125387Orig1s000]. Available from: 
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125387Orig1s000StatR.pdf  
Dixon JA, Oliver SC, Olson JL, Mandava N . VEGF Trap -Eye for the treatment of 
neovascular age -related macular degeneration. Expert Opin Investig Drugs. 
2009;18(10):1573 -80. 
European Medicines Agency (EMA). Eylea (aflibercept). An overview of Eylea and why it is 
authorised in the EU. EMA/481361/20 18. [cited 2020 Jul 23] Available from: 
https://www.ema.europa.eu/en/documents/overview/eylea -epar-medicine -overview_en.pdf  
Eylea® (aflibercept) Injection, for Intravitreal Use. Full Prescribing Information. Regeneron 
Pharmaceuticals, Inc. August 2019.  Available from: 
https://www.regeneron.com/sites/default/files/EYLEA_FPI.pdf  
Garc ía-Quintanilla L, Luaces -Rodriguez A, Gil -Martinez M, Mondelo -Garcia C, Maronas O, 
Mangas -Sanjuan V , et a l. Pharmacokinetics of Intravitreal Anti -VEGF Drugs in Age -Related 
Macular Degeneration. Pharmaceutics. 2019;11(8).  
Kanda A, Noda K, Saito W, Ishida S. Aflibercept Traps Galectin -1, an Angiogenic Factor 
Associated with Diabetic Retinopathy. Sci Rep. 2015;5 :[ZIP_CODE].  
Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, et al. Binding and 
neutralization of vascular endothelial growth factor (VEGF) and related ligands by [CONTACT_661609], ranibizumab and bevacizumab. Angiogenesis. 2012;15(2):171 -85. 
Santen Ph armaceutical Co., Ltd. Intravitreal VEGF Inhibitor “EYLEA® (aflibercept) 
Solution for Intravitreal Injection” Released on the Market for the Treatment of Wet Age -
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 103 Related Macular Degeneration. 2012 News release (Japan). Available  from: 
https://www.santen.co m/en/news/20121127_2.pdf   
Schneider U, Gelisken F, Inhoffen W. Natural course of occult choroidal neovascularization 
in age -related macular degeneration: development of classic lesions in fluorescein 
angiography. Acta Ophthalmol Scand. 2005;83(2):141 -7. 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 104 13 Appendices  
13.1 Appen dix 1: Slit Lamp Examination - Grading Scale  
Grading Scheme for Anterior Chamber Flare  
Grade  Description  
0 None  
1+ Faint  
2+ Moderate (iris and lens details clear)  
3+ Marked (iris and lens details hazy)  
4+ Intense (fibrin or plastic aqueous)  
Source: Jabs DA, Nussenblatt RB, Rosenbaum JT, et al., Standardization of uveitis nomenclature for 
reporting clinical data. Results of the First International Workshop, Am J Ophthalmol, 2005;140:509 –16. 
 
Grading Scheme for Anterior Chamber Cells  
Grade  Number of Cells  
0 <1 
0.5+ 1-5 
1+ 6–15 
2+ 16–25 
3+ 26–50 
4+ >50 
Source: Jabs DA, Nussenblatt RB, Rosenbaum JT, et al., Standardization of uveitis nomenclature for 
reporting clinical data. Results of the First International Workshop, Am J Ophthalmol, 2005;140:509 –16. 
 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 105 13.2 Appendix  2: Assessment of Vitreous Cells  - Grading Scale  
Grade  Description  
0 Clear  
Trace  Few opacities  
1 Scattered opacities  
2 Moderate opacities  
3 Many opacities  
4 Dense opacities  
Source: Nussenblatt RB, Whitcup SM, Palestine AG. Uveitis: fundamentals and clinical practice. 2nd rev. ed. 
[LOCATION_001]:Mosby, 1996, p. 64.  
 
Grading Scheme for Vitreous Haze  
Grade  Description  Cells in Retro -Illuminated Field  
0 Nil None  
1 Minimal  Posterior pole clearly visible  
2 Mild  Posterior pole details slightly hazy  
3 Moderate  Posterior pole details very hazy  
4 Marked  Posterior pole details barely visible  
5 Severe  Fundal details not visible  
Source: Nussenblatt RB, Palestine AG, Chan CC, et al., Standardization of vitreal inflammatory activity in 
intermediate and posterior uveitis, Ophthalmology, 1985;92:467 –71. 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.[ADDRESS_892394] : 
1. An interim analysis is planned to be per formed once approximately 200  subjects 
complete the Week 52  Visit  and once all planned ( approximately 560) treated subjects 
complete Week [ADDRESS_892395] that the IDMC will 
meet throughout the study and not only when all subjects complete the Week  8 Visit .  
The amendment also incorporate s the changes that were explained in protocol clarification 
letters dated 18  December  2020 and 29  April 2021 , and the details to include the causality 
assessment of AEs for an IVT injection procedure . 
Additions to the protocol text are shown in bold and deletions are shown in strikethrough 
text. Minor editorial  and administrative changes  and grammatical co rrections are not 
specified.  
Chapter/Section  Initial Wording  Amended or New Wording  Reason/Justification 
for Change  
Synopsis  
(Exclusion 
Criteria ); 4.1.2 
Exclusion Criteria  29. History or evidence of 
cardiac conditions including 
congestive cardiac failure 
leading to marked limitation 
on physical activity, or 
inability to perform any 
physical activity without 
discomfort, ventricular 
arrhythmia requiring ongoing 
treatment, and atrial 
fibrillation  29. History or evidence of 
cardiac conditions including  
with  congestive cardiac failure 
leading to resulting in  marked 
limitation on physical activity , 
or inability to perform any 
physical activity without 
discomfort ,; subjects with 
ventricular arrhythmia requiring 
ongoing treatment , and ; or 
subjects with  atrial fibrillation  To clarify the 
exclusion criterion 
for subjects with a 
history or evidence of 
cardiac conditions.  
Synopsis (Study 
Design)  This is a Phase III, 
randomized, parallel -group, 
double -masked, multicenter This is a Phase III, randomized, 
double -masked, parallel -group, 
double -masked, multicenter 
study in to demonstrate 
biosimilarity of SCD411 To be consisten t with 
Section 3.1.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 107 Chapter/Section  Initial Wording  Amended or New Wording  Reason/Justification 
for Change  
study in adult subjects with 
neovascular (wet) AMD  compared to Eylea 
(aflibercept) among adult 
subjects with neovascular (wet) 
AMD  
Synopsis  
(Immunogenicity 
Assessments ); 
2.4.2 Secondary 
Endpoints  Immunogenicity assessments 
and endpoints include the 
evaluation of development of 
anti-SCD411 antibodies 
using blood samples taken at 
Baseline, at Weeks 4, 8, 20, 
36, and 52.  Immunogenicity assessments 
and endpoints include the 
evaluation of development of 
anti-SCD411 or 
anti-aflibercept antibodies 
using blood samples taken at 
Baseline, at Weeks 4, 8, 20, 36, 
and 52.  To be consistent  with 
Section 6.5.  
Synopsis  (Rescue 
Treatment)  Subjects who will receive 
rescue treatment need to 
discontinue the study 
treatment and should have 
the reason for treatment 
discontinuation documented 
on the Treatment 
Discontinuation page of the 
eCRF and continue with their 
regularly s cheduled visits.  Subjects who will receive rescue 
treatment need to discontinue 
the study treatment and should 
have the reason for treatment 
discontinuation documented on 
the Treatment Discontinuation 
page of the eCRF and continue 
with their regularly sche duled 
visits and assessments until 
Week 52 except for study 
treatment administration . To be consistent  with 
other protocol 
sections . 
Synopsis (Sample 
Size)  Considering approximately 
5% loss from Day  1 through 
Week 8, the total sample size 
required is 560. Considering approximately 5% 
loss from Day 1randomization  
through Week 8, the total 
sample size required is 560.  To be consistent  with 
Section 7.2.  
Synopsis 
(Analysis Sets) ; 
7.3 Analysis Sets  - Modified FAS  (mFAS): all 
randomized subjects who 
received at least [ADDRESS_892396] 
1 postbaseline BCVA 
assessment in the study eye.  To be in line with the 
SAP.   
The primary set for efficacy 
analysis will be the FAS; 
however, for the EMA 
submission, the primary 
efficacy endpoint must meet 
equivalence for both the FAS 
and PPS sets.  The primary set for efficacy 
analysis will be the FAS; 
however, for the EMA 
submission, the primary efficacy 
endpoint must meet equivalence 
for both the FAS and PPS  sets. 
PMDA also requires an 
efficacy analysis to be 
conducted based on the mFAS 
without multiple imputation 
(MI) as a supportive analysis . 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 108 Chapter/Section  Initial Wording  Amended or New Wording  Reason/Justification 
for Change  
Synopsis 
(Statistical 
Methods) ; [IP_ADDRESS] 
Primary Efficacy 
Outcome 
Measures  The model will include the 
change from baseline as the 
dependent variable; treatment 
and visit as fixed effects, and 
baseline BCVA as a 
covariate.  The model will include the 
change from baseline as the 
dependent variable; treatment , 
visit,  and visit -by-treatment  as 
fixed effects, an d baseline 
BCVA as a covariate.  To be in line with the 
SAP.  
Synopsis 
(Statistical 
Methods)  Secondary Analyses:  
The estimated mean 
treatment difference in the 
change from baseline in 
BCVA as measured by 
[CONTACT_661561] 2702 
charts through 52 weeks 
along with the corresponding 
90% and 95% CIs from the 
same MMRM model as used 
in the primary analysis will 
be presented for the FAS and 
PPS. As per the Week  [ADDRESS_892397] rescue assessments 
set to missing prior to 
imputation. The estimated 
mean treatment difference at 
each visit along with the 
corresponding 90% and 95% 
CIs will also be presented. 
Raw values and changes 
from baseline will be 
summarized by [CONTACT_661610].  
The analysis of change from 
baseline in CRT as assessed 
by [CONTACT_661611] a MMRM model 
similar to the one used for 
the analysis of change from 
baseline in BCVA, with the 
corresponding 95% CI for 
the estimates of treatment Secondary Analyses : 
The estimated mean treatment 
difference in the change from 
baseline in BCVA as measured 
by [CONTACT_661561] 2702 
charts through 52 weeks along 
with the corresponding 90% and 
95% CIs from the same MMRM 
model as used in the primary 
analysis but including data 
from all weeks through Week 
[ADDRESS_892398] rescue 
assessments in the imputation . 
The estimated mean  treatment 
difference at each visit along 
with the corresponding 90% and 
95% CIs will also be presented  
model . Raw values and changes 
from baseline will be 
summarized by [CONTACT_661612] . 
The analysis of change fr om 
baseline in CRT as assessed by 
[CONTACT_661613] a the 
MMRM model similar to the 
one used for the analysis of 
change from baseline in BCVA, 
with the corresponding 95% CI To be consistent  with 
Section [IP_ADDRESS].  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 109 Chapter/Section  Initial Wording  Amended or New Wording  Reason/Justification 
for Change  
differences at Week 8 and 
Week 52 will be presented. 
Raw values and changes 
from baseline will be 
summarized by [CONTACT_661610]. Multiple 
imputation will not be 
performed. Dat a after the 
receipt of rescue therapy will 
be set to missing prior to 
analysis.  
The percentage of subjects 
who gain ≥15 letters in 
BCVA as measured by 
[CONTACT_661561] 2702 
charts at postbaseline visits 
(Week  8 and Week 52) 
compared with baseline will  
be summarized and 95% CI 
for the proportions in each 
treatment arm and difference 
in proportions between 
treatment arms will be 
presented. For subjects who 
have missing assessments at 
corresponding postbaseline 
visits or received rescue 
therapy prior to v isit, will be 
assumed to have a gain 
<15 letters in BCVA (eg, 
nonresponder imputation).  for the estimates of treatment 
differences at Wee k 8 and Week 
52 will be  presented. Raw values 
and changes from baseline will 
be summarized by [CONTACT_661610]. Multiple imputation 
will not be performed. Data after 
the receipt of rescue therapy will 
be set to missing prior to the 
MMRM analysis . Multiple 
imputation will not be 
performed and no sensitivity 
analyses will be performed . 
The percentage of subjects who 
gain ≥15 letters in BCVA as 
measured by [CONTACT_661597] 2702 charts at postbaseline 
visits (Week  8 and Week 52)  
compared with baseline will be 
summarized and 95% CI for the 
proportions in each treatment 
arm and difference in 
proportions between treatment 
arms will be presented. For 
subjects who have missing 
assessments at corresponding 
postbaseline visits or who 
received rescue therapy prior to 
a visit, will be assumed to have 
a gain of <15 letters in BCVA 
(eg, nonresponder imputation).  
No sensitivity analyses will be 
performed.  
Synopsis 
(Statistical 
Methods)  Immunogenicity Analysis  
The analysis on 
immunogenicity will be 
descriptive. Results will be 
summarized with observed 
values and change from 
baseline for titers (in log 
scale) ADA for the SAF. The 
number and proportion of 
ADA -positive subjects and 
ADA -negat ive subjects will 
be summarized for each 
assessment time point. NAb 
will be tested when ADA Immunogenicity  Analysis  
The analysis on immunogenicity 
will be descriptive. Results will 
be summarized with observed 
values and change from baseline 
for ADA titers (in log scale) 
ADA for by [CONTACT_661614]. The number and 
proportion of ADA -positive 
subjects a nd ADA -negative 
subjects will be summarized by 
[CONTACT_661615]. NAb will 
be tested when ADA results are To be consistent with 
text elsewhere in the 
protocol.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 110 Chapter/Section  Initial Wording  Amended or New Wording  Reason/Justification 
for Change  
results are confirmed to be 
positive. The number and 
proportion of NAb subjects 
will be summarized by 
[CONTACT_661615].  confirmed to be positive. The 
number and proportion of NAb 
subjects will be summarized by 
[CONTACT_661616].  
Synopsis 
(Statistical 
Methods)  - Interim Analyses  
An interim analysis of safety, 
secondary efficacy endpoints, 
and PK parameters will be 
performed once approximately 
[ADDRESS_892399] enrollment and 
data cleaning/programming 
activities.  To add an interim 
analysis to support 
regulatory filing to 
the PMDA.  
1.1 Background  • A higher affinity (~ 0.5 
pM dissociatio n constant 
for VEGF165 and 
VEGF121) than a 
humanized monoclonal 
antibody ( Papadopoulos 
et al 2012; García -
Quintanilla et al 2019 ) • A higher affinity (~0.5 pM 
dissociation constant for 
VEGF165 and ~0.36 pM 
for VEGF121) than a 
humanized monoclonal 
antibody ( Papadopoulos et 
al 2012; García -Quintanilla 
et al 2019 ) To be consistent  with 
the investigator 
brochure , version  3.0. 
3.1 Study Design  This is a Phase III, 
randomized, double -masked, 
parallel -group, multicenter 
study to demonstrate 
biosimilarity of SCD411 This is a Phase III, randomized, 
double -masked, paralle l-group, 
multicenter study to demonstrate 
biosimilarity of SCD411 
compared to Eylea (aflibercept) To be consistent  with 
synopsis . 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 111 Chapter/Section  Initial Wording  Amended or New Wording  Reason/Justification  
for Change  
compared to Eylea 
(aflibercept) among adult 
subjects with wet AMD . among adult subjects with 
neovascular  (wet) AMD . 
The study design 
incorporates an Independent 
Data Monitoring Committee 
(IDMC) that will review 
ongoing safety and will also 
make recommendations to 
the sponsor as described in 
the IDMC Charter. Details of 
the IDMC are given in 
Section 6.6 . The study design  incorporates an 
Independent Data Monitoring 
Committee (IDMC) that will 
review ongoing safety and will 
also make recommendations to 
the sponsor as described in the 
IDMC Charter. Details of the 
IDMC are given in Section 6.6 .  
An interim analysis will be 
performed once approximately 
200 subjects complete the 
Week  52 Visit and all subjects 
complete the Week 24 Visit or 
discontinue early from the 
study. Details of the interim 
analysis are given in 
Section  7.5.6 . To add an interim 
analysis to support 
regulatory filing to 
the PMDA.  
5.1 Method of 
Assigning 
Subjects to 
Treatment Groups  • During  the 4 -week 
intervals dosing: 
assessment and dosing 
can be done within a 
window of ±[ADDRESS_892400] 
visit window is out of 
the allowed window 
interval, dosing should 
be skipped.  • During the 4 -week intervals 
dosing: assessment and 
dosing can be done within a 
window of ±[ADDRESS_892401] should be prematurely 
withdrawn from the study , then 
the ET Visit should be 
completed as soon as possible 
after discontinuing the study 
treatment but no later than 28 
days after discontinuation . To clarify the text 
throughout.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 112 Chapter/Section  Initial Wording  Amended or New Wording  Reason/Justification 
for Change  
5.8.2  Prohibited 
Medications  Concurrent use of systemic 
or IVT anti -VEGF agents; 
IVT, subtenon, or peribulbar 
corticosteroids in study e ye, 
except as required to treat 
AEs.  Concurrent use of systemic or 
IVT anti -VEGF agents; IVT, 
subtenon, or peribulbar 
corticosteroids in study eye are 
not permitted , except as 
required to treat AEs.  To clarify the text.  
Table  5-1: 
Prohibited 
Medications  Topi[INVESTIGATOR_052] (duration of 
prohibition): 4 weeks prior to 
screening and throughout the 
study period  
Amiodarone (duration of 
prohibition): 12 weeks prior 
to screening and throughout 
the study period  Topi[INVESTIGATOR_052] (duration of 
prohibition): 4 weeks prior to 
screening randomization  and 
throughout the study period  
Amiodarone (duration of 
prohibition): 12 weeks prior to 
screening randomization  and 
throughout the study period  To be consistent  with 
exclusion criterion  
34. 
Table 6 -1: 
Schedule of 
Events  Study Day: 199  Study Day: 199197 Per calculation, a 
correction was made 
for the study day of 
the Week  28 Visit.  
l At screening, FA 
and FP will be performed on 
both eyes and those images 
will be sent to the central 
reading center. At Week 8 
and ET/EOS, FA and FP will 
be performed on the study 
eye prior to IVT injection of 
the study drug.  l At screening, FA and 
FP will be performed on both 
eyes and those images will be 
sent to the central r eading 
center. At Week 8 and ET/EOS, 
FA and FP will be performed on 
the study eye (prior to IVT 
injection of the study drug  at 
Week 8 ). To clarify the time 
point.  
6.1.3  Early 
Termination/End -
of-Study  End-of-Study Visit 
assessments will be 
conducted 28 days after the 
end of treatment for  Week 
52. End of Study Visit assessments 
will be conducted 28 days after 
the EOT at  end of treatment for  
Week 52.  To clarify the text 
throughout.  
[IP_ADDRESS] 
Fluorescein 
Angiography and 
Fundus 
Photography  At screening, FA and FP will 
be performed on both eyes 
and those images will be sent 
to the central reading center. 
At Week  8 and ET/EOS 
Visit, FA and FP will be 
performed on the study eye 
prior to IVT injecti on of the 
study drug and those images 
will be sent to the central 
reading center.  At screening, FA and FP will be 
performed on both eyes and 
those images will be sent to the 
central reading center. At 
Week  8 and ET/EOS Visit, FA 
and FP will be performed on  the 
study eye (prior to IVT injection 
of the study drug  at Week 8 ) 
and those images will be sent to 
the central reading center.  To clarify the time 
point.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 113 Chapter/Section  Initial Wording  Amended or New Wording  Reason/Justification 
for Change  
[IP_ADDRESS]  Definitions 
of Adverse Events  The investigator is 
responsible for reporting all 
AEs that are observed or 
reported during the study, 
regardless of their 
relationship to study drug or 
their clinical significance.  The investigator is responsible 
for reporting all AEs that are 
observed or reported during the 
study, regardless of their 
relationship to study drug or to 
IVT injection procedure or 
their clinical significance.  To include a n 
assessment of AEs 
for IVT injection 
procedure . 
An AE is defined as any 
untoward medical occurrence 
in a subject enrolled into this 
study regardless of its causal 
relationship to study drug.  An AE is defined as any 
untoward medical occurrence in 
a subject enrolled into this study 
regardless of its causal 
relationship to study drug or to 
IVT injection procedur e. 
[IP_ADDRESS] Reporting 
Adverse Events  • investigator -specified 
assessment of severity 
and relationship to study 
drug • investigator -specified 
assessment of severity and 
relationship to study drug 
and to IVT injection 
procedure  To include a n 
assessment of AEs 
for IVT injection 
procedure . 
[IP_ADDRESS]  
Assessment of 
Causality  The investigator’s 
assessment of an AE’s 
relationship to study drug is 
part of the documentation 
process, but it is not a factor 
in determining what is or is 
not reported in the study.  The investigator’s assessment of 
an AE’s relationship to study 
drug and IVT injection 
procedure  is part of the 
documentation process, but it is 
not a factor in determining what 
is or is not reported in the study.  To include a n 
assessment of AEs 
for IVT injection 
procedure . 
Unrelated:  This relationship 
suggests that there is no 
association between the study 
drug and the reported event.  
Related:  This relationship 
suggests that there is an 
association between the study 
drug and the reported event.  Unrelated:  This relationship 
suggests th at there is no 
association between the study 
drug or the IVT injection 
procedure  and the reported 
event.  
Related:  This relationship 
suggests that there is an 
association between the study 
drug or the IVT injection 
procedure  and the reported 
event.  
6.3.5 Vital Signs  On injection visits, vital signs 
will be measured prior to 
IVT injection of the study 
drug.  On injection visits, vital signs 
will be measured prior to IVT 
injection of the study drug. Vital 
signs will also be performed at 
any time during  the ET/EOS 
Visit.   To be consistent  with 
footnote n of the 
Table 6 -1. 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 114 Chapter/Section  Initial Wording  Amended or New Wording  Reason/Justification 
for Change  
6.4 
Pharmacokinetic 
Assessments  Quantification of free and 
bound SCD411 and 
aflibercept will be performed 
for subjects who agree to 
participate in the PK 
substudy using blood 
samples drawn at predose, 
and at +1 day, +3  days, 
+7 days, +14  days, and 
+[ADDRESS_892402] injection.  Quantification of free and bound 
SCD411 and aflibercept will be 
performed for subjects who 
agree to participate in the PK 
substudy using blood samples 
drawn at predose, and at +1 day, 
+3 days, +7  days, +14  days, and 
+[ADDRESS_892403] injection (Week 8) .  To be consistent with 
footnote p of the 
Table [ADDRESS_892404] 
completed Week  8 Visit. 
From this meeting, the IDMC 
members will make a 
decision to continue the 
study without change, 
modify study, or study 
termination. Any decision to 
terminate the study will be 
based on clinical judgment 
only and no formal stoppi[INVESTIGATOR_661539]. The 
sponsor is obligated to 
inform the study sit es, 
IRB/IEC and Competent 
Authorities of the IDMC 
recommendations according 
to country  specific  
requirements.  An Two  IDMC meeting 
meetings  will be held : one 
safety meeting will be held 
approximately [ADDRESS_892405] completed the 
Week  8 Visit. From this meeting 
After each meeting , the IDMC 
members will make a decision to 
continue the study without 
change, modify the study or 
enrollment to be placed on 
hold , or s tudy termination. Any 
decision to terminate the study 
will be based on clinical 
judgment only and no formal 
stoppi[INVESTIGATOR_661535]. The 
sponsor is obligated to inform 
the study sites, IRB/IEC and 
Competent Authorities of the 
IDMC recommendations 
accord ing to country -specific  
requirements.  To reflect the 
addition of an  interim 
analysis.  
7 Statistical and 
Analytical Plan  Details for all endpoint 
analyses will be provided in 
the final statistical analysis 
plan (SAP), which will be 
finalized prior to the database 
lock.  Details for all endpoint analyses 
will be provided in the final 
statistical analysis plan (SAP), 
which will be finalized prior to 
the Week [ADDRESS_892406] deviation (SD) for 
the mean change from 
baseline at early visits 
(Weeks 4 to 12) based on 
observed data for the FAS Standard deviation (SD) for the 
mean change from baseline at 
early visits (Weeks 4 to 12) 
based on observed data for the 
FAS ranged from and 8.[ADDRESS_892407] 
reference . 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 115 Chapter/Section  Initial Wording  Amended or New Wording  Reason/Justification  
for Change  
ranged from and 8.73 to 
11.99 considering all 
treatment groups from 
VIEW1 and from 7.4 to 11.0 
letters for the VIEW2 study 
(Eylea Statistical Review, 
Appendix Tables A.1 and 
A.2). 11.99 considering all treat ment 
groups from VIEW1 and from 
7.4 to 11.0 letters for the VIEW2 
study ( DHHS 2011  [Eylea 
Statistical Review, Appendix 
Tables A.1 and A.2 ]). 
[IP_ADDRESS] Primary 
Efficacy Outcome 
Measures  - Supportive analysis for the 
primary endpoint will be 
performed based on the mFAS 
per the PMDA’s request. Data 
after receipt of rescue therapy 
will be set to missing without 
employing MI. Both the 
MMRM and ANCOVA 
analyses will be performed 
using the non -imputed data.  To be in line wit h the  
SAP.  
[IP_ADDRESS] Secondary 
Efficacy Outcome 
Measures  The estimated mean 
treatment difference in the 
change from baseline in 
BCVA as measured by 
[CONTACT_661617] 
52 weeks along with the 
corresponding 90% and 95% 
CIs from the same MMRM 
model as used in the primary 
analysis but including data 
from all weeks through Week 
52 will also be presented.  The estimated mean treatment 
difference in the change from 
baseline in BCVA as measured 
by [CONTACT_661561] 2702 
charts  through 52 weeks al ong 
with the corresponding 90% and 
95% CIs from the same MMRM 
model as used in the primary 
analysis but including data from 
all weeks through Week 52 will 
also be presented for the FAS 
and PPS . To be consistent  with 
the text in the 
synopsis .  
The percentage of subjects 
who gain ≥15 letters in 
BCVA as measured by 
[CONTACT_661618] (Week 8 
and Week 52) compared with 
baseline will be summarized 
and 95% CI for the 
proportions in each treatment 
arm and difference in 
proportions b etween 
treatment arms will be 
presented.  The percentage of subjects who 
gain ≥15 letters in BCVA as 
measured by [CONTACT_661597] 2702 charts  at postbaseline 
visits (Week 8 and Week 52) 
compared with baseline will be 
summarized and 95% CI for the 
propo rtions in each treatment 
arm and difference in 
proportions between treatment 
arms will be presented.  
7.5.6 Interim 
Analyses  No interim analyses are 
planned for this study. The 
primary analysis of efficacy 
and all other efficacy and No interim analyses are planned 
for this study. The primary 
analysis of efficacy and all other 
efficacy and safety analyses will To add an interim 
analysis to support 
regulatory filing to 
the PMDA.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 116 Chapter/Section  Initial Wording  Amended or New Wording  Reason/Justification 
for Change  
safety analyses will be 
conducted at the Week 8 
database lock; ie, after all 
subjects have completed the 
Week [ADDRESS_892408] been 
discontinued from the study 
prior to this visit. 
Distribution of the Week 8 
analysis will be restricted 
only to the IDMC members 
in order to minimize bias 
through the end of the study.  be conducted at the Week 8 
database lock; ie, after all 
subjects have comp leted the 
Week [ADDRESS_892409] enrollment and 
data cleaning/programming 
activities.  
As the primary study endpoint 
is the bioequivalence 
comparison at Week 8, no type 
I error adjustments are 
required as the a nalysis 
performed after the Week 8 
database lock are considered 
final for the primary efficacy 
endpoint. No type I error 
adjustments are planned for 
the secondary efficacy 
endpoints; therefore, no error 
adjustments will be performed 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 117 Chapter/Section  Initial Wording  Amended or New Wording  Reason/Justification 
for Change  
due to the interim anal ysis as 
all analyses after the primary 
analysis at the Week [ADDRESS_892410] completed 
Week  8 Visit. From this 
meeting, the IDMC will 
make a recommendation to 
the sponsor regarding the 
study to continue without 
change, modify study or 
enrollment to be p laced on 
hold, or study termination.  An IDMC will be established for 
the study. An Two  IDMC 
meeting meetings  will be held : 
one safety meeting will be held 
approximately [ADDRESS_892411] the 
addition of an interim 
analysis.  
11.4 Final Report  Upon completi on of the 
study, the investigator, where 
applicable, should inform the 
institution; the 
investigator/institution 
should provide the IRB/IEC 
with a summary report of the 
study’s outcome and the 
sponsor and regulatory 
authorities with any reports 
required.  Upon completion of the interim 
and final analyses of the study, 
the investigator, where 
applicable, should inform the 
institution; the 
investigator/institution should 
provide the IRB/IEC with a 
summary report of the study’s 
outcome and the sponsor and 
regul atory authorities with any 
reports required.  To reflect the 
addition of an  interim 
analysis.  
[ADDRESS_892412]  - Department of Health and 
Human Services (DHHS), 
Food and Drug 
Administration, Center for 
Drug Evaluation and 
Research, Office of 
Translationa l Sciences, Office 
of Biostatistics (US). Statistical 
Review and Evaluation. 
Aflibercept ophthalmic 
solution (VEGF Trap -Eye). 
2011 [cited 2022 Jan 24] 
[application number 
125387Orig1s000]. Available To insert the correct 
reference.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 118 Chapter/Section  Initial Wording  Amended or New Wording  Reason/Justification 
for Change  
from:  
https://www.accessdata.fda.go
v/drugsatfda_docs/nda/2011/1
25387Orig1s000StatR.pdf  
Throughout  - Editorial and administrative 
changes, typographical error 
corrections, and document 
formatting revisions.  To improve the 
readability and 
overall quality of the 
document.  
14.2 Protocol Amendment, Version 2.0 , 24 November  2020  
This global protocol amendment is considered substantial mainly for the following reasons. 
The amendment incorporated the changes that had been updated in  the country -specific 
protocol amendments, including the Slovakia - and Korea -specific protocol amendments, as 
per the requests from the regulatory agencies in both countries. Additionally , the amendment 
incorporated the r ecommendati ons from the US FDA to 1)  change the FAS population  and 2) 
keep  subjects in the study to continue with their regularly scheduled visits and assessments 
until Week  [ADDRESS_892413]. Additional non -substant ial 
changes were made for clarity.  
Additions to the protocol text are shown in bold , and deletions are shown in strikethrough 
text. Minor editorial and grammatical corrections are not specified. Any notes for the section 
are included in brackets.  
Initial Wording  Amended or New Wording  Reason/Justification for Change  
Chapter/section concerned  
Section 2.[ADDRESS_892414] receipt of 
rescue therapy  in the study eye 
will be  set to missing, thereby  [CONTACT_661619].  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.[ADDRESS_892415] rescue will 
not be set to missing but will be 
included i n the mixed -effects 
model for repeated measures 
(MMRM ) analysis. The 
secondary estimands are 
constructed to estimate the 
treatment effect while including 
the impact of rescue therapy , 
which may better reflect actual 
real-world outcomes where 
rescue would l ikely be given 
when lack of efficacy is seen.  
Chapter/section concerned  
Section 3.1 Study Design  
... 
Approximately 560 subjects with 
wet AMD will be enrolled in this 
study across approximately 155 
sites in 14 countries. Upon entry 
into the study, subjects will be 
assigned a screening numbe r. 
Subjects who meet all inclusion 
and none of the exclusion criteria 
will return to the clinic on Day 1 
for further evaluation. Subjects 
who continue to meet all inclusion 
and none of the exclusion criteria 
will be randomly assigned and 
treated on Day 1. At this visit, the 
subjects will be randomly 
assigned in 1:[ADDRESS_892416] 3 
injections and every 8 weeks 
thereafter until Week 48 as 
detailed in the Schedule of Events 
(Table 6 -1). A schematic of the 
study design is presented in 
Figure  3-1. The details of the 
implementation in Interactive ... 
Approximately 560 subjects with 
wet AMD will be enrolled in this 
study across approximately 155 
sites in 14 countries. Upon entry 
into the study, subjects will be 
assigned a screening number. 
Subjects who meet all inclusion 
and none of the exclusion criteria 
will return to the clinic on Day 1 
for further evaluation. Subjects 
who continue to meet all inclusion 
and none of the exclusion criteria 
will be randomly assigned and 
treated on Da y 1. At this visit, the 
subjects will be randomly 
assigned in 1:[ADDRESS_892417] participation 
in the PK substudy.  Subjects in 
Israel will not participate in the 
PK substud y. Randomization 
will also be stratified by 
[CONTACT_661620].  ... 
... 
All subjects will be assessed once 
every 4 weeks as detailed in the 
Schedule of Events (Table 6 -1). 
The End -of-Treatment (EOT) 
Visit will be scheduled for 
Week  48. Subjects who  The PK substudy in Israel was 
clarified  as per the request from 
the Israel regulatory agency.  
 
Stratification by [CONTACT_661621] ’s decision.  
 
The paragraph on study treatment  
discontinuation has been  updated 
as per the US FDA 
recommendation to minimize 
missing data by [CONTACT_9377][INVESTIGATOR_661540] , so that 
their efficacy and safety data after 
treatment discontinuation can be 
collected  to support sensitivity 
analyses.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 120 Response Technology (IRT) wi ll 
be provided in the IRT manual and 
the randomization specification 
form.  
... 
All subjects will be assessed once 
every 4 weeks as detailed in the 
Schedule of Events (Table 6 1). 
Subjects who discontinue the 
study treatment should be 
encouraged to return f or the Early 
Termination (ET) Visit as soon as 
possible after discontinuing the 
treatment but no later than 28 days 
after discontinuation. The End -of-
Study (EOS) Visit will occur [ADDRESS_892418] the reasons 
for treatment discontinuation 
documented on the Treatment 
Discontinuation page of the 
electronic case report form 
(eCRF ). Treatment 
discontinuation in the study was 
defined as subjects 
discontinuing the study 
treatment due to adverse 
event/lack of efficacy/rescue 
treatment but not limited to 
these conditions.  Every effort 
should be made to have such 
subjects remain in the study and 
continue with their regularly 
sched uled visits and assessments 
until Week  [ADDRESS_892419] should be prematurely 
withdrawn, then should be 
encouraged to return for the Early 
Termination (ET) Visit should be 
completed  as soon as possible 
after discontinuing the treatment 
but no later than 28 days after 
discontinuation. The End -of-
Study (EOS) Visit will occur [ADDRESS_892420] in the study.  
Chapter/section concerned  
Section 4.1.1 Inclusion Criteria  
 
3. Active choroidal 
neovascularization lesions 
secondary to AMD evidenced by 
[CONTACT_228628] (FA) in 
the study eye at screening and 
confirmed by [CONTACT_178842].  
... ... 
3. Active choroidal subfoveal, 
juxtafoveal, or extrafoveal  
neovascularization lesions 
secondary to AMD evidenced b y 
fluorescein angiography (FA) in 
the study eye at screening and 
confirmed by [CONTACT_178842]  
... 
7. The area of CNV making up 
either 50% or more of the total 
lesion area and confirmed by 
[CONTACT_73475].  Inclusion criterion (IC) #[ADDRESS_892421] from the Korean 
Ministry of Food and Drug Safety 
(MFDS ), which ha s been 
incorporated  into the 
Korea -specific protocol 
amendment.  
 
IC#[ADDRESS_892422] 
from the Korean MFDS to clarify 
that CNV should be either 50% or 
more of the total lesion area in the 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 121 inclusion criteria.  This change has 
been applied to the Korea -specific 
protocol amendment.  
Chapter/section concerned  
Section 4.1.2 Exclusion Criteria  
 
12. Active extraocular 
inflammation in either eye or 
intraocular inflammation in study 
eye 
... 
24. Uncontrolled hypertension 
defined as systolic blood pressure 
(BP) >180 mmHg or diastolic 
BP >100 mmHg under appropriate 
antih ypertensive treatment  ... 
12. Active extraocular 
inflammation in either eye or 
intraocular  
intraocular/periocular infection 
and inflammation in either eye  
... 
24. Uncontrolled hypertension 
defined as systolic blood pressure 
(BP) > 180 160 mmHg or diastolic 
BP >100 mmHg under 
appropriate antihypertensive 
treatment  
... 
36. Intraocular pressure 
≥25 mmHg in spi[INVESTIGATOR_661541]-glaucoma treatment  
 
37. Any prior or ongoing 
systemic medical condition 
(including but not limited to 
infectious, inflammatory, 
psychiatric, neurological, renal, 
hepatic, respi[INVESTIGATOR_661542]) or clinically 
significant screening laboratory 
value that in the opi[INVESTIGATOR_661523] a 
safety risk, interfere with study 
compliance and fol low-up, or 
confound data interpretation 
throughout the study period.  Exclusion criterion (EC) #12 was 
updated to clarify that subjects 
with the conditions of 
intraocular/periocular infection 
and inflammation in either eye 
should be excluded  at screening. 
This change has been applied to 
the Korea -specific protocol 
amendment.  
 
The limit of systolic blood 
pressure was decreased from 180 
to 160  mmHg in EC#[ADDRESS_892423] from the Slovakia 
regulatory agency. The change has 
been applied to the 
Slovakia -specific protocol 
amendment.  
 
As per the requests from the 
Slovakia regulatory agency and 
the Korean MFDS , EC#[ADDRESS_892424] from the 
Slovakia regulatory  agency , 
subjects with a systemic medical 
condition shoul d be excluded 
from the study ; therefore , EC#37 
was added.  
Chapter/section concerned  
Section 4.[ADDRESS_892425] in the 
original protocol (version 1.0) . Only one eye ( study eye) must 
meet all the inclusion criteria 
and none of the exclusion 
criteria.  
 
Fellow eye should not show any 
signs of AMD that, in the 
investigator’s medical opi[INVESTIGATOR_1649], 
may need any treatment during 
study period.  The section of selection of study 
eye was added as per the US FDA 
requirement  to clearly define 
study eye in the protocol.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 122 Chapter/section concerned  
Section 4. 3.1 Discontinuation 
From Study Treatment  
Section 4.3.2  Withdrawal From 
the Study  
 
Subjects may withdraw from the 
study at any time at his/her own 
request or may be withdrawn at 
any time at the discretion of the 
investigator and/or sponsor for 
safety, behavioral, or 
administrative reasons. If the 
subject withdraws consent for 
disclosure of future information, 
the sponsor may retain and 
continue to use any data collect ed 
before such a withdrawal of 
consent. Subjects should undergo 
ET Visit assessments as soon as 
possible after discontinuing the 
study treatment, but no later than 
28 days after discontinuation, as 
described in the Schedule of 
Events (Table 6 -1). 
 
General reasons for 
discontinuation can include, but 
are not limited to:  
• Death.  
• Subject has a serious or 
intolerable AEs that in the 
Investigator’s opi[INVESTIGATOR_661543].  
• Lost to follow -up. 
• Decision by [CONTACT_661622].  
• Decision by [CONTACT_661623] a 
reason (eg, a suspi[INVESTIGATOR_661530], the subject enrolling in 
multiple clinical studies, lack 
of compliance, etc.) other 
than that of a n AE.  Section 4.3.1 Discontinuation 
From Study Treatment  
 
Subjects may withdraw from the 
study at any time at his/her own 
request or may be withdrawn at 
any time at the discretion of the 
investigator and/or sponsor for 
safety, behavioral, or 
administrative reasons. If the 
subject withdraws consent for 
disclosure of future information, 
the sponsor may retain and 
continue to use any data collect ed 
before such a withdrawal of 
consent.  In rare instances, it 
may be necessary for a 
participant to permanently 
discontinue (definitive 
discontinuation) the study 
treatment. If the investigational 
product is definitively 
discontinued, the Treatment 
Discont inuation page of the 
eCRF should be completed. 
Every effort should be made to 
have  such  subjects remain in the 
study and continue with their 
regularly scheduled visits  and 
assessments until Week  [ADDRESS_892426] should 
be prematurely withdrawn, 
then  the Ssubjects  should 
undergo ET Visit assessments as 
soon as possible after 
discontinuing the study treatment, 
but no later than 28 days after 
discontinuation, as described in 
the Schedule of Events 
(Table  6-1). 
 
A subject may discontinue from 
the study treatment for any of 
the following reasons:  
• Subject has a serious or 
intolerable AEs that in the As per the US FDA 
recommendation to keep  subjects 
who discontinue study treatment 
in the study to continue with their 
regularly  scheduled visit s, the 
reasons for 
withdrawal/discontinuation need 
to be  introduced separately. As per 
the latest [COMPANY_003] protocol template, 
the above reasons were placed in 
the corresponding sections  (The 
Section 4.2.1 Reason for 
Withdrawal/Discontinuation in  the 
original protocol was divided into 
two sections : Discontinuation 
From Study Treatment, and 
Withdrawal From the Study) . 
 
For clarity, c ertain specific criteria 
for treatment discontinuation were 
moved to the section of 
discontinuation of study 
treatmen t. 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 123 • Pregnancy.  
• Protocol deviation which 
may adversely affect the 
subject’s safety and/or 
integrity of data as agreed by 
[CONTACT_11219]/or upon 
request from the Sponsor.  
• New diagnosis or worsening 
neovascular AMD in the 
fellow eye at any point 
durin g the study.  
o Before 8 weeks of the 
study: Study treatment is 
continued till 8 weeks 
and then discontinued.  
o After 8 weeks of the 
study: Study treatment is 
immediately 
discontinued.  
• The subject has symptoms or 
an intercurrent illness not 
consistent with the protocol 
requirements or that justify 
withdrawal.  
• The subject withdraws 
consent.  
• If a subject withdraws his/her 
consent, the Investigator 
must inquire the reasons for 
consent withdrawal as to 
whether it is related to the 
study (eg, documented lack 
of effic acy, AE or 
pregnancy); however, the 
subject may refuse to provide 
such reason.  
• A subject misses any of first 
2 doses (IVT injection of IP 
at Week 0 [Day 1] or Week 
4) after randomization.  
 
Certain specific criteria for 
treatment discontinuation include:  
• Development of 
rhegmatogenous retinal 
detachment or stage 3 or 4 
macular holes  
• A decrease in BCV A of ≥[ADDRESS_892427] Investigator’s opi[INVESTIGATOR_661544].  
• Decision by [CONTACT_661622].  
• Pregnancy.  
• New diagnosis or worsening 
neovascular AMD in the 
fellow eye at any point 
during the study.  
o Before 8 w eeks of the 
study: Study treatment 
is continued till 8 
weeks and then 
discontinued.  
o After 8 weeks of the 
study: Study treatment 
is immediately 
discontinued.  
• A subject misses either  any 
of the first 2 doses (IVT 
injection of IP at Week 0 
[Day 1] or Week 4) after 
randomization.  
• Decision by [CONTACT_661623] a 
reason (eg, a suspi[INVESTIGATOR_661530], the subject enrolling 
in multiple clinical studies, 
lack of compliance, etc.) 
other than that of an AE.  
 
Certain specific criteria for 
treatment discontinuation include:  
• Development of 
rhegmatogenous retinal 
detachment or stage 3 or 4 
macular holes  
• A decrease in BCV A of ≥[ADDRESS_892428] assessment of V A  
• A subretinal  hemorrhage 
involving the center of the 
fovea or, if the size of the 
hemorrhage is ≥50% of the 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 124 assessment of V A  
• A subretinal hemorrhage 
involving the center of the 
fovea or, if the size of t he 
hemorrhage is ≥50% of the 
total lesion area  
• Clinical signs of irreversible 
ischemic visual function loss.  total lesion area  
• Clinical signs of irreversible 
ischemic visual function 
loss. 
 
 
Section 4.3.[ADDRESS_892429] may withdraw from 
the study f or any of the 
following reasons:  
• Death.  
• Lost to follow -up. 
• Protocol deviation which 
may adversely affect the 
subject’s safety and/or 
integrity of data as agreed by 
[CONTACT_661624]/or upon 
request from the Sponsor.  
• The subject has symptoms or 
an inter current illness not 
consistent with the protocol 
requirements or that justify 
withdrawal.  
• The subject withdraws 
consent.  
• If a subject withdraws 
his/her consent, the 
Iinvestigator must inquire 
the reasons for consent 
withdrawal as to whether it 
is related to the study (eg, 
documented lack of efficacy, 
AE or pregnancy); however, 
the subject may refuse to 
provide such reason.  
Chapter/section concerned  
Section 4.3. [ADDRESS_892430] 
withdraws from the study 
treatment or active participation in 
the study, the reason(s) for 
withdrawal shall be recorded by ... 
Subjects who discontinue study 
treatment or active participation in 
the study will no longer receive 
study drug. When a subject 
withdraws from the study 
treatment or active participation in 
the study, the reason(s) for 
withdrawal shall be recorded by 
[CONTACT_661625] (eCRF). Every effort The section was updated as per 
the US FDA recommendation to 
keep  subjects who discontinue 
study treatment in the study and 
continue  with their regularly 
scheduled visits.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 125 the investigator on the relevant 
page of the electronic case report 
form (eCRF). All subjects who 
discontinue study treatment or 
withdraw from the study 
prematurely will be asked  to 
complete the ET Visit procedures 
as soon as possible after 
discontinuing the study treatment, 
but no later than [ADDRESS_892431] 
discontinues the study treatment 
due to an AE/serious adverse 
event (SAE) or if AEs/SAEs were 
ongoing at the time of 
discontinuation, the subject will 
be followed -up until resolution or 
stabilization.  should be made to have such  
subjects continue with the ir 
regularly scheduled visits and 
assessments until Week  [ADDRESS_892432] 
discontinues the study treatment 
due to an AE/serious adverse 
event (SAE) or if AEs/SAEs were 
ongoing at the time of 
discontinuation, the subject will 
be followed -up until  resolution or 
stabilization.  
Chapter/section concerned  
Section 4.3. 4 Screen Failures  
... 
Subjects who do not meet the 
criteria for participation in this 
study may not be rescreened 
unless an image retransmission is 
requested from the central image 
vendor due to any possible 
technical issues. However, this is 
not considered  to be rescreening.  ... 
Subjects who do not meet the 
criteria for participation in this 
study may not be rescreened . 
unless an image  Image 
retransmission is requested from 
the central image center  vendor  
due to any possible technical 
issues . However, this  is not 
considered to be rescreening.  The text was revised for clarity.  
Chapter/section concerned  
Section 5.2 Treatments 
Administered  
... 
Subjects will receive their 
randomized study treatment 
injections  as per the Schedule of 
Events (Table 6 1) and according 
to the procedure manual. Clinic 
staff involved in the injection tray 
assembly, anesthetic preparation, 
and study drug preparation and 
administration will follow 
appropriate aseptic techniques to ... 
Subjects will receive their 
randomized study treatment 
injections as per the Schedule of 
Events (Table 6 -1) and according 
to the procedure manual. Clinic 
staff involved in the injection tray 
assembly, anesthetic preparation, 
and study drug preparation and 
administration will follow 
appropriate aseptic techniques to 
minimize the risk of potential AEs 
associated with IVT injections. If 
the pre-procedure IOP is equal 
to or greater  than [ADDRESS_892433] -injection 
assessments of IOP and dilate d 
fundoscopy by [CONTACT_661626], both assessments 
were removed for the unmasked 
staff and will only be conducted 
by [CONTACT_661578]. The sponsor 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 126 minimize the risk of potential AEs 
associated with IVT injections.  
... 
Immediately following the IVT 
injection, subjects should be 
checked for presence of optic 
nerve perfusion, formed vision, 
and excessive level of intraocular 
pressure (IOP) elevation or 
decrease. Appropriate monitoring 
consists of a fundoscopy check for 
perfusion of the optic nerve head, 
hand movement/finger counting 
vision and tonometry. If required, 
a sterile paracentesis needle 
should be available for the 
injecting physician to ensure 
control of excessive IOP 
elevation.  
 
Assessment of perfusion and 
presence of formed vision and 
hard globe due to excessive 
pressure is done immediately 
following the injection by [CONTACT_661627]. 
There is technological time 
between the su bject leaving the 
injecting room and going to the 
room where the IOP will be 
followed until safe to let the 
subject go home.  IVT injection will not be 
administered (either withheld or 
delayed) until the IOP is 
decreased to acceptable safety 
levels as per  the investigator’s 
medical judgement.  
... 
Immediately following the IVT 
injection, subjects should be 
checked by [CONTACT_661628], formed vision, an d 
excessive level of intraocular 
pressure (IOP) elevation or 
decrease. Appropriate monitoring 
consists of a fundoscopy check 
for perfusion of the optic nerve 
head,  hand movement/finger 
counting vision and tonometry  for 
subject safety. The information 
will not be captured in the 
eCRF. If subjects can recognize 
hand movement/finger counting 
vision immediately following the 
IVT injection, then the subjects 
should be transferred from the 
unmasked staff to the masked 
staff. If subjects cannot 
recognize hand 
move ment/finger counting 
vision immediately following the 
IVT injection, then the 
unmasked staff should further 
investigate the reason . If 
required, a sterile paracentesis 
needle should be available for the 
injecting physician to ensure 
control of excessive IO P 
elevation.  
Assessment of perfusion and 
presence of formed vision and 
hard globe due to excessive 
pressure is done immediately 
following the injection by [CONTACT_661627]. 
There is technological time 
between the subject leaving the 
injecting room and going to the 
room where the IOP will be 
followed until safe to let the confirmed that the hand 
movement/finger counting check s 
by [CONTACT_661629].  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.[ADDRESS_892434] go home.  
The safety data after 
administration of the study 
treatment is collected by [CONTACT_661630]. The 
information will be captured in 
the eCRF.  
Chapter/section concerned  
Section 5.2.[ADDRESS_892435] is newly diagnosed 
with neovascular AMD or has  
worsening neovascular AMD in 
fellow eye after Week 8, the 
principal investigator (PI) will 
perform ET/EOS Visits, 
discontinue the subject from the 
study, and will continue treatment 
of neovascular AMD in both eyes 
as per PI’s standard of care (SOC) 
and hi s/her discretion.  Treatment of fellow eye will be 
allowed at any time during the 
study  if If a subject is newly 
diagnosed with neovascular AMD 
or has worsening neovascular 
AMD in the fellow eye . The 
fellow eye should be treated 
only with Eylea as per 
inves tigator’s discretion . before 
completion of [ADDRESS_892436] is newly diagnosed 
with neovascular AMD or has 
worsening neovascular AMD in 
fellow eye after Week 8, the 
principal investigator (PI) will 
perform ET/EOS Visits, 
discontinue the subject from the 
study, and will continue treatment 
of neovascular AMD in both eyes The section was revised as per the 
sponsor’s decision to allow 
treatment of fellow eye only with 
Eylea for the whole duration of  
the study.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 128 as per PI’s standard of care (SOC) 
and his /her discretion.  
Section 5.8.1 Rescue Treatment  
... 
Subjects who will receive rescue 
treatment will need to perform 
ET/EOS Visits and discontinue 
from the study.  ... 
In the study eye, rescue treatment 
for neovascular AMD is not 
permitted at any point in time. If it 
is observed that efficacy is not 
achieved by [CONTACT_104841], 
as determined by [CONTACT_093], 
subjects can be considered for 
rescue treatment after Week 4 if 
any 1 of the following conditions 
are met as assessed by [CONTACT_661560]:  
• Decrease of VA letter score 
of [ADDRESS_892437] assessment and/or  
• Increase in t he central 
subfield thickness of [ADDRESS_892438] 
assessment (OCT) by [CONTACT_1275],  an An increase 
in intraretinal fluid, 
subretinal fluid, or subretinal 
hyper -reflective material, 
that in the investigator’s 
opi[INVESTIGATOR_661545]’s 
neovascular AMD  
 
Subjects who will receive rescue 
treatment need to discontinue the 
study treatment and should 
have the reason for treatment 
discontinuation documented on 
the Treatment Discontinuation 
page of the eCRF and continue 
with their regularly scheduled 
visits  and assessments until 
Week  [ADDRESS_892439] should be prematurely 
withdrawn, then the ET Visit 
should be completed as soon as 
possible after discontinuing the 
study treatment but no later 
than 28 days after The section was updated as per 
the US FDA recommendation to 
remain subjects who discontinue 
study treatment due to receipt of 
rescue treatment in the study 
continuing with their regularly 
scheduled visits .  
 
Due to  SCD’s concern on the 
potential error caused by [CONTACT_661631], the condition for rescue 
treatment of an  increase in the 
central subfield thickness of 
[ADDRESS_892440] 
assessment (OCT) by [CONTACT_661632].  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 129 discontinuation will need to 
perform ET/EOS Visits and 
discontinue from the stud y. 
Chapter/section concerned  
Section 5.8.2 Prohibited 
Medications  
 
The details of the prohibited 
medications during the study are 
presented in Table 5 -1. Concurrent 
use of systemic or IVT anti -VEGF 
agents; IVT, subtenon, or 
peribulbar corticosteroids in eithe r 
eye, except as required to treat 
AEs.  
... The details of the prohibited 
medications during the study are 
presented in Table 5 -1. 
Concurrent use of systemic or 
IVT anti -VEGF agents; IVT, 
subtenon, or peribulbar 
corticosteroids in either  study  
eye, except as required to treat 
AEs.  
... Prohibited medications applied to 
the fellow  eye have been 
removed, as per sponsor’s 
decision to allow fellow  eye 
treatment only with Eylea  for the 
whole duration of the study.  
Chapter/section concerned  
Section  6.1.3 Early 
Termination/End -of-Study  
 
All subjects who discontinue 
study treatment should return for 
the ET Visit as soon as possible 
after the discontinuation but no 
later than [ADDRESS_892441]  to keep  
subjects who discontinue study 
treatment in the study to continue 
with their regularly scheduled 
visits.  
Chapter/section concerned  
Section [IP_ADDRESS] Suspected 
Unexpected Serious Adverse 
Reactions and Nonserious Section [IP_ADDRESS] Suspected 
Unexpected Serious Adverse 
Reactions  and Nonserious 
Adverse Events of Special Interest  The title of the section and the 
body text on nonserious adverse 
events of special interest (AESI s) 
were removed because  there is no 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.[ADDRESS_892442]  
 
The spons or will promptly 
evaluate all suspected unexpected 
serious adverse reactions 
(S[LOCATION_003]Rs) and nonserious AEs of 
special interest against cumulative 
product experience to identify and 
expeditiously communicate 
possible new safety findings to 
investigators, IRBs /IECs, and 
applicable health authorities based 
on applicable legislation.  
...  
The sponsor will promptly 
evaluate all suspected unexpected 
serious adverse reactions 
(S[LOCATION_003]Rs) and nonserious AEs of 
special interest  against cumulative 
product experience to identify and 
expeditiously communicate 
possible new safety findings to 
investigators, IRBs/IECs, and 
applicable health authorities based 
on appli cable legislation.  
,,, definition of AESI in the protocol.  
Chapter/section concerned  
Section 6.4 Pharmacokinetic 
Assessments  
 
Blood samples, for determination 
of concentrations of SCD411 and 
aflibercept, will be collected at the 
timepoints specified in the 
Schedule of Events (Table 6 1) 
and detailed sampling window is 
provided in Table 6 3. 
Quantifica tion of free and bound 
SCD411 and aflibercept will be 
performed for subjects who agree 
to participate in the PK substudy 
using blood samples drawn at 
predose, and at +1 day, +3 days, 
+7 days, +14 days, and +[ADDRESS_892443] 
injecti on. Samples should be 
collected before performing FA, 
when performed on the same day. 
Plasma concentrations of SCD411 
and aflibercept will be determined 
using validated analytical 
procedures. PK parameters 
assessed in the study include 
AUC0 -t, AUC0 -tau, AU C0-inf, 
Cmax, tmax, and t1/2.  
… Blood samples, for determination 
of concentrations of SCD411 and 
aflibercept, will be collected at the 
timepoints specified in the 
Schedule of Events (Table 6 1) 
and detailed sampling window is 
provided in Table 6 3. As per the 
Schedule of Events, addition al 
visits will be arranged for 
collecting the PK blood samples. 
Quantification of free and bound 
SCD411 and aflibercept will be 
performed for subjects who agree 
to participate in the PK substudy 
using blood samples drawn at 
predose, and at +1 day, +3 days,  
+7 days, +14 days, and +[ADDRESS_892444] 
injection. Samples should be 
collected before performing FA, 
when performed on the same day. 
Plasma concentrations of SCD411 
and aflibercept will be determined 
using validated analytical 
procedures. PK parameters 
assessed in the study include 
AUC0 -t, AUC0 -tau, AUC0 -inf, 
Cmax, tmax, and t1/2.  
… For clarity, the sentence on the 
additional visits to be arranged for 
collecting the PK blood samples 
was added.  
Chapter/section concerned  
Section 6. 7 Pregnancy  
 
… No pregnancy test is required 
for women of non -child -bearing 
potential.  Serum pregnancy test 
will be performed for women of 
child -bearing potential  at the The section was updated to clarify  
that the  serum pregnancy test will 
be only administered  to women of 
child -bearing potential  and to 
implement the change to keep 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.[ADDRESS_892445] 
should be followed for safety 
until the outcome of the 
pregnancy is known.  
 
 subjects  in the study to continue 
regularly scheduled visits and 
assessments after study treatment 
discontinuation. Additionally , 
follow -up for safety until the 
outcome of the pregnancy is 
known was emphasized.  
Chapter/section concerned  
Section 7.[ADDRESS_892446] are 
receipt of rescue therapy and 
treatment/study discontinuation. 
Subject s who discontinue 
treatment are to discontinue the 
study.  
 
Week 8  
 
The estimand is the mean 
treatment difference for BCV A 
change from baseline at Week 8. 
For the EMA, the primary analysis 
will be assessed for both the full 
analysis set (FAS) and per -
protoc ol set (PPS). For the FDA, 
PMDA, and any other 
submissions, the primary analysis 
will be performed for the FAS. 
The primary analysis will be 
based on a mixed model for 
repeated measures (MMRM) Intercurrent events of interest are 
receipt of rescue therapy and 
treatment/study discontinuation. 
Subjects who discontinu e 
treatment are to discontinue the 
study . 
 
Week 8  
The estimand is the mean 
treatment difference for BCVA 
change from baseline at Week 8. 
For the EMA, the primary 
analysis will be assessed for both 
the full analysis set (FAS) and 
per-protocol set (PPS). For  the 
FDA, PMDA, and any other 
submissions, the primary analysis 
will be performed for the FAS. 
The primary analysis will be 
based on a mixed model for 
repeated measures (MMRM) 
including data for Week [ADDRESS_892447] to change the FAS 
population and to not discontinue 
subjects from the study when they 
discontinue study treatment due to 
AE/lack of efficacy/rescue 
treatment.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 132 including data for Week 4 and 
Week 8 based on observed data 
and baseline BCV A value as a 
covariate. Subjects who 
discontinue treatment are to 
discontinue the study and 
observations after receipt of 
rescue therapy should be missing; 
however, in the event the subject 
continues follow -up, BCV A values 
after treatment disc ontinuation or 
receipt of rescue therapy will be 
set to missing prior to performing 
the MMRM. The MMRM 
approach assumes data is missing 
at random (MAR) and treatment 
estimates are as if subjects 
continued as on their original 
treatment. Sensitivity analyse s 
will be performed using single 
imputation approaches of last 
observation carried forward 
(LOCF) and baseline observation 
carried forward (BOCF) 
approaches for observations after 
treatment discontinuation/receipt 
of rescue therapy prior to 
performing the MMRM analysis 
(intermittent missing data will be 
considered MAR and not 
imputed). An ANCOV A model 
comparing the Week 8 BCV A 
change from baseline and 
including baseline BCV A value as 
covariate will be performed based 
on observed data, using LOCF, 
and BOCF a pproaches. As with 
the MMRM analysis, for the 
ANCOV A, intermittent missing 
data at Week 8 will be considered 
MAR and observations after 
treatment discontinuation/receipt 
of rescue therapy will be set to 
missing. LOCF also approaches 
treatment estimates as if subjects 
who discontinue had continued on 
their original treatments and 
BOCF approaches treatment 
estimates as if subjects who 
discontinue received no treatment 
or returned to their original observations after receipt of 
rescue therapy should be missing; 
however, in the event the subject 
continues follow -up, BCVA 
values after treatment 
discontinuation or re ceipt of 
rescue therapy will be set to 
missing prior to performing the 
MMRM. The MMRM approach 
assumes data is missing at random 
(MAR) and treatment estimates 
are as if subjects continued as on 
their original treatment. 
Sensitivity analyses will be 
perform ed using single imputation 
approaches of last observation 
carried forward (LOCF) and 
baseline observation carried 
forward (BOCF) approaches for 
observations after treatment 
discontinuation/receipt of rescue 
therapy prior to performing the 
MMRM analysis (in termittent 
missing data will be considered 
MAR and not imputed). An 
ANCOVA model comparing the 
Week 8 BCVA change from 
baseline and including baseline 
BCVA value as covariate will be 
performed based on observed 
data, using LOCF, and BOCF 
approaches. As wit h the MMRM 
analysis, for the ANCOVA, 
intermittent missing data at Week 
8 will be considered MAR and 
observations after treatment 
discontinuation/receipt of rescue 
therapy will be set to missing. 
LOCF also approaches treatment 
estimates as if subjects who 
discontinue had continued on their 
original treatments and BOCF 
approaches treatment estimates as 
if subjects who discontinue 
received no treatment or returned 
to their original condition. 
Multiple imputation approached 
including tippi[INVESTIGATOR_661546].  
Primary Estimand: The 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.[ADDRESS_892448]-treatment 
discontinuation/rescue therapy 
assessments prior to pe rforming 
the MMRM analysis (intermittent 
missing data will be considered 
MAR and not imputed). An 
ANCOV A model comparison the 
Week [ADDRESS_892449] -treatment 
discontinuation/rescue therapy 
observations. Multiple imputation 
approached including tippi[INVESTIGATOR_661547].  
 
Data imputation/analysis methods 
which generate treatment 
estimates  as if subjects continued 
original treatment are considered primary estimand is the mean 
treatment difference in BCVA 
change from baseline at Week 8. 
For the EMA, the primary 
analysis will be assessed for 
both the full analysis set (FAS) 
and per -protocol set  (PPS). For 
the FDA, PMDA, and any other 
submissions, the primary 
analysis will be performed for 
the FAS. The primary estimand 
treats subjects in the analysis as 
if subjects do not receive rescue 
therapy .  
 
Target Population: Subjects 
with wet AMD as defined in the 
enrollment criteria.  
 
Endpoint: Change from 
baseline in BCVA at Week 8.  
 
Treatment Condition(s): Dosing 
at Day 1, Week 4 and Week 8 
with one of the following: 
SCD411 or aflibercept, both 
without rescue therapy . 
 
Population -level Summary: The 
difference in mean change from 
baseline in BCVA at Week 8 
between SCD411 and 
aflibercept and the 
corresponding confidence 
interval for the mean difference.  
 
Intercurrent Events and 
Strategies to Address 
Intercurrent Events  
• Discontinuation of study 
eye study treatment with 
continued participation in 
study without receipt of 
rescue therapy  
o Treatment Policy – no 
imputation; use 
observed data  
• Receipt of rescue therapy  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.[ADDRESS_892450] 
treatment is not equivalent/less 
efficacious to the reference 
product. Sample Size 
Determination  
 
The equivalence margin agreed 
upon with EMA and PMDA was 
determined using the  data 
presented from MARINA (and 
ANCHOR) and VIEW studies. 
These data were used to estimate 
the efficacy of aflibercept 
compared to the placebo treatment 
in subjects with wet AMD. It was 
shown that in MARINA, subjects 
on average lost 2.[ADDRESS_892451] compared to 
the placebo would be estimated as 
approximately 9.3 to 10 letters. A 
margin of 3.8 letters would be 
translated to a preservation of 
59% to 62% of the difference 
between Eylea and sham and is 
less than a 1 line change in V A. 
Equi valence discussions for EMA 
and PMDA were based upon a 
95% CI approach or 2 one -sided 
tests (TOST) at the α=0.025 level.  
The FDA requested a tighter 
equivalence margin of 3 letters but 
agreed equivalence can be 
determined from a 90% CI 
approach (equivalent  to TOST at in the study eye  
o Hypothetical approach 
– data after receipt o f 
rescue will be set to 
missing and post rescue 
data will be imputed 
employing multiple 
imputation (MI) 
assuming missing at 
random (MAR) using 
randomized treatment -
based Markov Chain 
Monte Carlo (MCMC) 
methodology.  
• Discontinuation from 
study, regardless of  reason  
o Hypothetical approach 
- missing data after 
discontinuation will be 
imputed via MI 
assuming MAR  using 
randomized treatment 
based MCMC 
methodology.  
 
Rationale for Strategy: As the 
primary objective of this study 
is to show biosimilar 
equivalence betw een SCD411 
and aflibercept, the primary 
estimand is constructed to 
estimate the treatment effect 
under the assumption that all 
subjects take study treatments 
without  the use of rescue 
therapy  while allowing for 
subjects to discontinue study 
treatment. Mult iple imputation 
under MAR  assumptions results 
in treatment estimates as if 
subjects continued as on their 
original treatment. Treating 
discontinuation as MAR  and 
setting the post rescue 
assessment to missing prior to 
performing MI was chosen to 
avoid infla tion of the SCD411 
treatment effect. Subjects who 
receive rescue therapy  or 
discontinue will have shown 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 135 the α=0.05 level).  
 
Standard deviation (SD) for the 
mean change from baseline at 
early visits (Weeks 4 to 12) based 
on observed data for the FAS 
ranged from and 8.73 to 11.99 
considering all treatment groups 
from VIEW1 and from 7.4 to 11.0 
letters for the VIEW2 study (Eylea 
Statistical Review, Appendix 
Tables A.1 and A.2). For power 
calculations, a range of SD of 
between 10.[ADDRESS_892452] 80% power for 
the FDA, EMA, and PMDA 
analyses for the range of SD 
considered when using 2 one -
sided t -tests on data from  a 
parallel -group design. For the 
FDA analysis based on 
equivalence limits of -3.0 and 3.0 
letters, α=0.05 significance level 
(90% CI), assuming the true 
difference between the means is 
0.0, power of 91% is achieved for 
SD is 10.4 letters and power of 
80% is achieved for SD of 11.8 
letters. For the EMA and PMDA 
analyses based on equivalence 
limits of -3.8 and 3.8 letters, 
α=0.025 significance level (95% 
CI), assuming the true difference 
between the means is 0.0, power 
of 98% is achieved for SD is 10.4 
letters and power of 92% is 
achieved for SD of 11.8 letters 
when sample size is 266 per 
treatment arm. Considering 
approximately 5% loss from 
randomization through Week 8, 
the total sample size required is 
560. 
A subset of 40 subjects ([ADDRESS_892453].  
  
Secondary Estimand: A 
secondary estimand for the 
primary efficacy endpoint is the 
mean treatment difference in 
BCVA change from baseline at 
Week [ADDRESS_892454] actual real -world 
outcomes , where rescue would 
likely be given when lack of 
efficacy is seen.  
 
Week 52  
Primary Estimand: The 
primary estimand is the mean 
treatment difference in BCVA 
change fro m baseline at Week 
52. For the EMA, the primary 
analysis will be assessed for 
both the FAS and PPS. For the 
FDA, PMDA, and any other 
submissions, the primary 
analysis will be performed for 
the FAS. The primary estimand 
treats subjects in the analysis as 
if subjects do not receive rescue 
therapy . 
 
Target Population: Subjects 
with wet AMD as defined in the 
enrollment criteria.  
 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 136 group) will be sel ected for 
collection of PK samples. The 
sample size is not test -driven since 
no equivalence test will be 
performed for PK parameters.  Endpoint: Change from 
baseline in BCVA at Week 52  
 
Treatment Condition(s): Dosing 
at Day 1, Week 4 and Week 8, 
Week 16, Week 24, Week 32, 
Week 40, and Week 48 with one 
of the following: SCD411 or 
aflibercept, both without rescue 
therapy.  
 
Population -level Summary: The 
difference in mean change from 
baseline in BCVA at Week 52 
between SCD411 and 
aflibercept and the 
corresponding conf idence 
interval for the mean difference.  
 
Intercurrent Events and 
Strategies to Address 
Intercurrent Events  
• Discontinuation of study 
eye study treatment with 
continued participation in 
study without receipt of 
rescue therapy  
o Treatment Policy – no 
imputatio n; use 
observed data  
• Receipt of rescue therapy  
in the study eye  
o Hypothetical approach 
– Data after receipt of 
rescue will be set to 
missing and post rescue 
data will be imputed 
employing MI assuming 
MAR  using randomized 
treatment -based 
MCMC methodology.  
• Discontinuation from 
study, regardless of reason  
o  Hypothetical ap proach 
- Missing data after 
discontinuation will be 
imputed via MI 
assuming MAR  using 
randomized treatment -
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 137 based MCMC 
methodology.  
 
Rationale for Strategy: As the 
primary objective of this study 
is to show biosimilar 
equivalence between SCD411 
and afliberc ept, the primary 
estimand is constructed to 
estimate the treatment effect 
under assumption that all 
subjects take study treatments 
without the use of rescue 
therapy  while allowing for 
subjects to discontinue study 
treatment. Multiple imputation 
under MAR  assumptions results 
in treatment estimates as if 
subjects continued as on their 
original treatment. Treating 
discontinuation as MAR  and 
setting the post rescue 
assessment to missing prior to 
performing MI was chosen to 
avoid inflation of the SCD411 
treatmen t effect. Subjects who 
receive rescue therapy  or 
discontinue will have shown 
lack of efficacy in assessments, 
so the MAR approach should be 
conservative if the test 
treatment is not equivalent  to or 
less efficacious than the 
reference product.  
 
Secondary E stimand: A 
secondary estimand for the 
secondary efficacy endpoint is 
the mean treatment difference 
for BCVA change from baseline 
at Week [ADDRESS_892455] 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.[ADDRESS_892456] actual re al-world 
outcomes where rescue would 
likely be given when lack of 
efficacy is seen.  
Chapter/section concerned  
Section 7.2 Sample Size 
Determination  
 
The equivalence margin agreed 
upon with EMA and PMDA was 
determined using the data 
presented from MARINA (and 
ANCHOR) and VIEW studies. 
These data were used to estimate 
the efficacy of aflibercept 
compared to the placebo treatment 
in subjects with wet AMD. It was 
shown that in MARINA, subjects 
on av erage lost 2.[ADDRESS_892457] compared to 
the placebo would be estimated as 
approximately 9.3 to 10 letters. A 
margin of 3.8 letters would be 
translated to a preservation of 
59% to 62% of the difference 
between Eylea and sham and is 
less than a 1 line change in V A. 
Equivalence discussions for EMA 
and PMDA were based upon a 
95% CI approach or 2 one -sided 
tests (TOST) at the α=0.025 level.  The equivalence margin agreed 
upon with EMA and PMDA was 
determined using the data 
presented from MAR INA (and 
ANCHOR) and VIEW studies. 
These data were used to estimate 
the efficacy of aflibercept 
compared to the placebo treatment 
in subjects with wet AMD. It was 
shown that in MARINA, subjects 
on average lost 2.[ADDRESS_892458] compared  to the 
placebo would be estimated as 
approximately 9.3 to 10 letters. A 
margin of 3.8 letters would be 
translated to a preservation of 
59% to 62% of the difference 
between Eylea and sham and is 
less than a 1 line change in VA. 
Equivalence discussions for EMA 
and PMDA were based upon a 
95% CI approach or 2 one -sided 
tests (TOST) at the α=0.[ADDRESS_892459].  Upon agreement within the 
internal [COMPANY_003] team, justification 
for the 3.8 letter margin was 
briefly mentioned in the protocol 
amendment.  
Chapter/section concerned  
Section 7.3 Analysis Sets  ... 
Full Analysis Set (FAS) : aAll 
randomized subjects who received The definition of FAS has been 
updated as per the request from 
US FDA.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 139  
Full Analysis Set (FAS):  all 
randomized subjects who received 
at least [ADDRESS_892460] 1 
postbaseline BCV A assessment in 
the study eye.  
... 
Safety Set (SAF) : all randomized 
subjects receiving at least 1 
injection of the study  drug.  
 
Pharmacokinetic Analysis Set 
(PK Set) : the subset of subjects in 
SAF who have sufficient 
evaluable blood samples to be 
included in the PK Set.  at least [ADDRESS_892461] 1 
postbaseline BCVA assessment in 
the study eye.  
 
Per-protocol Set (PPS) : aAll 
subjects in the FAS, excluding 
those with significant protocol 
violations.  
 
Safety Se t (SAF ): aAll 
randomized  subjects receiving at 
least 1 injection of the study drug.  
 
Pharmacokinetic Analysis Set 
(PK Set) : tThe subset of subjects 
in SAF FAS  who have sufficient 
evaluable blood samples to be 
included in the PK Set.   
The definitions of SAF and PK set 
were updated for clarity . 
Chapter/section concerned  
Section [IP_ADDRESS] Prima ry Efficacy 
Outcome Measures  
... 
The primary analysis of the 
change from baseline in BCV A as 
measured by [CONTACT_661597] 2702 charts through 8 weeks of 
treatment will be performed via 
MMRM including data for the 
Week 4 and Week 8 visits. The 
model wi ll include the change 
from baseline as the dependent 
variable; treatment and visit as 
fixed effects, and baseline BCV A 
as a covariate. An appropriate 
covariance matrix will be selected, 
and details will be provided in the 
SAP. The estimated mean 
treatment difference at Week 8 
along with the corresponding 90% 
and 95% CIs will also be 
presented. Equivalence will be 
determined if the upper and lower 
CI limits for the difference 
between treatments are within the 
equivalence margins. Raw values 
and changes from baseline at 
Week 4 and Week 8 will be 
summarized by [CONTACT_1570] ... 
The primary analysis of the 
change from baseline in BCVA as 
measur ed by [CONTACT_661597] 2702 charts through 8 weeks of 
treatment will be performed via 
MMRM including data for the 
Week 4 and Week 8 visits. The 
model will include the change 
from baseline as the dependent 
variable; treatment and visit as 
fixed effects , and baseline BCVA 
as a covariate. An appropriate  
unstructrued  covariance matrix 
will be selected  used.  In the 
event of convergence issues, 
compound -symmetry will be 
used instead. Rubin’s rules will 
be used to combine the 
estimates from the MMRM 
analyses and the  and details will 
be provided in the SAP. The 
estimated mean treatment 
difference at Week 8 along with 
the corresponding 90% and 95% 
CIs will also be presented. 
Equivalence will be determined if 
the upper and lower CI limits for 
the difference betwe en treatments 
are within the equivalence The section of primary efficacy 
outcome measures was updated as 
per the US FDA request to change 
the FAS population and to not 
discontinue subjects from the 
study when they discontinue study 
treatment due to AE/lack of 
efficacy/rescue treatment.  
 
The covar iance structure was 
specified as per the request from 
US FDA.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 140 using descriptive statistics.  
... 
For the FDA submission and other 
countries submission, a 90% CI 
(equivalent to 2 one -sided tests 
evaluated at an α of 0.05) will be 
assessed using an equi valence 
margin of 3 letters. If the upper 
bound of the 90% CI from the 
MMRM model is less than 3 and 
the lower bound is greater than -3, 
then study success will be 
claimed. For the EMA and 
PMDA, a 95% CI (equivalent to 2 
one-sided tests evaluated at an α 
of 0.025) will be assessed using an 
equivalence margin of 3.8 letters. 
If the upper bound of the 95% CI 
from the MMRM model is less 
than 3.[ADDRESS_892462] squares mean estimate 
of treatment difference and 
corresponding 90% (FDA and 
other countries) and 95% 
(EMA/PMDA) CIs will be 
provided. The primary analysis set 
for the FDA, PMDA, and any 
other submissions will be the FAS. 
For the EMA submission, both the 
FAS and PPS are considered 
primary analysis and equivalence 
will need to be shown for both 
analysis sets. As the extent of 
missing data and/or treatment 
discontinuation/rescue therapy is 
expected to be less than 5%, the 
primary analysis will be based on 
observed data assuming data is  
missing at random. Non -missing 
observations after treatment 
discontinuation/receipt of rescue 
therapy will be set to missing prior 
to analysis. Sensitivity analyses to 
the primary analysis will be 
performed by [CONTACT_661633]/rescue 
therapy BCV A scores using the margins. Raw values and changes 
from baseline at Week 4 and 
Week 8 will be summarized by 
[CONTACT_661634] . 
... 
For the FDA submission and 
other countries submission, a 90% 
CI (equivalent to 2 one -sided tests 
evaluated at an α of 0.05) will be 
assessed using an equivalence 
margin of 3 letters. If the upper 
bound of the 90% CI from the 
MMRM model  is less than 3 and 
the lower bound is greater than -3, 
then study success will be 
claimed. For the EMA and 
PMDA, a 95% CI (equivalent to 2 
one-sided tests evaluated at an α 
of 0.025) will be assessed using 
an equivalence margin of 3.8 
letters. If the upper bound of the 
95% CI  from the MMRM model  
is less than 3.[ADDRESS_892463] squares mean estimate 
of treatment difference and 
corresponding 90% (FDA and 
other countries) and 95% 
(EMA/PMDA) CIs will be 
provided. The primary analysis 
set for the FDA, PMDA, and any 
other submissions will be the 
FAS. For the EMA submission, 
both the FAS and PPS are 
considered primary analysis and 
equivalence will need to be shown 
for both analysis sets. As the 
extent of missing  data and/or 
treatment discontinuation/rescue 
therapy  is expected to be less than 
5%, the primary analysis will be 
based on observed data assuming 
data is missing at random. 
Nonmissing observations after 
treatment discontinuation/receipt 
of rescue therapy will be set to 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 141 LOCF and BOCF prior to the 
MMRM analysis (intermittent 
missing data will be considered 
MAR and not imputed). In 
addition, analyses will also be 
repeated for the PPS using 
observed data as well as imputin g 
missing data using the LOCF and 
BOCF approaches.  
 
An ANCOV A model comparing 
the change from baseline in BCV A 
at Week 8 and including baseline 
BCV A value as covariate will be 
performed based on observed data 
with nonmissing observations 
after treatment 
discontinuation/receipt of rescue 
therapy being set to missing prior 
to analysis. The ANCOV A model 
will also be performed by 
[CONTACT_661635] -treatment 
discontinuation/rescue therapy 
BCV A values using LOCF and 
BOCF approaches.  
 
Additionally, the MMRM analysis 
will be performed using data from 
multiple imputation (MI) 
including a tippi[INVESTIGATOR_661537]. Observations after 
treatment discontinuation/receipt 
of rescue therapy will be set to 
missing prior to the MI. Multiple 
imputation assuming MAR will be 
applied to all missing data. After 
conclusion of MI,  post treatment 
discontinuation/rescue therapy 
observations for the SCD411 arm 
will have fixed value C added to 
the imputed values. The imputed 
data included the fixed penalty 
will be analyzed by [CONTACT_661636]. A range of values for C 
will be considered to identify the 
point at which equivalence can no 
longer be claimed. Details will be 
provided in SAP.  missing prior to analysis.   
 
As a senstitivity analysis a n 
ANCOVA model comparing the 
change from the baseline in 
BCVA at Week [ADDRESS_892464] study  
treatment  discontinuation/rescue 
therapy BCVA scores using the 
LOCF and BOCF prior to the 
MMRM analysis (intermittent 
missing data will be considered 
MAR and not imputed)  for both 
the FAS and PPS . In addition, 
analyses will also be repeated for 
the PPS using observ ed data as 
well as imputing missing data 
using the LOCF and BOCF 
approaches.  An an ANCOVA 
model comparing the change from 
baseline in BCVA at Week 8 and 
including the baseline BCVA 
value as a covariate will be 
performed based on observed data 
with nonmissi ng observations 
after treatment 
discontinuation/receipt of rescue 
therapy being set to missing prior 
to analysis. The ANCOVA model 
will also be performed  by 
[CONTACT_661637]/rescue therapy 
BCVA values using LOCF and 
BOCF ap proaches for the FAS 
and PPS . 
 
Additionally, the MMRM analysis 
will be performed using data from 
multiple imputation ( MI) 
including a tippi[INVESTIGATOR_661537]. Observations after 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 142 treatment discontinuation/receipt 
of rescue therapy will be set to 
missing prio r to the MI. Multiple 
imputation assuming MAR will 
be applied to all missing data. 
After conclusion of MI, post 
study  treatment  
discontinuation/rescue therapy 
observations for the SCD411 arm 
will have fixed value C added to 
the imputed values. The imputed 
data included the fixed penalty 
will be analyzed by [CONTACT_661638]. A range of values for C 
will be considered to identify the 
point at which equivalence can no 
longer be claimed. Details will be 
provided in SAP.  
Chapter/section concerned  
Section [IP_ADDRESS] Secondary 
Efficacy Outcome Measures  
 
The estimated mean treatment 
difference in the change from 
baseline in BCV A as measured by 
[CONTACT_661617] 52 
weeks along with the 
corresponding 90% and 95% CIs 
from the same MMRM model as 
used in the primary analysis but 
including data from all weeks 
through Week 52 will also be 
presented. Data after the treatment 
discontinuation or receipt of 
rescue therapy will be set to 
missing prior to analysis.  
 
The estimated mean treatment 
difference at Week 52 along with 
the corresponding 90% and 95% 
CIs will also be presented using 
the same MMRM and ANCOV A 
models as used in the Week 8 
analysis. Raw values and changes 
from baseline will be summarized 
by [CONTACT_661639]. 
Sensitivity analyses will be 
performed using LOCF and BOCF The estimated mean treatment 
difference in the change from 
baseline in BCVA as measured by 
[CONTACT_661617] 52 
weeks along with the 
corresponding 90% and 95% CIs 
from the same MMRM model as  
used in the primary analysis but 
including data from all weeks 
through Week 52 will also be 
presented. Data after the treatment 
discontinuation or receipt of 
rescue therapy will be set to 
missing prior to analysis.  
 
The estimated mean treatment 
difference at Week 52 along with 
the corresponding 90% and 95% 
CIs will also be presented using 
the same MMRM and ANCOVA 
models as used in the Week [ADDRESS_892465] to change 
the FAS population and to not 
discontinue subjects from the 
study when they discontinue study 
treatment due to AE/lack of 
efficacy/rescue treatment.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.[ADDRESS_892466] -treatment discontinuation 
assessments or after receipt of 
rescue therapy prior to performing 
the MMRM and ANCOV A 
analysis (intermittent missing data 
will be considered MAR and not 
imputed). Additionally, the 
MMRM analysis will be 
performed using data from 
multiple imputation (MI) 
including a tippi[INVESTIGATOR_661537].  
 
The analysis of c hange from 
baseline in CRT as assessed by 
[CONTACT_661640] a 
MMRM model similar to the one 
used for the analysis of change 
from baseline in BCV A, with the 
corresponding 95% CI for the 
estimates of treatment difference s 
at Week [ADDRESS_892467] -treatment  study  
discontinuation assessments or 
after receipt of rescue therapy 
prior to performing the MMRM 
and ANCOVA analysis 
(intermittent missing data will be 
considered MAR and not 
imputed). Add itionally, the 
MMRM analysis will be 
performed using data from 
multiple imputation ( MI) 
including a tippi[INVESTIGATOR_661537].  
 
The analysis of change from 
baseline in CRT as assessed by 
[CONTACT_661640] a 
MMRM model similar to the one 
used for the analysis of change 
from baseline in BCVA, with the 
corresponding 95% CI for the 
estimates of tre atment differences 
at Week [ADDRESS_892468] treatment discontinuation or 
after receipt of rescue therapy will 
be set to missi ng prior to the 
MMRM analysis. Multiple 
imputation will not be 
performed and no No sensitivity 
analyses will be performed.  
Chapter/section concerned  
Section 11.2.2 Protocol Deviations  
... 
A deviation from the protocol is 
an unintend ed or unanticipated 
departure from the procedures or 
processes approved by [CONTACT_549109]/IEC and agreed to by 
[CONTACT_093]. A significant 
deviation occurs when there is ... 
A deviation from the protocol is 
an unintended or unanticipated 
departure from the procedures or 
processes approved by [CONTACT_661641]/IEC and 
agreed to by [CONTACT_093]. A 
significant deviation occurs when 
there is nonadherence t o the 
protocol by [CONTACT_55704] a Section 11.2.[ADDRESS_892469] serious protocol 
violations in the protocol. The 
update has been applied to the 
Korea -specific protocol 
amendments.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.[ADDRESS_892470] being 
withdrawn from the study (Sec tion 
4.2). significant, additional risk to the 
subject. Significant deviations can 
include nonadherence to inclusion 
or exclusion criteria, or 
nonadherence to FDA regulations 
or ICH GCP guidelines, and w ill 
lead to the subject being 
withdrawn from the study 
(Section 4.2). Significant 
protocol deviations may include 
below but not limited to the 
following deviations:  
 
• ICH/GCP deviation  
• Deviation from 
inclusion/exclusion criteria  
• Deviation on study 
treatment randomization  
... 
Chapter/section concerned  
Section [ADDRESS_892471] in 
version 1.0.  ... 
European Medicines Agency 
(EMA). Eylea (aflibercept). An 
overview of Eylea and why it is 
authorised in the EU. 
EMA/481361/2018. [cited 2020 
Jul 23] Available from: 
https://www.ema.europa.eu/en/
documents/overview/eylea -epar -
medicine -overview_en.pdf  The reference was added as it was 
missing in the original protocol . 
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 145 Chapter/section concerned  
Section 5.[ADDRESS_892472]  
Initial wording  
 
 
Amended or new wording  
 
 

SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 146 Reason/Justification for Change  
As per the US FDA request, the column regarding the treatment of Eylea (aflibercept) was updated to clarify the source of Eyl ea. 
 
Table concerned  
Table 5 -1  Prohibited Medications  
Initial wording  
 
… 
Abbreviations: AE, adverse event; AMD, age -related macular degeneration; EOS, end -of-study; ET, early termination; IP, investigational product; IVT, intravitreal; NA, not applicable; PDT, 
photodynamic therapy; SOC, standard of care; VEGF, vascular endothelial growth factor.  
 

SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 147 Amended or new wording  
 
… 
Abbreviations: AE, adverse event; AMD, age -related macular degeneration; EOS, end -of-study; ET, early termination; IP, investigational product; IVT, intravitreal; NA, not applicable; PDT, 
photodynamic therapy; SOC, standard of care; VEGF, vascular endothel ial growth factor.  
 
Reason/Justification for Change  
Due to the sponsor’s decision to allow treatment of fellow eye only with Eylea for the whole duration of the study, the VEGF treatment was updated as a 
prohibited medication only applicable to the study e ye. Additionally, the note on treatment of fellow eye was updated.  
 
Table concerned  
Table 6-1  Schedule of Events  
Amended or new wording  
Footnote:  
a. For subjects who discontinue study treatment  and choose to withdraw from the study or if, in the opi[INVESTIGATOR_871], the subject should be 
prematurely withdrawn , ET Visit assessments are to be performed as soon as possible after discontinuing the study treatment but no later than 28 d ays 
after discontinuation  
c. Slit lamp examination will be performed on both eyes at screening and prior to IVT injection of the study drug. Slit lamp will also be performed at any time 
during the visit at ET/EOS Visit  all the planned scheduled visits during the study . 

SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 148 d. Dilated fundoscopy will be performed on the study eye at all the planned scheduled visits during the study, including the time  prior to IVT injection of 
the study drug, and within 60±30 minutes after IVT injection of the study drug ,. Dilated fundosc opy will also be performed  and at any time during the visit 
at ET/EOS Visit.  
e. Serum pregnancy test will be done at screening, and urine pregnancy test at baseline, ET, and EOS Visits for female subjects of child -bearing potential. If 
urine pregnancy test is  positive, serum pregnancy test should be performed; and if found positive, study treatment will be discontinued and the subject should 
complete ET Visit procedures  continue with their regularly scheduled visits and assessments until Week  52 except for study treatment 
administration. Pregnancy cases should be followed until resolution of the pregnancy . 
f. Concurrent use of systemic or intravitreal anti -VEGF agents, IVT, subtenon, or peribulbar corticosteroids in either  study  eye, except as required to treat  
AEs, and use of photocoagulation or PDT with verteporfin are prohibited during the study. Antimicrobial drops can be used at the discretion of the 
investigator. For IVT corticosteroid implant, the exclusion period would be 36 months from the date of the p rocedure to the date of screening.  
h. Rescue treatment for the study eye is not permitted at any point in time  if it observed that efficacy is not achieved by [CONTACT_104841], as determined by 
[CONTACT_093] . Subjects can be considered for rescue treatm ent after Week 4 if the following conditions are met as assessed by [CONTACT_286823]: 
visual acuity letter score decrease of [ADDRESS_892473] assessment and/or increase in the central subfield thickness of [ADDRESS_892474] assessment (OCT) by [CONTACT_093] , an increase in intraretinal fluid, subretinal fluid, or subretinal hyper -reflective material, that in the investigator’s 
opi[INVESTIGATOR_661524]’s neovascular AMD. Subjects who will receive rescue treatment need to perform ET/EOS Visits and 
discontinue from the study  discontinue the study treatment and should have the reason for treatment discontinuation documented on the Treatment 
Discontinuation page of the eCRF and continue with all their regularly scheduled visits and assessments until Week  [ADDRESS_892475] should  be prematurely 
withdrawn, then the ET Visit should be completed as soon as possible after discontinuing the study treatment but no later than 28 days after 
discontinuation . 
i. Intraocular pressure will be measured on both eyes at screening, and on the study eye prior to IVT injection of the study  drug, and 60±30 mins after IVT 
injection of the study drug at each visit from baseline/Day 1 to EOT (48 weeks). If the pre -procedure IOP is equal to or greater than 30 mmHg, IVT 
injection will not be administered (either withheld or delayed) until IOP is decreased to acceptable safety levels as per investigator’s medical 
judgement.  IOP should be measured after OCT and FA are completed to avoid corneal erosion. Finger counting test to be performed immediat ely after the 
IVT injection of the study drug. IOP w ill also be performed at any time during the ET/EOS Visit.  
… 
m. Hematology, chemistry, and urinalysis samples will be collected prior to IVT injection of the study drug. Urine samples will be collected prior to performing 
FA to avoid false elevations in urine  protein values. No pregnancy test is required for women of non -child -bearing potential. For women of child -
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.[ADDRESS_892476] during the study;  urine pregnancy test 
will be performed at the Baseline, ET and EOS Visits;  Tthe FSH and LH levels to be measured at screening for women of child -bearing potential. 
Hematology, chemistry, and urinalysis samples will also be performed at any time during the visit at ET/EOS Visit.  
 
Reason/Justification for Change  
The following changes were made to the footnotes of Table  6-1. 
• Footnote a: As per the US FDA request to keep subjects in the study to continue with their regularly scheduled visits after s tudy treatment discontinuation, 
the relevant text has been updated.  
• Footnote c: For clarity, the timing of slit lamp examination has been updated to all planned scheduled visits during the stud y. 
• Footnote d: For clarity, the timing of dilated fundoscopy has been updated to all planned scheduled visits during the study.  
• Footnote e: As per the US FDA recommendation on collecting data after study treatment discontinuation, women who have a posit ive serum pregnancy test 
will continue with their regularly scheduled vis its after study treatment discontinuation and should be followed -up until the resolution of pregnancy.  
• Footnote f: As per the sponsor’s decision to allow treatment of fellow eye for the whole duration of the study, prohibited me dications that were initiall y 
applied to both eyes have been changed to only study eye.  
• Footnote h: Part of the text on rescue treatment was updated due to  the US FDA recommendation of collecting data after study treatment discontinuation 
due to receiving rescue treatment. Additional ly, the  condition for rescue treatment of an increase in the central subfield thickness of [ADDRESS_892477] assessment (OCT) by [CONTACT_661642].  
• Footnote i: The pre -injection IOP pressure was added as per the request from the Russian regulatory agency to add this condition to ensure participant 
safety.  
• Footnote m: The pregnancy tests were specified for women of non -child -bearing potential and women of child -bearing potential.  
SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 150 Table concerned  
Table 6-2 Clinical Laboratory Evalua tions  
Initial wording  
 
 
 
 
 
 
 
 
 
 
 

SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 151 Amended or new wording  
 
Reason /Justification for Change  
The table of clinical laboratory evaluations was updated to include all the laboratory tests provided by [CONTACT_55412].  

SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 152 Figure concerned  
Figure  3-1  Study Schema  
Initial wording  
 
 
 
 
 
 

SamChunDang Pharm. Co. Ltd.  SCD411  
Protocol : SCD411 -CP101 , Version 3.0  24 Jan  2022  
 Page 153 Amended or new wording  
 
Reason/Justification for Change  
In Figure [ADDRESS_892478] been removed.  
 
